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ABSTRACT � 
Physicochemical and phaimacokiiietic studies of some pain relief drugs 
Sensitive, selective and accurate analytical techniques based on gas-
liquid chromatography (with 3% WAV SP 2250 column linked to a nitrogen 
sensitive detector) have been developed which enable the determinations of 
bupivacaine, a family of six local anaesthetics and pethidine with its major 
metabolites in human biological fluids. Using these useful procedures, the 
physicochemical properties, clinical pharmacokinetics and metabolism of the 
drugs have been fully determined. 
Kinetic analyses in the investigation of the effect of adrenaline 
(1:200,000) on bupivacaine indicated the addition of vasoconstrictor had no 
subsequent effect on the pharmacokinetics of bupivacaine. However, the mean 
peak plasma concentration was significantly lower (2.57±0.61 and 3.22土0.27 
|ig/ml with and without adrenaline respectively) and the mean time for 
maximum absorption was longer (24.2±2.7 and 15.0±1.3 min respectively) in 
the adrenaline group. The results showed that the addition of adrenaline 
appeared prudent to minimize bupivacaine toxicity. 
• f 
An examination of physicochemical properties and buccal 
absorptions of six local anaesthetics (amethocaine, bupivacaine, etidocaine, 
lignocaine, mepivacaine and prilocaine) has revealed the onset of action and 
the duration were shown dependent on the pKa values and the logarithms of 
partition coefficients (K) in n-hexane-S^rensen buffer system. The buccal 
absorption test supplemented by the n-hexane-bufFer partition coe伍cient could 
be used as a reference for the ability of a local anaesthetic molecule to 
penetrate biological barriers. 
Studies on the plasma concentrations of pethidine and norpethidine 
m patients have shown that pethidine was absorbed rapidly and reached its 
peak concentration within 2 hours after intramuscular administration The 
metabolite, norpethidine, appeared in the plasma from 0.25 to 0.75 hour The 
companson of pharmacokinetic profiles of pethidine and norpethidine among 
Caucasian, Chinese and Nepalese showed that Asian patients did not 
eliminate pethidine as effectively as the Caucasians but they produced more 
norpethidine which stayed longer in the plasma. 
frnrr^  Proteiii binding ranged from 72±2.8 to 43±2.7% and 
fro^ 57±3 0 to 27±3.9%，respectively, at various concentrations of pethidine 
and norpethidine in the protein binding study. Albumin was found to be the 
i i i 
major plasma component responsible for drug binding. The binding affinities 
of pethidine were comparatively higher than' those of norpethidine in all 
circumstances. There was no direct displacement effect on the binding 
between pethidine and norpethidine, indicating these two compounds 
exhibited no displacement action on the binding site to one another. The mean 
pethidine bound in Caucasian, Chinese and Nepalese patients at about 100 
ng/ml pethidine was similar, implying the absence of interethnic protein 
binding variation. 
The determination of pethidine and its major metabolites in urine 
samples showed that these compounds excreted in the urine were varied 
remarkably among subjects. The mean 24 hours urinary recoveries in eight 
Chinese patients of pethidine, norpethidine, pethidinic acid, norpethidinic 
acid，glucuronides of pethidinic and norpethidinic acids were 6.62±5 05 
4.33±1.19，18.9土6.29，9.10土4.26，15.1±3.02 and 7.57±2.28% respectively. It 
showed that the major metabolic pathways of pethidine in the eight patients 
were hydrolysis followed by conjugation. Over 60% of the dose was accounted 
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1.1. PLANS FOR THE PRESENT INVESTIGATION 
The present work concerns the studies of physicochemical properties 
and pharmacokinetics of pain relief drugs. The drugs that were examined in 
the studies fall into two major categories: local anaesthetics and narcotic 
analgesics. The main reason of choosing these compounds in our research 
was because these agents are the most commonly and widely used pain relief 
drugs in Hong Kong as well as many other overseas countries, particular in 
obstetrics and controlling post-operative pain. In general, the study involved 
the collaboration with physicians in hospitals (The Prince of Wales Hospital 
and The British Military Hospital of Hong Kong) for obtaining plasma or 
urine samples from patients who had usually undergone various kinds of 
surgery. The whole course of the research initially required the development 
of novel chromatographic methods as well as the improvement of present 
available methods and thereafter, these methodologies were 
applied to a j i ^ e ^ l e amount of the parent drug together with its 
nietabolite(s) in the biological samples. Results obtained from these 
investigations could provide important information on the adequate handling 
the pharmacokinetic profiles and metabolic patterns of the above named 
drugs when they were used post-operatively. 
The following investigations were intended to carry out in our work: 
6 
s 
1.1.1, Evaluation of the effect of vasoconstrictor： on the phamacokinetics of 
‘ h 
bupivacaine after interpleural administration 
The interpleural administration of local anaesthetics is a recently 
introduced technique to provide post-operative analgesia. Like other new 
techniques, a number of questions associated! were not fully understood and 
广. 
more scientific studies were required to find out some of the answers. One of 
s p ^ questions was the usefulness of co-administrating with vasoconstrictor 
in the interpleural administration of local anaesthetics. Thereforej^)propose 
to develop a simple and accurate GC method which will conveniently measure 
COvi,咖, 
the plasma l^^h of bupivacaine and to apply this method to define the 
effect on patients caused by the vasoconstrictor, adrenaline, on the disposition 
of local anaesthetics. This part of work will be reported in Chapter 2. , 
1.1.2. Simultaneous gas-liquid chromatographic determination of some 
clinically used local anaesthetic|{ drugs and their physicochemical 
properties 
The analytical assay will be based on the modification of the method 
參 determining bupivacaine, ^ ^ l a n to use this assay to measure the lipid、背見 
solubilities and buccal absorptions of the compounds simultaneously and to 
examine whether there is any correlation between these characteristic 
properties and the pharmacological activities, such as drug potency, duration 
and onset of action, of these local anaesthetics. This part of/work will be 
reported in Chapter 3. 
7 
1.1.3. Gas-liquid chromatographic determination of plasma pethidine and 
its metabolite, norpethidine in Chinese patients after intramuscular 
administration 
Norpethidine, the only metabolite of pethidine that can be found in 
the blood circulation after administration of the parent drug, ewM produce 
seizuresellect on patrgnts. The chromatographic property of this compound is 
poor, the previously reported GC methods were tedious, and always required 
sample derivatization. Further, the pharmacokinetic data ^ pethidine and 
norpethidine in the Chinese population was relatively scarce. Therefore /w^, 
would like to develop a simple and useful GC method to determine these 
compounds in the plasma of Chinese patients and the data so obtained will be 
compared with those from other ethnic groups. This part of work will be ‘ 
reported in Chapter 4. 
1.1.4. Gas-liquid chromatographic determination of pethidine and all its 
major metabolites in uriiie samples 
Apart from norpethidine, other metabolites such as pethidinic and 
norpethidinic acids, conjugates of pethidinic and norpethidinic acids (formed 
by the conjugation reaction of a glucuronide group to the corresponding acid) 
respectively, can also be found in urine. The chromatography of these 
metabolites has not been reported. Therefore/w^ would like to 
develop a GC method to measure these drugs in^rine of patient^ after 
pethidine administration, which should help to elucidate the disposition of 
pethidine more clearly among individuals and different ethnic groups. This 
8 
4f 
part of—ork will be reported in Chapter 5. , 
1.1.5. Study of the plasma binding characteristics of pethidine and 
norpethidine 
There is little information on the binding of these two compounds in 
<[LijL the literature, especially that for norpethidine was not plentiful. The aspects y . 
of protein binding behaviour of pethidine and norpethidine, using incubation 
tt^ 一 、 
and dialysis experiments, will thereforejincluded i n / o i ^ study. shall 
examine the binding properties of these two agents to various isolated protein 
components as well as|the plasma proteins from patients and healthy 
subjects. The binding activities of a number of clinical drugs have shown to be 
altered or influenced by its metabolite. Hence @ s h a l l also look at the effect of ^ 
this type by performing displacement binding experiments between pethidine 
and norpethidine and the results will probably show @ the nature of the 
binding sites involved. This part of work will be reported in Chapter 6. 
1.1.6. Investigation of the existence of different pethidine metabolic 
pathways among different ethnic groups 
A recent report showed that the metabolic routes of pethidine were 
different between Chinese, Indian and Caucasian healthy subjects and 
hypothesized the Asian groups were better N-demethylators whereas the 
Caucasian was better hydrolyzers： ( Q t h o u g h t c o u l d extend � w o r k 
using the analytical method that has been developed in Section 1.5.3., to study 
the plasma pethidine and norpethidine in the three groups of patients (viz, 
9 
Chinese, European and Nepalese) and to verify'if the recent observation was 
also apparent in patients, ^^wi l l also further examine whether the presence 
i. k J 
of plasma protein binding variability of pethidine and norpethidine exist 
among these three ethnic groups. This part of work will be reported in 
Chapter 7. 
1 0 
1.2. CLASSIFICATION OF PAIN RELIEF DRUGS 
Pain is a subjective experience and can either be produced by an 
external or endogenous stimulus. If pain is continuous and severe, disorders 
such as fear and anxiety may be aroused. In man, these are important 
components of the perception of pain and treatment for anxiety may be as 
important as relief of pain. Pain can be alleviated by specific/therapy and the 
drugs used in such process are called analgesics. The choice of analgesics 
depends upon both the source and the severity of the pain. Strong analgesics 
that act on pain perception within the central nervous system are grouped as 
narcotic analgesics. They are mainly used to relieve pain originating in the 
viscera，or arising from severe injuries, burns or neoplasms. The prototype of 
this class of drugs is morphine. Another class of drug which also produces an , 
intense analgesic effect isAhe local anaesthetics. These drugs interrupt 
impulse transmission in all fibres when applied locally near a nerve trunk. 
In the smallest effective doses, they act relatively selectively on pain fibres and 
may therefore be termed as local analgesics. Weaker analgesics, which act 
chiefly by a peripheral mechanism, have little effect on visceral pain or pain 
due to wounding, but they are useful for the relief of low grade, aching pain. 
They are called antipyretic analgesics because their actions are usually 
associated with temperature lowering effect. Most of these type of analgesics 
are derivatives of salicyclic acid, aniline pyrazolone, isoindazole and 
anthranilic acid. As far as the present research concerned, this chapter will 
only deal with the stronger analgesics. 
1 1 
1.2.1. Narcotic analgesics 
1 
Narcotic analgesics can be classified into four main groups: the 
natural opium alkaloids (Gp. I), semi-synthetics (Gp. II)，synthetics (Gp. Ill) 
and miscellaneous (Gp. IV). Table 1 summarizes these groups with examples 
of currently used drugs in clinical practice. 
Opium is the dried exudate from unripe seed capsules of the opium 
( 
poppy，Papaver somniferum. The natural opium alkaloids, which relief pain 
t 
as well as promote sleep and induce a general feeling of peace and well-being, 
have been used for centuries. Pure morphine was isolated in 1816 and its 
structure was suggested in 4924 which was proved to be correct after the 
success of total synthesis in 1952. Minor chemical alterations in various 
functional groups of the morphine molecule produced new semi-synthetic 
narcotics such as dihydrohydroxycodeinone. Also, attempts to synthesize part 
of the morphine molecule which possessed analgesic activity resulted in the 
Gp. Ilia analgesics, the morphinan series and Illb analgesics, the 
benzomorphan series. The discovery of morphine antagonists such as 
nalorphine stimulated investigations on the morphine antagonists from the 
morphinan and benzomorphan series. Notably, pentazocine was marketed as 
a non-addictive, potent analgesic. However it was found to produce similar 
side effects to other narcotic analgesics. 
The 4-phenylpiperidine synthetic analogues, Gp. IIIc analgesics, are 
the oldest synthetic groups. They were developed in the search for an ideal 
analgesic without any of the undesirable adverse effects. This led to the 
production of newer and more potent drugs. Pethidine was the first to be 
1 2 
synthesized and newer analgesics of this group currently use include 
alfentanil, fentanyl, phenoperidine and sufentanil. . 
The miscellaneous narcotic analgesics are those which include 
morphine antagonist, antihistamine and major tranquillizers in the same 
formulation in the hope that inclusion of these drugs may help to reduce the 
side effects associated with these agents. 
Table 1. Classification of narcotic analgesics. 
i. 
Group Examples | 
• ,,, • 
H a — ? ， ^ { i , (My-fhwrL I 
I. Natural alkaloids Morphine, Codeine and^Papaveretum：^!) 
II. Semi-synthetics Diamorphine, Dihydrohydroxycodeinone 
and Heroin 
III. Synthetics 
(a) Morphinans Levorphanol, Cyclorphan 
(b) Benzomorphans Phenazocine, Pentazocine 
(c) 4-Phenylpiperidines Alfentanil, Fentanyl, phenoperidine 
(d) Diphenylpropylamines Methadone 
IV. Miscellaneous 
(a) With opiate antagonists Levallorphan 
(b) With antihistamines Cyclizine 
(c) With tranquillizers Droperidol 
1 3 
1.2.1.1. Mechanism of action 
The mechanisms of action by which morphine and its similar 
analogues produce analgesia are complex. Part of the analgesic action of 
morphine probably derives from its power to exert a calming, soothing and 
fear-relieving effect. Although this effect is generally assumed to occur in the 
cerebral cortex, the neurophysiologic mechanisms are entirely unknown. 
However, morphine also elevates the pain threshold measurably and this 
effect was shown to be mediated by specific morphine receptors located in the 
central nervous system important for the transport of pain impulses. Since it 
is unlikely that all mammalian species should have developed receptors for 
‘ 广 ‘ ‘ 
an alkaloid occurring elsewhere but in the oriental poppy, it appeared more 
probable that the specificity of these receptors is directed at some morphine-
like substance in the brain. Several such substances (endorphins) were 
discovered and all are peptides with a common N terminal group. The 
endorphins are morphine-like analgesics and it is not yet certain whether the 
clinically used opioid drugs act by endorphin release or by direct action on 
morphine receptors. 
1.2.1.2. Adverse effects 
The cardinal acute toxic effect of narcotics is respiratory depression. 
Morphine depresses respiration even in normal therapeutic doses and death 
from this acute poisoning is the result of cessation and breathing. Long-term 
chronic dosage leads to tolerance and physical dependence which develop 
rapidly and are often accompanied by psychological or emotional dependence 
1 4 
of compelling intensity. Tolerance, characterized by decreased intensity and 
shortened duration of the analgesic, euphoric, sedative and respiratory 
depression effects of morphine, is preceded by a marked elevation in the lethal 
dose. Individuals who have become tolerant to morphine are also tolerant to 
other morphine analogues, that is, there is a cross-tolerance between drugs of 
the same group. � i 
1-2.2. Classification of local anaesthetics 
Most useful local anaesthetics are composed of three structural 
entities: a carbocyclic or heterocyclic aromatic ring (lipophilic portion), an 
intermediate chain and an amino group (hydrophilic group) as shown in Fig. 
1. Such entities can be readily seen in the structural formula for amethoca ine . ‘ 
The aromatic ring is essential for anaesthetic activity, and useful injectable 
local anaesthetics require a delicate balance between the degree of lipid 
solubility, represented by a particular ring structure, and the potential water 
solubility of a compound which is this case depends on the presence of the 
amine group. In addition to the characterization of local anaesthetics on the 
traditional basis of solubility, ^ s t local anaesthetics can be classified 
chemically as to the type of linkage between the aromatic group and the 
intermediate chain. One group is represented by the ester linkage susceptible 
to plasma hydrolysis; another group is the aromatic ring connects to the rest 
of the molecule by an amide linkage，more resistant to enzymatic inactivation 
in the blood. 
1 5 
1.2.2.1. Mechanism of action , 
Local anaesthetics generally prevent the generation and conduction 
of nerve impulses. Their site of action is the cell membrane and the block they 
produce is the result of interference with changes in membrane permeability 
to potassium and sodium ions. These permeability changes are responsible 
for the rising and falling phases of action potential and follow depolarization 
of the membrane. In the presence of a local anaesthetic the electrical 
excitability of the tissue gradually decreases until, eventually, complete block 
ensures. 
How local anaesthetics affect the transient changes in ionic 
permeability is unknown but the potency of these compounds is matched by 
) their ability to increase the surface pressure of monomolecular lipid films. It ‘ 
L has been(^Sge^d>hat the anaesthetic squeezes the lipid molecules closer 
together. In the lipid membrane layers of nerves this could have the effect of 
closing membrane pores so as reducing ionic permeability; this would have 
the effect of stabilizing the membrane and reducing its excitability. 
1 6 
Fig. 1 • Comparison of chemical structures of amide (bupivacaine) and ester 
(amethocaine) types. 
/ = \ 严 
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1.2.2.2. Adverse effects 
Excessive and rapid absorption of these drugs into the general 
circulation result in nervousness, tremors and convulsions. These effects are 
very dangerous and are followed by respiratory depression. Nausea, vomiting 
and abdominal pain may occur sometimes with sudden cardiovascular 
collapse and respiratory failure for which there is no specific treatment other 
than respiratory and cardiac resuscitation. Allergic reactions such as rashes, 
asthma and anaphylactic shock may exist and the subject may be allergic to 
more than one drug. Local inflammatory or necrotic effects may occurs as 
these drugs can damage all cells. 
1 7 
1.3. SOME PRINCIPLES OF PHARMACOKINETICS 
Pharmacokinetics, a discipline that concerns the study and 
(m 
characterization of the time course of drug^^v^els in the body after 
administration. It is best defined as the study of the rates of the transfer 
processes associated with the absorption, distribution, metabolism and 
elimination of a drug in the body (Fig 2). 
The administration of a bolus dose intravenously is to introduce the 
drug as one dose directly into the blood stream in a relatively short time. 
Usually extensive dilution occurs within a short time of injection, and mixing 
with blood is essentially complete within 10 minutes. While being transported 
• -
in the blood stream the drug rapidly diffuses into the surrounding tissues as it 
passes in through capillary beds. Decline of the drug in the blood continues as ‘ 
it passes into highly perfused organs and then out of these into less perfused 
tissues. The blood concentration of the drug equilibrates rapidly with that in 
various tissues until a distribution equilibrium is obtained. The phase prior to 
attainment of distribution equilibrium is commonly refered to as distribution 
phase. The subsequent phase, when the decline in blood reflects a 
proportional loss of drug from the body, is the elimination phase. 
Pharmacokinetics uses the techniques of compartmental analysis 
(the body is assumed to consist of different compartments) in explaining the 
parameters obtained from plasma or urinary concentration profiles of drugs. 
This approach involves the adoption of the simplest mathematical model 
which is composed of the least number of compartments required to interpret 
the data. In the simpler of the two models, the drug is assumed to distribute 
1 8 
f , 0 
\X WVCK 'TK'O • -
instantaneouly into a space called the central compartment. Then the drug is 
I 
simultaneously distributed into a second space and eliminated. The three-
compartment model assumes that there are two distinct spaces to which the 
drug distributes from the central compartment at measurable different rates. • • 
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1.3.1. Distribution and Elimination 
The transfer of drug from its absorption site to the blood stream is 
! comi^ fete within a relative short time. While being transported in the blood 
stream the drug rapidly diffuses into the surrounding tissues as it passes 
through capillary networks. Since most drugs are sufficiently lipid soluble to 
cross cell membranes and distribute in the intracellular fluids of various 
tissues, the body can be assumed to consist of several separate compartments 
and each containing some fraction of the administered dose. The transfer of 
drug from one compartment to another (Fig 3) is associated with a rate 
constant (k) and this process is called distribution. Distribution is usually a 
rapid and reversible process. The transfer of drug from the blood to the urine 
or other excretory compartments and the enzymatic or biochemical > 
transformation (metabolism) of drug, are usually irreversible processes, 
termed as elimination. Elimination is tp^gl^gn^ie^f� the physical and 
biochemical removal of drug from the body. 
Distribution and elimination occur simultaneously, but the rate of 
distribution is often faster than the elimination. Therefore drugs usually 
attain distribution equilibrium before a measurable fraction of the dose is ^ 
eliminated. In such circumstances, the body appears to have the 
k , 
characteristics of a single compartment. Unfortunately this simpl|cation can 
not be applied to all drugs. In some cases, a considerable fraction of the drug 
liO u爲•二. 
dose is eliminated before the distribution equilibrium is reached. |Such drugs 么 
exhibit the beha-viours of a multicompartment system the body, j 
V —乂 
2 0 
Fig 3. Schematic representation of drug absorption, distribution and 
eliminatiorL 
^^^^^^^^^^ Drug in urine 
absoD^Jifofsite ^ Drug in blood > Metabolite(s) 
」 k N v 
k k k ko Drug in other 
- 1 1 excretory fluids 
k k 
Drug in ^ wDrug in 
other fluids ， tissues “ 
of distribution -3 
1.3.2, Non-compartmental analysis 
The calculations involved in the multicompartmental methods Of 
analysis (mentioned in Section 1.3.) are complicated and therefore 
non-compartmental or one compartmental methods have been widely used 
7 nowadays. @ a s s u m q the drug does not exhibit the distribution phase (no 
compartment) but is homogenously distributed throughout tissues and fluids 
of the body. Tl^ anayiis;;;are based on the theory of statistical moments (1-2). 
f A 、 - 一 ‘ 
^ W � r n i 
^iVt two most important primary pharmacokinetic parameters, clearance 
and volume of distribution at steady state, can be easily obtained by these 
methods. 
Clearance (Clp) is defined as the volume of plasma cleared of drug 
per unit time. We can refer to Clp by a particular organ, metabolic pathway or 
2 1 
by the whole body. Total body Clp is the sum 'of all different Clp processes 
occurring for a given drug. Clp determines the maintenance dose rate 
required to achieve a desired plasma concentration or drug effect at steady 
state. We' can use Eq. 1 to obtain the Clp of a drug from the steady state drug 
concentration during a constant intravenous infusing. 
… Clp 二 dose rate/steady state blood concentration [1] 
,j Alternatively, for a single d o s e ， c a n take frequent blood samples and 
J measure the drug concentration and calculate the area under the drug 
concentration versus time curve (AUG). The Clp can then be obtained by 
means of Eq. 2. 
Clp = dose/AUC [2] 
7 The volume of distribution of a drug at steady state (Vss) rarely 
corresponds to the anatomic volume such as the volume of total body fluids but 
represents the proportionality constant relating the amount of drug in the 
body at steady state after prolonged constant rate of intravenous infusion, or 
repetitive administration or average drug concentration at that time. Vss 
depends on the drug's physicochemical properties and patient characteristics 
like body weight and composition. It is a valuable parameter that can allow 
one to determine or predict the distribution of drug and to compare the 
distribution characteristics of various drugs. Estimation of Vss does not 
require data obtained at steady state; this distribution parameter can be 
calculated after the administration of single dose of a drug (3-4) Eq. 3 and 4. 
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Vss = dose(AUMC)/(AUC)2, [3] 
Vss = Clp X MRT [ 4 ] -
where AUMC is the total area under the first moment curve and MRT (mean 
residence time) is govWned by 
‘ MRT = AUMC/AUC [5] 
Biological or elimination half-life (tl/2) is defined as the time required 
for the reduction to one-half of the initial drug concentration or activity after 
the drug has been absorbed and has reached a desirable level of activity. Its 
value can be readily determined for most drugs by administering, a do&e of the 
drug to a subject. Blood samples are then taken at various time intervals and 
followed by assay for drug content. The valuelis equal to the slope of the curve ‘ 
when the logarithmic concentrations are plotted against time on 
semilogarithmic graph paper. The elimination half-life is a unique property 
of a given drug and hence it is an important parameter which can help to 
establish rational regimes for drugs, eg. initial doses, maintenance doses or 
doses for sustained action dosage forms. The tl/2 is also a composite 
pharmacokinetic parameter determined by both Clp and Vss according to Eq. 
5. 
tl/2 = ln2 (VssVClp [5] 
The elimination of a drug from the body is usually a result of 
metabolic and excretion processes. The rate of elimination for most drugs is 
: ‘ usually described by a first-order kinetic (and the elimination rate constant 
(ke) for a first-order process is inversely proportional to tl/2 (Eq. 6). 
2 3 
ke = ln2/(tl/2) [6] 
Like tl/2, ke is the other secondary pharmacokinetic parameter (derived from 
primary parameters) that deterimnes the action of the body when it is 
disposing of a drug. 
f 
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1.4. PHYSICOCHEMICAL PROPERTIES OF DRUGS 
I 
Although the passage of drugs through biological membranes also 
伊 ^ involves aqueous diffusion and carrier-facilitated transport, in most 
(jt)^  
y circumstances, absorption of drugs from the site of administration into the 
Vh乂 blood circulation, its distribution, excretion and renal tubular reabsorption ‘ » 
I • 
；are mainly achieved by passive lipid diffusion of nonionized drug molecules 
Q i 
across biological membranes. The cells of the membrane barriers can be 
described as a lipid phase separating two aqueous phases. Lipid soluble 
substances are taken up at one interphase according to their lipid/water 
partition coefficient, diffuse across the lipid phase according to their 
concentration gradient, and are redistributed in accord with their lipid/water 
partition coefficient at the opposite interphase. It is assumed that lipid cell 
membranes are impermeable to the ionized form of a weak electrolyte drug, 
but that the nonionized form can equilibrate freely across the membranes. 
Therefore these membranes act like lipoid barriers which restrict the 
movements of the molecules, and the rate of lipid diffusion of drug molecules 
across membranes is represented by the Pick's law which in .turn is governed 
by the physicochemical properties of the drug, such as the degree of 
ionization, lipid solubility and protein binding ability. Factors that favour 
rapid diffusion are a low degree of ionization of weak electrolyte drug, a high 
lipid-soluble nonionized form at physiological pH and an absence of protein 
binding. These physicochemical properties can be measured with ease by 
simple laboratory procedures. The [obtained fvaluesl will be useful in 
determining the relative penetration power of a series of drugs across 
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membranes and one can also relate these values to interpret the 
( 
corresponding pharmacologic activities and pharmacokinetics of drugs. 
1.4. l.CIonizati^^ 
The molecular structures of many drugs contain groups ionizable in 
aqueous solutions to anionic or cationic forms, which may be quantitatively 
( 
expressed by its acidic ionization constant (Ka). This dissociation exponent, 
represented by pKa, is the negative logarithm of the dissociation or ionization 
constant. Since only the nonionized molecules are lipid soluble and hence the 
ability of such drugs to pass through lipid membranes depends on the 
proportion of nonionized molecules. A knowledge of the pKa is necessary in 
establishing whether the drug is predominantly in the nonionized form in the 
biological fluids. The degree of ionization is dependent on the ionization 
constant (Ka) and the pH of the aqueous solution which can be readily 
illustrated by following equations derived from the Henderson-Hasselbalch 
Equation (Eq. 7). 
% ionization for an acid = 100/[l+antilog(pKa-pH)] [7] 
% ionization for a base = 100/[l+antilog(pH-pKa)] [8] 
Hence the higher the pH of the medium, the higher is the ionization of acidic 
drugs and the lower is the ionization of basic drugs. When the pH values of 
the aqueous phases on either sides of a membrane are different, acidic drugs 
will be in a higher concentration on the more alkaline side whereas basic 
drugs will be in a higher concentration on the more acidic side. The ratio of 
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the concentration (R) of a drug on either side of a membrane is thus 
proportional to the tendency of the drug to ionize and to the difference in pH 
across the membrane. General equations to describe this concentration ratio 
of acidic and basic drugs are illustrated as follows: 
For acidic drugs, R = (1+10 pHi-pKa)/(l+10 pH2-pKa) [9] 
For basic drugs, R = (1+10 pKa-pHi)/(l+10 pKa-pH?) [10] 
where pHi and pH2 are the values on either sides of the membrane. 
A number of methods have been available to determine the ionization 
constants. Potentiometric titration is by far the most convenient and usually 
enables the Ka to be determined in a short time. Although ultraviolet^iSi^ 
spectrophotometry is a time consuming method and can only be used for 
substances which absorb ultraviolet or visible light, it is particular suitable for 
sparingly soluble substances and can also work at either very low or high pH 
values which are beyond the range of potentiometry. Conductimetry is 
- . . 
another possible alternative and as useful for very weak acids. Like 
1 conductimetry, solubilities determination is not so accurate a method, but it is 
adequate in the cases where a substance is too insoluble in water for 
potentiometry or conductimetry, and has no obvious ultraviolet absorption. 
1.4.2, Partition coefficient 
It is known that the lipid solubility of the unionized forms plays a 
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major role in determining the rate of drug diffusion and absorption. The term 
“lipid solubility" is often used to characterize the ratio or partition coefficient 
-
(K) between ^bsolut^ solubility in a lipid phase and in aqueous phase. Since 
the investigation by Collander and Barlund (5) on the significance of lipid 
solubility for the penetration of drugs through biological membranes, various 
physicochemical model systems have been sought to reflect the in vivo drug 
penetration. However the measurement of lipid solubility of drugs with 
respect to a biological membrane in vivo is rather difficult. A reasonable 
experimental estimate of this factor�i^by measuring the lipid/water partition 
coefficient of the unionized form. Buffer or saline solution at pH 7 4 is 
^ 飞 P r 讓 m 幽 used as the aqueous phase so as to simulate physiological 
conditions as far as possible. Even within the same compound, different 
lipid/water systems give different K values and therefore the applicability to 
the biological system of K obtained in this manner will(JuSg>epend on the 
nature of organic solvent used to represent the lipid phase, i.e.，how closely its 
characteristics resemble the complicated lipoprotein structures of a cell 
membrane. Therefore when considering the lipid solubility of a series of 
compounds, it is essential to measure K in several different solvents-buffer 
system in order to find trends which can be expected to apply to membrane 
structures. Some workers (6-7) have shown that the K value of 
n-heptane/water can be used as a reliable criterion for the ability of substances 
to diffuse into the central nervous system. Good correlations with the rates of 
passage across biological membranes are also obtained with solvents ( g ) ？ 
dichloromethane and octanoL The absolute values of K do not prove/ useful, 
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rather, it is the rank order in a series of compounds that can be used to reflect 
the rates of penetration. In general, the higher the partition coefficient the 
higher is the affinity for lipid membranes and the more rapidly the drug 
passes through the membranes. Endogenous end products (metabolites) 
usually have relatively lower K values than their parent drugs because of the 
additional hydrophilic group(s). 
1.4.3. Plasma Protein Binding , ^ 
Plasma proteins are composed of amino acid with/polar and f 
nonpolar side chains that protrude into the surrounding whicW are largely 
responsible for drug binding. This type of binding is reversible and the 
magnitude is dependent on the concentrations of both proteins and drugs in ‘ ‘ 
the plasma. The affinity of/drug m proteins is governed by |ts^hemical and 
physical properties. The forces involved in drug binding to protein are 
primarily hydrogen and hydrophobic bonds although ionic interaction and 
van der Waals forces may contribute. The presence of protein binding can 
reduce the passive diffusion firstly because the total free drug concentration is 
decreased which cause a drop in concentration gradient across the 
membrane and secondly the bound drug is not freely diffusible through 
membrane due to its enormous size. Protein bindings can be altered by a 
variety of pathological conditions such as hepatic insufficiency (8) and 
hypoalbuminemia (9). This consequent alteration of binding could have 
varying effects on the pharmacokinetic parameters (10-11). 







i reaction: o l r 敬 山 、 � 
i � ^K i [D][P]/[DP] [11] 
1 广 、•^ 
？ where K — equilibrium dissociation constant, [D] 二 drug concentration, [P]= 
3 protein concentration and [PD] is the drug-protein complex concentration 
\ Since the total concentration of protein [Pt] equals the sum o f the 
； concentrations of free protein ([P]) and protein engaged in binding ([DP]), the 
! term [Pt] - [PD] can be substituted for [P] in Eq. 11: 
1 
K = [D]([Pt] - [PD])/[PD] [12] 
which may be rearranged to the form: 
i 
J r = [D]/(K +[D]) [13] 
i where the ratio [PD]/[Pt] is represented by r. If there ^ a number (n) of 
i identical separate binding sites, there aSs a series of equations of the type 




+ r2 + ra + . . . + rn = rtotal = n[D]/(K + [D]) [14] 
The values of [D] and r can be measured experimentally, hence the values of n 
炉 and K can be determined from the appropriate graphical plots. The most 
：广 commonly used procedure for the analysis of data on protein-binding is the 
Scatchard plot of r/[D] against r. The equation, obtained by rearranging Eq. 14 
is given by: 
3 0 
r = j i - r [15' 
而 K K ‘ 
Scatchard in 1949 has shown that straight line plots are obtained from 
analysis of binding data for various inorganic ions and for some drugs, but 
with many drugs and endogenous metabolites the plots depart substantially 
from linearity. A curvilinear Scatchard plot indicates that there is more than 
one type of binding site and that the different types differ in their dissociation 
constants for the binding. 
A number of methods have been applied to the study of drug-protein 
binding interaction. Equilibrium dialysis is often regarded as the standard 
method which is based on the principle that unbound drug will equilibrate 
across a semipermeable membrane between a protein solution containing 
• ^ 
bound drug and a protein-free (buffer) solution. At equilibrium the drug 
concentration in the buffer compartment is considered to represent the 
unbound drug concentration in the original sample (12). The convenience and 
simplicity of the method make the technique well suited for the 
determinations involving large numbers of samples although nonspecific 
membrane binding and sample dilution may hamper interpretation of free 
drug values. Ultrafiltration，a new and promising procedure, is often used by 
means of a fine-mesh membrane filter to isolate unbound from protein-bound 
drug. Its major advantages are speed and the absence of dilutional effects 
seen in equilibrium dialysis. Nonspecific membrane binding and protein 
leakage are the generally recognized limitations which could produce 
unreliable and erroneous results (13). Ultracentrification is a technique to 
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separate fractions of a plasma sample into concentration gradients relied on 
relative size, shape and molecular weight of the particles in the centrifuge 
tubes. The goal of this method is the absence of nonspecific binding because a 
membrane is not used. The common disadvantages are slow and extremely 
expensive. In summary each separation method has been observed to produce 
some bias, which complicates the comparison of results between different 
methods. Until recently no method has been considered sufficiently reliable 
and convenient to apply directly to the study. Therefore the choice of method 
involved in binding study is very important. It always depends on the nature 
of the bound drug, available sample size,- number of studied -samples, time 
’ -
and cost of the experimental work. 
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1.5. GAS-LIQUID CHROMATOGRAPHY 
I 
1.5.1. Introduction 
Chromatography embraces a variety of processes which are based on 
differential distributions of the sample components between two phases. One 
phase remains fixed in the system and is called ^stationary phases. The 
(V mX • f街 一;：：；：^"^、 
another phase, called mobile phasey(^colate^through the interstices, or over 
I the surface, of the fixed phase. The movement of the mobile phase causes a 
秒巧 differential migration of the sample components. The migration rates of 
various components depend on their physical and chemical properties, thus 
chromatography provides an important analytical tool in res^olving the 
components from a sample mixture. ‘ 广-
A gas-liquid chromatographic system essentially consists of a carrier 
^asJan injector port, a column, a detector and a signal analyzer. The carrier 
gas，supplied from a pressurized tank, passes through one or more pressure 
re卯lators which control the flow rate through the apparatus. The sample is 
introduced into a heated chamber either through a silicone rubber septum 
with hypodermic syringe if it is a liquid, or by means of a special sampling 
valve if it is a gas. From here the carrier gas carries the sample components 
through the column where they are separated accordingly and one after the 
other pass through a detector which sends a signal to a recorder or integrator. 
A thermostatted oven is provided for the column, injector and detector. 
1.5«2. Quality control in chromatography 
The analysis of therapeutic agents offers problems that challenge the 
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best analytical techniques and instrumentation available. The measurement 
of low concentration of therapeutic agents and their metabolic or degradative 
products in biological fluids is particularly difficult. The compounds are 
usually found in minute quantities and other compounds present may cause 
I 
analytical interferences. Most measurement techniques are not selective 
enough to measure individual components in a sample mixture. In many 
cases it is necessary to separate the desired compound from the others. Good 
separation reduces selectivity problems and permits the use of maximum 
detector sensitivity with minimum background interferences. The 
development of chromatography (gas-liquid chromatography, GC and high 
performance liquid chromatography, HPLC) has tackled this analytical task 
and its application in the analysis of exogenous substances in biological fluids 
has passed from the realm of the experimental to a routine procedure for 
everyday chemical and clinical analysis. One of the most important features 
in the development of the modern chromatographic techniques is to acquire a 
high-quality of quantitative analysis. Therefore laboratories, either in 
academic or industrial firms, which employed chromatography must take 
appropriate and considerable measures to institute and maintain an adequate 
quality control. In most circumstances, it is of great value to have the ability 
for accurate and rapid quantitative analysis. This ability is usually depending 
on the attention to details given by the chromatographer as to the design of the 
equipment, A careful calibration will certainly minimize the effect of 
unavoidable variations in instrumentation and procedures, and from 
different operators and laboratories. Also, careful attention must be given to 
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all preparation stages of the analysis from sample collection to the final 
calculation of the results. “ 
Quality control of the assay must start long before the sample is 
actually analyzed. In summary, meticulous adherence to properly established 
a 
operational procedures as well as the use of proper controls and internal and 
recovery standards are necessary if any meaningful approach to quantitative 
analysis is to be made. In determining whether a substance should ever be 
examined for quantitation in a particular biological sample, special attention 
must be paid to the following important items. With reasonable attention to 
these details, chromatography with appropriate detection mean乡 can be 
regarded as a routine, highly accurate, sensitive and reproducible analytical 
technique (14). ‘ 
1.5.2.1. Sampling 
Since a non-representative sample is of no value however carefully it 
has been analyzed, no result of a determination can be of any meaning unless 
the material submitted for analysis is a statistically valid, -representative 
sample of what is to be W r n ^ d . This of itself can be a complicated problem 
(15). Any portion of a liquid preparation may be considered as representing 
the whole, provided the liquid has been thoroughly mixed immediately before 
the sample is taken; e.g., an aliquot is sampled from a bulk urine sample is 
thought to be representative. Similarity in the production of pharmaceutical 
products like tablets, there is seldom a reason to believe that any one tablet is 
more representative than any other. In all sample collection procedures it is 
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recommended that several sub-samples are taken from each product or bulk 
sample. These should be processed individually and the results compared. 
Any significant variation of the results will immediately indicate whether or 
not the procedure adopted was satisfactory. 
1.5.2.2. Storage 
Samples may be perishable and subject to decomposition under 
certain experimental conditions (enzymatic or bacterial degradation may 
occur). Sometimes it may be better to extract and then store the analyte in the 
sample rather than to store the whole sample directly. Hence the method and 
stability of the storage are very important. Preliminary tests should be 
performed to investigate the stability of the analyte(s) in different s a m p l e � ‘ 
media such as serum, whole blood and urine under various conditions. In 
general，samples of various types are kept from direct sunlight and stored in a 
freezer at low temperature (usually at -20°C). 
1.5.2.3. Extraction and clean-up procedures 
Homogenation of the sample in a blender, automatic shaker or by 
ultrasonic disintegration may be necessary before extraction. Extraction is an 
important step, especially for biological fluids, to isolate the desired substance 
(and its metabolites) from endogenous materials so that these substances are 
in pure enough form to allow detection and determination without serious 
interference. A large variety of solvents or solvent mixtures are available for 
liquid-liquid extraction. If a biological substance has metabolites, then the 
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extraction efficiency must be high for both the parent compound and its major 
metabolites. The pertinent up-to-date literature should be consulted for 
specific substances. Buffering of the material at one or more pH values may be 
necessary to optimize extraction with organic solvents or resin columns (16). 
For more polar chemicals which can not be extracted by those organic 
solvents or the recovery is not satisfactory, it is also possible to conduct a solid 
phase extraction (using disposable cartridge, switching column or 
pre-column in HPLC). 
Other clean-up procedures involved back extraction (acid or base 
wash)，ultrafiltration, centrifugation and deproteiiiization of plasma followed 
by filtration are the commonly applied methods before the injection of 
analyte(s) into the chromatography. ， 
1.5.2.4. Recovery 
� 
“ Recovery study is often performed by adding recovery standards to the 
samples before extraction. Losses may occur at each step in the operation and 
therefore the overall recovery for the whole procedure is important. In 
general，this should not fall below 70% if the method is considered to be 
satisfactory. It may be desirable to fortify (or spike) samples with a series of 
increasing amounts of the recovery standard to develop a standard recovery 
curve. Ideally, recoveries should be determined at several concentrations over 
the range in which results are being reported. But it is still useful if the 
recoveries are determined either at both the maximum and minimum 
concentrations or at a particular concentration within the calibration curve. 
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These standards can be used to estimate the proportion of analyte actually 
extracted from biological fluids. They may also be added to the samples or to 
known controls run with the analysis. 
1.5.2.5. Internal standards 
For accurate quantitati|^ analysis of liquid samples, internal 
standards are desirable provided they do not create difficulties in sample 
I r 
preparation. An internal standard is a m^ker compound which is added in 
h 
accurately known concentration to the sample. It may be added in the last 
extraction or to the sample before clean-up and extraction. should be a 
substance, not expected to be present in the biological fluid examined, which 
is compatible with the sample and differs in retention time from the 
substances to be measured so that its peak is separate from all the other 
peaks. It provides a scale value for quantitation. Ratios of the analytical peaks 
i 
(either peak heights or peak areas) to that of the internal standard permit 
determination of concentration ratios. As with the recovery standards, a 
standard curve for various internal standards may be prepared in the range 
of the sample concentrations to be determined. Such curves may be 
compensate for non-linear detector response (17). 
1.5.2.6, Derivatization 
Since quantisation requires good peak separation, it may be necessary 
to treat the sample to permit peak separation if several substances in the 
sample with closely related peaks are present or the substance itself is not a 
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good ^^^tan，e.g., poor ultraviolet and fluorescence absorption properties in 
HPLC, or non-volatile enough to be detected by GC. Derivatization may also 
permit separation due to changes in column adsorption and consequent 
changes in retention times for the various substances. The formation of 
f 
derivatives usually increase! the selectivity as well as the sensitivity of the 
method and may allow the measurement of nano- or picogram quantities of 
substances. Some commonly used derivatization techniques are acetylation, 
methylation, chemical reduction and halogenation. For most quantitative 
purposes derivatization is carried out in the final extraction stage prior to 
evaporation. On-column derivatization is used primarily for tentative 
identification by 'peak shifts' rather than for quantisation (18-19). 
1.5.2.7. Calibration standards 
Pure，properly characterized standards at various concentrations 
should be used frequently to calibrate the instrument. A calibration curve is 
necessary to allow accurate quanti|ation as well as to determine the linear 
portion of the operating curve for the detector and the point where detector 
overload begins. ‘ 
1.5.2.8. Controls 
As in every other chemical analysis, known accurate controls 
should be run with the samples to verify that each step in the overall 
procedure is under control. The controls should be in the same concentration 
range as the substances to be measured. 
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1.5.2.9. Quality control in the experimental set up 
The above mentioned preparative stages arid treatments are the 
essential and key elements to establish a good laboratory practice (GLP). In 
order to achieve an accurate and reproducible procedure, ^ j h a v e to not only 
adequately followed these working steps as the routine analysis control, but 
1 
also pay considerable attention in the relevant factors during the course of the 
experimental work, such as precise evaluation of column status and rigid 
maintenace of the injector ports, analytical columns gas flow rates and 
detector. If '^^believe that developed chromatographic methods are 
reliable and sensitive enough in the determination of drugs in biofluids and 
these methods will work equally well if someone uses the methods in other 





A GAS-LIQUID CHROMATOGRAPHIC METHOD FOR STUDYING THE 
EFFECT OF ADRENALINE ON VENOUS PLASMA CONCENTRATIONS OF 
BUPIVACAINE AFTER INTERPLEURAL ADMINISTRATION 
/ 
2,1. INTRODUCTION 
Bupivacaine (Marcain®)，an anilide type of local anaesthestics with 
high potency and long duration of action, is recently used to provide 
post-operative analgesia, via interpleural administration for patients who had 
undergone abdominal, thoracic and renal operation (20). The adverse effects 
of bupivacaine are correlated with its concentrations in the systemic 
circulation and therefore studies of the plasma bupivacaine concentrations 
are often performed to determine the relative risk of systemic toxicity in order 
to make its use safer for patients. 
Several methods for the determination of bupivacaine in plasma have 
？ . . , . 
been reported recently, using GC (21,27)，GC-mass spectrometry (28) or HPLC 
(29-33). In all these methods, bupivacaine was initially isolated from biological 
fluids via solvent extraction before chromatography. A single-step extraction 
with n-hexane (22)，ether (23) or dichloromethane (24) was employed for the 
determination of bupivacaine using capillary gas chromatography. 
Although nowadays capillary GC is established as a routine 
technique, yet the demand for GC methods employing packed columns is still 
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great because packed columns are more economical and they have higher 
sample capacity and are not easily overloaded. Unfortunately, when packed 
'-V columns were used for the determination of bupivacaine, the extraction 
1 ‘ ‘ 
J procedure became more tedious. For instances, the drug was first extracted at 
alkaline pH into diethyl ether, back extracted into IM HCl and finally 
extracted again at an alkaline pH into ether (24); or the plasma in O.IM H2SO4 
was washed with dichloromethane and then made alkaline with ammonium 
buffer followed by dichloromethane extraction (25). Other sample treatment 
such as precipitation of proteins with trichloroacetic acid (26) was also 
required. Chan (27) has developed a single-step extraction with a diethyl ether 
and dichloromethane mixture in the ratio of 3:1. However, the solvent mixture 
could only recover about 70% of bupivacaine from plasma under alkaline ‘， 
�� conditions. We describe here an accurate, rapid and selective/GCMmethod to 
？ \ y 
\ « \一， 
^ ^ ^ determine bupivacaine in human plasma. The procedure was based on a 
single-step extraction of the drug from t^isifie^lasina into n-hexane. 
The position of interpleural analgesia in modern anaesthetic practice 
is under review and many questions remain to be answered (34). The 
successful dose of bupivacaine has varied from 0.5% bupivacaine 8 ml (35) for 
pancreatic cancer pain, to 0.5% bupivacaine 30 ml (36) for cholecystectomy 
and even 0.75% bupivacaine 60 ml has been used in bilateral block (37). As 
with intercostal block (38), interpleural bupivacaine is absorbed rapidly 
(36,39-41) and concern regarding toxic concentrations of bupivacaine led to the 
routine addition of adrenaline (vasoconstrictor) to the local anaesthetic 
solution. However, there have been no controlled studies to confirm that this 
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decreased the absorption of bupivacaine. The' use of adrenaline has been 
criticized because significant cardiovascular side effects have been reported 
when infusions have been used (42). A recent study of interpleural 
bupivacaine, with and without adrenaline, administered a fixed volume and 
dose of local anaesthetic but did not analyse the effect of patients，body weight 
and size on the peak concentrations of bupivacaine (43). The time to peak 
absorption was much later in their adrenaline group compared with the 
previous reports while, in the control group, results were skewed by one 
patient who had valuejthree times that of the other patients. 
The aim of this study was to apply the GC method described here to 
determine the plasma concentrations of bupivacaine after the intrapleural 
administration of a body-weight related dose to patients and to examine the 





2.2,1. Reagent and apparatus 
Bupivacaine and etidocaine (internal standard) hydrochlorides were 
supplied as gift by Astra Pharmaceutical Production AB (Sweden). 
Glass-distilled AnalaR-grade n-hexane and methanol were purchased from 
E. Merck (Darmstadt, FRG). The following glassware was used: 15-ml 
capacity centrifuge tubes with well fitted screw caps containing PTFE linings, 
and 15-ml capacity Quick-fit glass tubes with tapered base of 50 All 
glassware was cleaned and silanized with 3% hexamethyldisilazane (HMDS) 
in chloroform before use to avoid possible loss due to adsorption onto the glass 
wall. 
2.2,2. Gas chromatograph 
• . 0 
A Varian Model 6000 gas chromatograph (Varian Association, P^o 
Alto，CA，USA) equipped with a nitrogen-phosphorus detector was used for 
analysis. The coiled glass column (2m x 2mm i.d.，6mm ‘o.d.) was packed with 
3% WAV SP2250 material on Chromosorb W，80-100 mesh. The column 
temperature was maintained at 240�C and that of the injector a n d c g g ^ ^ r � � 
300�C. The gas flow rates were: nitrogen (carrier gas) at 30 ml/min; air at 175 \ 
V \ 
ml/inin and hydrogen at 4.5 ml/min. The signal was recorded and displayed i 







2«2.3. Standard solutions and recovery test 
Stock solutions containing 1 mg/ml of bupivacaine and etidocaine 
hydrochlorides were prepared separately in methanol and stored at -20°C 
until use. Working standard solutions with concentration of 50 jj,g/ml were 
freshly prepared when required by appropriate dilution of the respective stock 
solutions with methanol. 
Drug plasma standards were prepared by spiking blank control 
plasma (0.5 ml) with appropriate microlitre volumes of working standard 
drug solution to obtain seven calibration, standards with the. following | 
concentrations of bupivacaine: 0.1，0.2，0.5，1.0，1.5，2.0 and 4.0 ^ig/mlf and an 
aliquot of the etidocaine (8 \il) working standard solution was added to each ‘ 
solution as the internal standard. 
To assess the recovery of bupivacaine from plasma samples by the | 
extraction procedure, the drug was added to drug-free plasma at 2.0 [ig/ml \ ，、f 
and assayed with the internal standard (often referred as marker bv some # i 
authors) as described. For comparison, the same concentration of bupivacaine 
and marker were prepared in methanol, evaporated and assayed with the t 




2.2.4. General analytical procedures 




internal standard solution was added, followed by 30 |il of 5M sodium 
i 
hydroxide solution. The extracting organic solvent'(5 ml n-hexane) was 
added. After mixing thoroughly with the aid of an automatic shaker (10 min 
漏 .、， 
I ^ at 30 r.p.mj, the organic extract was separated by centrifugation and then 
evaporated to dryness at 45°C under a gentle stream of nitrogen in a 15-ml 
) 2 / evaporating tube. The residue was redissolved in 10 [il of methanol and 1 ul 
aliquot was injected into the GC for analysis. 卜 c i l f 息、f�’）卜（ 
4 kjQuD jif ；々ferxl ,�,.o一'， ,'”。、：」、 
f • I � 
2.2.5. Data analysis 
I Plasma concentration 少 t a were analysed by a model-independent 
y method (non-compartmental method) based on statistical moment theory 
: T h e principle of non-compartmental method has been briefly outlined 
in Chapter 1. The analysis was carried out using a microcomputer program 
PKCALC (45) and the augmented ESTRIP (45) which determined the 
9 elimination half-life according to the terminal linear position (usually the last 
j • I ••'" 11”. .，"•丨_| •丨丨"丨 
fbur to six points) of the plasma concentration-time curve. The computer 
calculated the linear least squares regression line associated with the data 
subset, ^ r ea under the plasma concentration-time curve (AUG), apparent 
volume of distribution (Vss) and total body clearance (Clp) were^c^puted by 
PKCALC. ^ ^ u j e n t l unpaired t-test was used for comparisons where 
appropriate.|p<0.05 was accepted as statistically significant. 
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2.2.6. Post-operative analgesia procedures for patients 
After approval from the Research Ethics Committee of the Faculty of 
Medicine, The Chinese University of Hong Kong, twelve Chinese patients for 
elective cholecystectomy gave informed consent for this study. Patients were 
not currently taking any medications before the operation and had no history 
of pulmonary disease or allergy to local anaesthetics. No patient admitted to 
regular alcohol intake or smoking history. All patients had normal routine 
haemotology and biochemistry, including liver function teste. 
Anaesthesia was induced with thiopentone 4 mg/kg, fentanyl 2 
mg/kg and atracurium 0.5 mg/kg. An interpleural catheter (16-gauge 
extradural) was inserted at the end of the operation, before antagonism of 
neuromuscular block with neostigmine and atropine. Patients were allocated ‘ 
randomly to receive bupivacaine 2.5 mg/kg with or without the inclusion of 
1:200,000 adrenaline as available commercially from Astra Pharmaceuticals. 
This was injected over 2 min with the patient lying supine. Further 
interpleural injections were not performed. If the patient was still in pain 
7 after 30 min, morphine in 2.5 mg was administered intraveneously until the 
patient was feeling comfortable. Pethidine was given via intramuscular route 
for additional post-operative analgesia when required by patient./Dilration of 
interpleural analgesia was taken as the time from interpleural injection to 
the time that patients first requested pethidine. 
Patients were questioned directly about severity of pain on a simple 
scale from 0 to 3，with 0 representing no pain, 1 slight pain，2 moderate pain 
and 3 severe pain. Assessment of pain score was repeated at 5，10，15，20, 30， 
4 7 
45，60，120，240, and 480 min after bupivacaine was administered and blood 
{p^^ ‘ samples were obtained before and at the above time intervals. The collected 
samples were centrifugated to yield plasma and immediately stored at -20°C 





2.3.1. Choice of extraction medium and internal standsurd 
7 Diethyl ether was commonly used to extract drugs from 
I pharmaceutical preparations and biological fluids. This solvent usually gives 
i i 
reasonable high extraction recovery and is easy to remove at room 
temperature owing, to its high volatility ^rp^^erty. In our) preliminary study, 
however, m^) have found that some endogenous plasma materials were 
extracted with bupivacaine, resulting in interfering peaks overlapping with 
the analytical peaks in gas chromatography when packed columns were 
I used. The suitability as the extraction medium of several organic solvents, 
� ^ 
产.！ if'i . -
？ ；乂4 including chloroform, dichloromethane, dichloroethane, n-hexane and a 
I mixture of ether and dichloromethane (3:l/v:v) was therefore examined (Table ‘ 
2). It was shown that chloroform, diethyl ether and n-hexane gave a good 
recovery (>85%) however, chloroform, like diethyl ether, was not suitable to 
use as an extraction medium because interfering substances were present in 
the extract. Although interfering peaks were not detected in the case of 
dichloroethane, the corresponding recovery was relatively poor (about 60%) 
and therefore n-hexane was chosen as the organic extract in the study. 
Etidocaine was selected as the internal standard because its chemical 
structure and properties such as lipophilicity are similar to those of 




Comparison of various organic solvents for the extraction of bupivacaine. 
Solvent % recovery (n=6) Comment 
Meap 土 SD. 
Chloroform 85.6士 1.9 analytical peaks were interfered 
Dichloromethane 48.6±2.5 same as above 
Diethyl ether 95.8±3.3 same as above 
Ether/CH2Cl2 52.7土4.5 same as above 
• 广 -
Dichloroethane 61.4±2.2 no interferring peaks observed 
•. ^� 
n-Hexane 广 9 1 . 9 ± 2 . 8 � same as above ‘ 
、 、 . — … ― ― 一 一 ） 
Fig 4. Chemical structures of bupivacaine and etidocaine (internal standard). 
~ 、 I \ C3H7 
CH3 C4H9 CH3 C2H5 
Bupivacaine Etidocaine 
sB- … 
2.3.2. Gas chromatograph 
Typical chromatograms of the extracts from blank plasma and from 
plasma of patient during interpleural analgesia obtained using the procedure 
described above are shown in Fig 5. The anlytical peaks of both internal 
standard and drug were well resolved with good symmetry and their retention 
times were 3.0 and 7.2 min respectively. No interfering peaks which masked 
the analytical peaks were observed from the blank and patient's plasma 
samples. 
As illustrated by Table 3，the performance of the GC system was 
considered satisfactory for the assay of bupivacaine. The calibration graph 
(Fig 6) was linear over the range of 0.1 to 4.0 jig/ml. The least-squares linear 
regression line which related the best fit peak height ratios (y) and ‘ 
bupivacaine concentrations in ^g/ml (x) could be described by an equation of y 
=0.996x4-0.0190 and the correlation coefficient was 0.9994. The relative 
standard deviation (RSD) for the determination of bupivacaine varied from 2.0 
to 5.8% within the linear calibration range. The RSD for the day-to-day 
variation using a standard at 2.0 ^g/ml (n=10) was 6.9% and the lowest 
detection limit of the assay was 0.01 ^ig/ml when a 0.5 ml plasma sample was 
used. 
2,3.3. Patients study . h 
There were no deteeted variationlwith age, weight or total anaesthetic 
5 1 
Fig 5. Chromatograms obtained from: (left) blank plasma extract and 
(right) extract of plasma of patient containing 2.8 |ig/ml of 
bupivacaine. Chromatographic conditions were as described above. 
Peaks: l=bupivacaiije and 2=etidocame (internal standard). 
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Calibration and precision of the GC assay (n*=6). 
Concentration Bupivacaine to etidocaine Relative standard 
(|ig/ml) peak-height ratio deviation (R.S.D.) 
(mean 士 S.D.) 
i 
0.1 0.09510.005 5.8 
0.2 0.200±0.008 4.1 
0.5 0.49510.022 4.4 
1.0 1.070±0.050 4.6 . 
1.5 1.485±0.044 3.0 
2.0 2.09310.054 2.6 
4.0 3.972±0.081 2.0 
Batch staiidard# 2.090±0.144 6 9 
at 2 .0 jLig/ml . 
Calibration graph y=0.9957x+0.0190 (r=:0.9994) 
* Number of determinations for each concentration. 
# D二plica’ determinations done daily for five consecutive working days to 
indicate day-to-day variation. 
5 3 
j Fig 6. A calibration curve of peak height ratio (bupivacaine/internal 
i 
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time between the groups (Table Al，p.184). Derived pharmacokinetic variables 
were presented in Table 4. The addition of adrenaline did not alter the Clp, 
Vss and tl/2 of bupivacaine. Peak plasma concentration (Cmax) were 
significantly lower in the adrenaline group (meanlS.D. [range]: 2.57土0.61 
[1.52-3.11] |Lig/ml) and the time to maximum concentration (tmax) was delayed 
(median [range]: 25 [15-30] min) compared with the control group (3.2210.27 
[2.84-3.53] [ig/ml and 15 [10-20] min respectively for Cmax and tmax) (Fig 7). 
The difference in Cmax was still significant when adjusted for the initial dose 
of bupivacaine. 
There were no differences in the pain scores between the two groups 
but the duration of analgesia was variable. Two patients in the control group 
required morphine 5 mg intraveneously at 30 minutes, although one 
subsequently required no more opioid analgesia throughout her hospital stay; 
one patient had excellent analgesia requiring no pethidine, and analgesia 
lasted 1.5, 7.5 and 12.8 min in the remaining three patients. Duration of 
analgesia was more consistent in the adrenaline group (range 3.3-10.8 h, 
median 9.2 h). Two patients in the adrenaline group requested no further 
pethidine after the first dose. 
I 
There were no signs of local anaesthetic toxicity after interpleural 
injection. Two patients complained of transient retrosternal chest discomfort, 
but clinical examination and chest radiographs failed to reveal any 





Pharmacokinetic variables in patients after interpleural injection of 0.5% 
bupivacaine 2.5 mg/kg without (control) and with added adrenaline 1:200,000. 
Total body clearance (CI), apparent volume of distribution at steady state 
(Vss)，elimination half-life (tl/2) and peak concentration (Cmax) are presented 
as meari±S.D. Time to peak concentration (tmax) is given as median (range). 
Pharmacokinetic Control Adrenaline p values 
parameters (n=6) (n=6) 
？ (^AUC^jigmin/ml) 595.3±144.8 592.7±181.9 >0.05 
Clp (ml/minkg) 4.6011.92 4.67±1.83 2 0.05 
Vss (1/kg) 1.70±0.91 2.0510.93 > 0.05 
tl/2 (min) 234.8±42,6 278.8±50.4 > 0.05 
Cmax (^g/ml) 3.22±0.27 2.57±0.61 < 0.05氺 
tmax (min) 15 (10-20) 25 (15-30) < 0.05* 
* Indicates significance exists. 
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Fig 7. Mean±S.D. venous plasma concentration-time profiles after 
interpleural administration of bupivacaine 2.5 mg/kg plain (A) and 
with 1:200,000 adrenaline (•). 
j f k ‘ 
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As mentioned before, packed columns have higher sample capacity 
and are not easily overloaded. The use of packed columns is relat ively cheaper 
compared w i t h capi l lary columns and thus they are found to be suitable for 
economic rout i i |p analysis，part icularly i n those laboratories wh ich are not 
i p t 
well equipped|rhe retent ion t imes of the in terna l standard and bupivacaine 
were 3,0 and 7.2 m i n respectively, which meant that the total runn ing t ime 
was about 10 m i n only. Therefore the assay could be achieved i n a short period 
of t ime (rapid extract ion and chromatographic analysis required 20 and 10 
m i n respectively) and can cope w i t h emergency as wel l as rout ine drug 
moni tor ing or pharmacokinetic study. The relative standard deviation for the 
cal ibrat ion standards was lower than 5.8% and the between batch var ia t ion , 
(inter-assay var iab i l i ty ) was only 6.9%. These results demonstrated the h igh 
accuracy and reproduc ib i l i t y of the described method. The m i m m n 
detection l im i t was around 0.01 ^ g / m l by us ing 0.5 m l plasma wh ich was 
lower than the methods reported by Ber l in et a l (25) and Desch et a l (26) and 
comparable w i t h those using capi l lary chromatography (22-23). A detection 
l i m i t of 0.001 ^g /m l us ing cap i l la ry GC has been reported (24)，with a 
coefficient of var ia t ion of 15% so tha t the obtained value was very dubious. 
A l though greater sensi t iv i ty migh t be possible by increasing the volume of 
plasma used i n the analysis, the proposed method was sensitive enough to 
measure plasma bupivacaine i n surgical patients who were treated w i t h this 
local anaesthetic. The l inear cal ibrat ion range was suff iciently wide (0.1-4.0 
5 8 
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M-g/ml), fur ther indicat ing the high versat i l i ty of the GC method. 
The indiv idual plasma bupivacaine concentrations of each pat ient of 
the two groups were presented i n Tables A2 and A3 (p.185-186). The addit ion of 
adrenaline delayed and decreased peak concentrations of bupivacaine after 
interpleural injection (Fig 7). Absorption of in terpleural bupivacaine appeared 
/ 
to be as rap id as tha t fo l lowing intercostal block (46) w i t h tmax usual ly 
between 10 and 20 m i n after both routes. Peak venous plasma concentrations 
of bupivacaine were h igh compared w i t h other studies. The potent ia l range 
for CNS toxici ty was estimated to be 2-4 [ig/ml (46). Cmax var ied wide ly 
between studies, par t l y because of d i f ferent doses, long in tervals i n blood 
sampling and in terpat ient var iab i l i ty . I n thoracic surgery, there is var iable , 
damage to lung tissue, d i lut ion of local anaesthetic by blood and loss f rom the 
chest drain. Greater concentrations t h a n { Q S l have been reported (37) i n 
adults and peak ar te r ia l concentrations of 4-7 |Lig/ml a f ter i n t e r p l e u r a l 
infusion caused no complication (47). There is continued debate on the opt imal 
dosage，volume and concentrat ion of local anaesthetic, so lu t ion given, 
a l though the m i n i m u m effective dose should be used. A n i m a l studies 
demonstrate tha t the mechanism of i n te rp leu ra l analgesia is mu l t i p l e 
intercostal block (48) and an increased volume cause a more extensive block 
(49). Qual i ty of analgesia after 0.25% and 0.5% bupivacaine may be s imi lar 
(41). 
^ c a l c u l a t e d the in te rp leu ra l dose and volume of bupivacaine 仇 ^ 
solution used from the patient's weight. Weight has been shown to affect the 
5 9 
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pharmacokinetics of local anaesthetics (46), but i t is logical that weight should 
have some effect on Cmax. I f the same dose is given to two patients w i t h 
markedly different body weight, we would expect the peak concentration to be 
comparatively lower i n the heavier patient i f the rate of absorption is similar. 
The drug would distr ibute through a greater volume of distr ibut ion i n the 
heavier patient before achieving a peak concentration. Patient's weights i n 
this study ranged from 46 to s j kg a n d ( ^ d i d not wish to give the same dose to 
the patients at each extreme. Therefore ^ i ^have adopted the dose by weight 
regime. 
Pharmacokinet ic var iables for i n te rp leu ra l bupivacaine w i t h 
adrenaline have been estimated in Caucasian patients (36). Tmax and Vss 
were similar，but Clp and t l /2 were greater (p<0.05) compared w i t h our 
patients. Cmax was not signif icantly different (p=0.12). The patients were 
mucli younger t h a n p a t i e n t s and no weight data were given. Details of 
general anaesthetic technique were not provided and al l patients were given 
bupivacaine 150 mg w i th a greater concentration of adenaline (1:100,000). 
However, ethnic race, age and weight are n o t usual ly signif icant factors 
affecting the pharmacokinetics of local anaesthetics (46). ^ \ a v e no other 
explanation for the differences i n Clp and tl/2 and a further comparative study 
would be required to clarify this. 
Efficacy of analgesia has been variable and this is apparent even i n 
series from proponents of interpleural analgesia. Effective pain rel ief i n 78 of 
81 patients, w i th a mean duration of 10 hours, was reported in i t ia l ly (50)，but 
subsequent papers by the same group were less consistent. There was 
6 0 
unsatisfactory analgesia in two of the 30 patients, w i th a further six requiring 
addit ional analgesia w i th in 4 hours (41). Total postoperative analgesic 
requirement was not decreased by interpleural bupivacaine (51)，although 
reduced morphine usage has been shown in the f i rst 4 hours after operation 
(52). After cholecystectomy, three of 11 patients required addit ional opioid 
analgesia (36) and there was no pain rel ief i n five of 24 patients after 
thoracotomy (43). Inadequate analgesia (40,42,53), pneumothorax and lung 
trauma (54) have been common problems in other studies. 
The addition of adrenaline has been postulated to improve the quality 
of analgesia: by decreasing the absorption of bupivacaine, i t might provide 
increased time for the local anaesthetic to diffuse through the pleura to the 
intercostal nerves. This has not been apparent i n the present study or i n the 
previous work (43). 
I n summary Q described here an accurate, rapid, simple and 
sensitive method for the gas chromatographic determination of bupivacaine 
i n human plasma, using n-hexane as the single-step extraction solvent from 
、- • • -
alkaline medium and an inexpensive packed glass： c o l u m n . a l s o found 
that adrenaline seemed to be useful to avoid toxic effects of bupivacaine during 
the early stage of interpleural analgesia. For those workers and situations 
where in terp leura l analgesia w i t h bupivacaine is found to be a useful 
technique, Q r e c o m m e n d the addit ion of adrenaline 5 収 / m l to delay 
absorption and decrease peak drug concentrations. 
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2.5. CONCLUSION 
A sensitive and selective gas-l iquid chromatographic method for the 
determination of bupivacaine i n human plasma was described. The technique 
was based on a simple extract ion of the drug and the in te rna l standard, 
etidocaine, f rom alkal inized plasma w i t h n-hexane. The gas chromatograph 
was equipped w i th a glass column (2.0m x 2mm) packed w i t h 3% W/W SP 2250 
； 、 on Chromosorb W (80/100 mesh), and a ni trogen detector. The method could 
\ 
、 accurately measured plasma bupivacaine concentrations down to 0.01 p.g/mL 
The day-to-day variation/of：bupivacaine at 2.0 }ig/ml was 6.90% (n=10). The 
K ‘ 
cal ibrat ion graph was l inear over the range of 0.1 to 4.0 \ig/ml and the 
recovery at 2.0 j ig/ml was 91.9士2.8% (n=6). The method was accurate, fast and ‘ 
sensitive, and was suitable for the therapeutic mon i to r ing of pat ients who 
were chron ica l l y t rea ted w i t h bup ivaca ine for p a i n r e l i e f and for 
pharmacokinetic study of the drug. 
I n th is study, bupivacaine, 2.5 mg/kg (0.5 m l /kg of 0.5% solution), 
w i t h or w i thou t adrenal ine 5 ^ig/ml, was admin is te red by i n te rp leu ra l 
injection to 12 patients after elective cholecystectomy. Kinet ic analyses using 
the non-compartmental technique indicated that addi t ion of adrenal ine had 
no effect on total body clearance, apparent volume of d is t r ibut ion at steady 
state or el iminat ion half-l i fe of bupivacaine. However, the mean (± S.D.) peak 
plasma concentrat ion (2.57土0.61 and 3.22±0.27 叫 / m l ， w i t h and w i thou t 
adrenaline respectively) was signif icantly lower i n the adrenaline group and 
6 2 
the mean (土 S.D.) t ime for maximum absorption (24.7±2.7 and 15.0±1.3 m in 
respectively) was longer when adrenaline was co-administered. Analgesia 
was variable and no differences were detected between the two groups. The 
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CHAPTERS 
GAS-LIQUID CHROMATOGRAPHIC DETERMINATION AND 
PHYSICOCHEMICAL STUDIES OF SIX CLINICALLY USED LOCAL 
ANAESTHETICS 
3.1. INTRODUCTION 
Local anaesthetics are mainly used for regional analgesia dur ing 
surgery or for post-operative pain relief. As mentioned i n Chapter 1，these 
clinically useful agents essentially fa l l into two chemical categories: amino 
esters and amino amides. The chemical difference between the heterologous 
group is reflected biologically i n the rate of metabol ism such tha t ester 
compounds are hydrolysed in plasma, whereas amide compounds undergo 
enzymatic degradation i n the l iver. A l terat ion i n the chemical structure 
w i t h i n an homologous groups produces quant i ta t i ve changes i n the 
pharmacological potency and rate of metabolism and the type of metabolites 
formed which w i l l affect systemic toxicity. Therefore the judicious use of 
different local anaesthetics i n hospital practice not only requires the technical 
ski l l i n the performance of the different nerve blocks and a careful evaluation 
of the patients' clinical statues, but also the thorough understanding of their 
pharmacological properties (54). On the other hand, i t is known that the 
act ion of a drug i n the body (pharmacological act iv i t ies) and the 
characteristics of disposit ion are determined to a large extent by i ts 
physicochemical properties. This valuable knowledge w i l l help to interpret 
6 4 
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and possibly predict the behaviour of a drug after administrat ion to the body. 
Although a lot of work has been done on the clinical evaluation (55) and 
- U:丨於•:、也u 
pharmacokinet ics of local anaesthestics ( (46,56-57)，data of t he i r 
physicochemical properties are not plentiful. I n order to bridge this gap, six 
common local anaesthetic agents, having similar chemical s t ruture (Fig 8) 
and clinical usage, teveHbeen： chosen for the present investigat ion. They 
included amethocaine (Am), bupivacaine (Bu), etidocaine (Et), lignocaine (Li), 
mepivacaine (Me) and pri locaine (P r ) . /WeJ found tha t the publ ished 
chromatographic methods (58-60) for measuring either one of the six local 
anaesthestics was not sui tably applicable i n the simultaneous assay. 
Although methods concerning the simultaneous determination of some local 
anaesthetics by GC (61-64) and HPLC (65-66) have been reported recen t l y , (w^ 
are not aware of a chromatographic method for these six local anaesthetics i n 
biological samples i n the literature. To facilitate the s t u d y , ( ^ h a v e developed 
a simple, reliable, and sensitive gas-liquid chromatographic method for the 
simultaneous determination of the six local anaesthetics mentioned above, 
and applied the method to investigate the part i t ion coefficients (K) i n various 
organic/aqueous systems and the buccal absorptions of the drugs. The results 
so obtained together w i th the pKa values were employed to find out i f there is 
an inter-relat ionship among these parameters and a correlat ion w i t h the 
pharmacological activit ies l ike the durat ion of action, onset of action and 
anaesthetic potency. 
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Fig 8. Chemical structures of the six clinically-used local anaesthetics and 
the internal standard, clomipramine. 
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3.2 EXPERIMENTAL 
3.2.1. Reagents and apparatus 
Amethocaine, bupivacaine, clomipramine, etidocaine, l ignocaine, 
mepivacaine and pr i locaine hydrochlor ides were suppl ied by As t ra 
Pharmaceutical Production AB (Sweden). AnalaR-grade dichloromethane, 
chloroform, diethyl ether, n-hexane, methanol, octanol were supplied by E. 
Merck (Darmstadt, F.R.G.), hydrochloric acid and sodium hydroxide by B D H 
(England). Disodium citrate, disodium phosphate, double d is t i l led water, 
glycine and monopotassium phosphate. The fo l lowing glassware and 
instruments were used: 15-ml capacity Quick-f i t evaporating tubes w i t h 
tapered base of 50 pl，15-ml capacity centrifuge tubes w i th wel l - f i t ted screw 
caps l ined w i th Telfon septa (Pyrex, England), automatic t i l t shaker and p H 
meter. A l l glassware was cleaned and silanized w i th 3% HMDS i n chloroform 
before use. 
3.2.2. Gas Chromatograph 
The gas chromatograph was a Va r i an Model 6000 (Var ian 
Association, Palo Al to, CA, USA) equipped w i t h a nitrogen-phosphorus 
detector. The coiled glass column (2m x 2mm i.d.) was packed w i t h 3% W/W 
SP2250 material on Chromosorb W, 80-100 mesh. The column was silanized 
w i th 2 X 50 ml 3% HMDS and conditioned at 320。C overnight before use. The 
analysis was performed w i t h temperature programming such tha t the 
colrnnn temperature was in i t ia l ly kept at 210。C for 5 min, then raised to 280。C 
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for 3 min at the rate of 10。C/min. The injector and detector temperature were 
maintained at 300°C and the gas flow rates were: nitrogen (carrier gas) at 30 
ml/min; air at 175ml/min and hydrogen at 4.5 ml /min. The signal was 
recorded and displayed by a flat-bed recorder (Linseis, Model L6512). 
3.2^. Calibration and general analytical procedures 
I 
A stock solution of drugs containing 1 mg/ml of each of the six 
chemicals i n methanol was prepared. Work ing drug standards were 
prepared by spik ing 0.5 m l of d i luted saliva solut ion w i t h appropriate 
microlitres of the stock solution to obtain seven standards w i t h the following 
concentrations: 0.1，0.2，0.5，1.0，1.5, 2.0 and 4.0 |ig/ml. A quanti ty (1.5 jil) of 0.4 
mg/ml clomipramine HCl as internal standard was added to each standard ‘ 
followed by the addit ion of 30 |li1 of 5M sodium hydroxide solution. The 
a l ka l i ne / samples were extracted w i t h 5 m l n-hexane w i t h the aid of a 
mechanical shaker for 10 min and then centrifuged i n order to separate the 
two layers. The organic extract was dried under a gentle stream of nitrogen at 
450c i n a water bath. The residue was redissolved i n 10 of methanol and an 
1 卞1 aliquot was injected onto the GC for analysis. 
Recovery of the drugs using this procedure was est imated by 
comparing values obtained from spiked samples after extraction w i t h those 
adding i n n-hexane solutions wi thout extraction step (100 percent) at the 
concentration of 2.0 ^ig/ml. Precision was also checked at the concentration of 
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2.0 \ig/ml before and after the analysis everyday. 
3.2.4. The determination ofpKa 
The pKa values were determined using a simple acid-base t i t ra t ion 
method according to Cookson (61). /Six local Anaesthetic hydrochlorides 
equivalent to 5 x l ( H mol were dissolved separately i n 25 m l aliquots of carbon 
dioxide-free disti l led water i n volumetric flasks. Each solution of the drug was 
t i t rated at 25±loC w i th 9.763x10-3 M sodium hydroxide solution (which was 
in i t ia l ly standardized w i th 0.0100 M HCl). The base was added i n successive 
2.5 m l quantities w i th the p H being recorded after each addi t ion. The pKa was 
the value corresponding to the p H at 50% neutralization. A blank t i t ra t ion was 
carried out using 25 m l methanol alone. The above pKa determinat ion for 
each drug was repeated two times using fresh solution. 
3么5. The determination of partition coefficiente 
A mixture of the six local anaesthetics (each containing 0.01 mg/ml) 
i n 5 m l of Sc^rensen phosphate buffer at p H 7.4 was placed i n a glass 
centrifuged tube containing 5 m l of dichloromethane (previously saturated 
witi^ buffer). The tube was tightly screw-capped and shaken for 24 hours, after 
which the tube was centrifuged to ensure complete separation of the two 
phases. Tubes containing the mixture of the six drugs in the same buffer were 
stored at 25。C and -20。C as control samples. The in i t ia l (C.) and final (Cp) 
concentrations of the drugs in the buffer were determined by tak ing 0.5-mI 
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al iquots of the aqueous layers i n the control and wo rk i ng samples 
respectively, and using the procedures described under the Analyt ical Section 
3.2.3. The values of K were then calculated from the equation: 
K = (CI - CFVCF [15] 
The whole procedure was repeated by replacing dichloromethane i n t u r n w i th 
chloroform, d ie thy l ether, n-hexane and octanol. Each analysis was 
performed in a set of triplicate. 
3.2.6, The buccal absorption tests (BA.T.) . + 釣 成 liy^oJij^d .bj 
These were carr ied out according to I Chan (69). Ora l solutions 
containing the drugs alone or a m ix tu re of the six, were prepared by 
dissolving the drugs i n disti l led water. Each solution contained 2.0 mg of drug 
per ml. An aliquot of the drug solution (0.5 ml) was di luted w i t h 24.5 m l of the 
appropriate buffer solution (pH 3.0-9.0) i n a 25 m l volumetric flask. S(^rensen 
buffer of p H 3.0 to 5.0 were prepared from disodium citrate and hydrochloric 
acid ( IM) ; pH 5.0 to 8.0 from disodium and monopotassium phosphates; p H 
8.0 to 9.0 from glycine and sodium hydroxide ( IM) . The resultant solution was 
then placed i n the subjects mouth and circulated about 300 times around the 
mouth by the movement of cheeks and the tongue dur ing a 6 minutes period, 
after which the solution was expelled into a clean beaker and the mouth was 
rinsed w i th 10 ml of disti l led water for 10 seconds. The rinse was expelled into 
a second beaker. The volume and pH of the expelled solution in the f i rst beaker 
70 
were measured immediate ly . The solutions i n both beakers were then 
combined, adjusted to 250 m l w i th dist i l led water and analyzed for drugs 
using a l - m l aliquot (following the procedures i n the Analyt ical Section 3.2.3.). 
Dur ing the wai t ing t ime between successive tests (30 min), the mouth was 
rinsed w i t h three changes of dist i l led water. A blank solution representing 
the in i t ia l concentration of the drugs before B.A.T. was prepared by tak ing 0.5 
m l of the drugs solution (2.0 mg/ml) and adjust ing to 250 m l w i t h dist i l led 
water and l - m l aliquot was used for analysis, again fol lowing the procedures 
i n the Analyt ical Section 3.2.3. The absorption of the six drugs i n the B.A.T. 
was taken to be the difference between the amount introduced and the amount 
remaining i n the expelled solution. Two healthy male volunteers who had 
fasted and cleaned their buccal cavities before the experiment took part i n this 
buccal absorption test. 
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3.3. RESULTS 
3.3.1. Gas chromatograph 
Two types of GC columns (3% WAV 0V17 and 3% WAV OVIOI) were 
in i t ia l ly tested but the six drugs were not successfully resolved. Dur ing the 
course of development of the GC method for the determination of bupivacaine 
i n plasma (Chapter 2)，various local anaesthetics were screened as possible 
internal standard. I t was found that lignocaine, prilocaine and mepivacaine 
could be assayed by the same GC method using a SP2250 column. Thus the 
simultaneous determination assay of the six local anaesthetics i n this study 
was developed based on the established bupivacaine method, which required n-
hexane as the extracting medium. 
As shown in Fig 9，the analytical peaks of Pr, Li , Et, Me, Am, Bu and , 
clomipramine were well resolved w i th good symmetry and good peak shapes. 
The retention times were 4.0, 4.6，6.6, 8.7，10.5，11.1 and 12.7 m in respectively. 
The calibration graphs (Table 5) covering the concentration range of 0.1-4.0 
)ig/ml were l inear for all six compounds w i th acceptable coefficients of l inear 
regression between 0.9968 and 0.9999. The between-day coefficients of variat ion 
of the six local anaesthetics at 2.0 ^ig/ml were satisfactory (ranging from 2.2 to 
7.1%) which indicated that the assay was reliable and reproduci^ble and their 
：‘？ 
recoveries were reasonably high (ranging from 76 to 95%). 
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Fig 9. Gas chromatogram of the six local anaesthetics under the optimized 
conditions. 1，prilocaine (0.8 jig/ml); 2, lignocaine (0.8 |Lig/ml); 3， 
etidocaine (0.7 |Lig/ml); 4, mepivacaine (0.7 |ig/ml); 5，amethocaine (0.6 
1 
|Lig/ml); 6，bupivacaine (0.7 )Lig/ml) and 7, clomipramine (internal 
standard, 0.6 |ig/ml). 
1 6 














UU I I 
<厂〜-、. ,•/ ； / 
• 里 • 里 I 




Calibration (mean peak height ratio土S.D.) and precision of the GC assay 
(n=6). 
Cone. A m B u Et L i Me Pr 
( l ig/ml) 
0.1 0.20110.018 0 . 2 5 0 1 0 . 0 2 5 0.203±0.013 0.154±0.013 0.174±0.011 0.205±0.015 
0 . 2 0.40Q±0.018 0 . 4 7 7 ± 0 . 0 3 9 0 . 4 1 5 ± 0 . 0 2 2 0 . 3 5 4 ± 0 . 0 1 0 0 . 3 9 1 1 0 . 0 3 9 0 . 4 4 3 土 0 . 0 2 4 
0 . 5 1 . 0 3 2 1 0 . 0 7 6 1 . 1 7 8 ± 0 . 0 8 6 1 . 1 1 6 ± 0 . 0 7 6 0 . 8 8 1 土 0 . 0 7 3 0 . 9 0 5 ± 0 . 0 2 7 1 . 1 7 7 ± 0 . 0 7 3 
1 . 0 2 . 0 8 5 ± 0 . 1 8 3 2 . 3 0 0 ± 0 . 1 1 0 2 . 1 5 2 土 0 . 1 4 5 . 1 . 8 1 6 ± 0 . 0 9 5 1 . 8 1 6 ± 0 . 1 6 9 2 . 2 8 8 ± 0 . 0 7 9 
1.5 2.872±0.171 3.270±0.145 3.078±0.187 2.764±0.095 2 . 8 0 4 1 0 . 2 0 6 3.260±0.103 
2.0 4.178±0.184 4.406±0.194 4.222±0.260 3.648+0.193 3.766±0.130 4.848±0.118 
4.0 8.018±0.193 8.554±0.141 8.526±0.339 7.441±0.144 7 . 5 7 2 ± 0 . 2 3 4 8.346±0.147 
Batch 
Std 4.206土0.093 4.398土0.096 4.312±0.154 3.677±0.261 3.75110.224 4 86010 134 
at 2.0 ！ig/ml — ’ 
r 0.9995 0.9998 0.9998 0.9999 0.9999 0.9968 
Recovery 83.113.6 94.6±1.4 92.4±2.3 77.5±2.1 80.4±2.0 75 7±2 6 
(n=3) 、.. . 一 . 
、、 
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3.3.2, The pKa values 
Using the acid-base t i t ra t ion method described, the mean pKa (土 
S.D.) values (n=3) of amethocaine, bupivacaine, etidocaine, l ignocaine, 
mepivecaine and prilocaine were 8.45±0.24，8.05±0.13，7.60±0.18，7.95±0.09， 
7.75±0.11 and 7.90土0.15 respectively, indicating that al l drugs are weak bases. 
I n the t i t rat ions of amethocaine, bupivacaine and etidocaine hydrochlorides, 
( 
the free base was precipi tated and i t was necessary to use methanol to 
redissolve the precipitates otherwise the p H of the result ing solution was not 
stable and might affect the accuracy of the results. The addit ion of methanol 
did not interfere w i th the t i t rat ion results since the blank t i t ra t ion showed that 
aqueous methanolic solution did not cause deviation'to the p H values. 
3«3.3. The lipid-buJffer partition coefficients and buccal absorption tests 
The mean par t i t i on coefficients of the six compounds i n organic 
solvent-buffer (pH 7.4) systems var ied substanst ial ly (Table 6). However, 
amethocaine was almost completely t ranferred into dichloromethane and 
octanol w i t h K approaching i n f i n i t y . S im i la r observat ion occurred i n 
bupivacaine, etidocaine and lignocaine w i t h dichloromethane-buffer system. 
However, the part i t ion coefficients of Am, Bu and Et were generally greater 
than those of Li , Me and Pr. Hence i t could be concluded that the relative l ip id 
solubil i ty of the former group was higher than the lat ter group. The samples 
at -20°C served as 100% of the start ing materials while samples at 25。C were 
controls to check i f the drug would be decomposed i n buf fer at room 
temperature. Analysis of buffer solutions i n the control tubes stored at-20°C 
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Table 6. 
Summary of physicochemical data of the six local anaesthetics. 
Parameter A m B u Et L i Me Pr 
Onset of Action* slow medium fast fast fast fast 
/ 
Durat ion (min)* 180-600 180-600 180-600 90-200 120-240 120- 240 
Relative potency* 4 4 3 1 1 1 
pKa 8.45 8.05 7.60 7.95 7.75 7.90 
% of buccal abs. 33.3 36.8 43.2 26,6 21.6 23.4 
a t p H 7.4 
Part i t ion Coefficient (K) 
(i) CH2Cl2/buffer oo oo oo oo 208 74.5 
(ii) ether/buffer 363 236 353 59.3 15.4 27.7 
( i i i )hexane/buffer 0.64 15.4 56.2 2.08 0.47 0.87 
(iv) octanol/buffer oo 356 492 50.0 22.8 19.1 
* In format ion obtained f rom the l i terature, 
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and 25°C indicated negligible decomposition or loss of the drug dur ing the 
experiment (Table A7, p.190). 
The effect of buffer pH on the buccal absorption of the six LA i n the 
two male subjects was shown i n Table A8. There was l i t t l e intersubject 
var iat ion i n the buccal absorption of al l these compounds, representing the 
biological structure of the buccal membrane was almost the same w i t h 
i 
respect to different individual. The volume of the buffer solution (Table A8) 
was increased (especially at low pH) dur ing the 6 minutes mouth wash period 
which was due to the st imulation of saliva secretion, but the change i n the p H 
of the expelled was not very obvious. I t could be seen that the percentage of 
drug absorbed increased as the buffer p H increased. The graphs (Fig 10) of the 
percentage absorbed of drug against buffer p H take the form of a S-shape w i th 
a slow increase in i t ia l ly , followed by a phase of rapid absorption, as shown by 
the steep slope. The percentage of buccal absorption of the six compounds at 
p H 7.4 ranged from 21.6 to 43.2%. Whether determined alone or i n a mixture 
of six, the results of buccal absorption were similar imply ing no saturat ion of 
buccal absorption dur ing successive experiments or the wa i t i ng t ime was 
long enough for removing the remaining drug inside the buccal cavity. 
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Fig 10. The effect of pH on the buccal absorption o f : (a) amethocaine; (b) 
bupivacaine; (c) etidacaine; (d) lignocaine; (e) mepivacaine and (f) 
prilocaine in volunteers I (•), II (•) and theoretical case (*)• 
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3.4. DISCUSSION 
Although ^ e ^ id not perform a prel iminary test for optimum mouth 
contact time for the buccal absorption of the local anaesthetics, Q recogn i zed 
that the contact time can not exceed 10 minutes. For a longer contact time, the 
volume of saliva secreted into the buffer solution would be increased so that i t 
might overload the capacity of the buccal cavity and disturbed the 
investigation. The previously reported opt imum time for pethidine (69)， 
phenoperidine (70) and ethmozine (71) were around 6 minutes and therefore 
g expected that this durat ion would also be suitable for the six local 
anaesthetics drugs under study. Since more sensitive and better qual i ty p H 
meter was not available in our laboratory, t i t ra t ion w i th concentration less 
than 5x10-4 mol of the drugs could not be carried out. The procedure for the 
determination o ^ values i n our study was not ideal (68) but i t showed 
similar results [compared wi th the l i terature values. f t / 
The present study has provided some i n W a t i o n on the 
Physicochemical properties of the six LA. A knowledge of these parameters 
was essential for interpret ing the absorption and disposition -of the drugs i n 
the body. As mentioned in Chapter 1，the absorption ofdn igs from the site of 
application into the blood stream and its distr ibut ion, excretion and renal 
tubular reabsorption are largely achieved by passive diffusion of nonionized 
molecules a^oss the biological cell membranes. Although some workers (72) 
have usedjammal model w i th the aid of buccal application cells to investigate 
this passive diffusion, we believed that B.A.T. was the best in _ model to 
i l lustrate passive drug transfer through these biological membranes, 
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The S-shape of the buccal absorption-pH curves for the six local 
anaesthetics suggested that the drugs belong to Class Four of Beckett's 
grouping (73) The percentages of the drug absorbed in this category were a 
function of buffer pH. The pKa values of the six local anaesthetics showed that 
they were weak bases which were almost i n the ionized form i n acidic 
condition and therefore the rate of difFussion through the buccal membrane 
i 
was slow. The opposite was observed when the drug was in alkaline medium; 
the percentage of the nonionized form increased and hence the rate of 
absorption increased unt i l i t reached a saturated level. The behaviour of the 
ionization of abase was governed by the Henderson-Has selbalch Equation (Eq. 
8，Chapter 1). . ” 
The theoretical percentages of absorption of the six LA at different 
buffer p H were calculated by assuming that only the l ip id soluble and 
nonionized form penetrated the buccal mucosa and the nonionized form was 
absorbed completely. Using the following equation, 
Theoretical % absorption = . C^___ x 100 . . . . [16] 
Ci + C T " . ' " " . . 
'4 
where C i and C2 were the concentrations of drug i n the blood and the buccal 
cavity (buffer solution) respectively. When the theoretical % absorption plotted 
against buffer pH was compared wi th the experimental results (Fig 10)，it was 
found that the experimental absorption curves followed the same pattern and 
shape as the theoretical one, except that the acutal % absorption on the 
experimental curves were lower at pH 7.4. The discrepancy between the two 
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curves might be due to the relatively low permeabil ity of the nonionized form 
across the buccal membranes, which was not accounted for i n the equation 
used for calculating the theoretical % absorption. Another consideration 
might be that there was an equi l ibr ium of the nonionized form across the 
buccal membrane. Comparing the % ionized (Table A7) and the B.A.T. 
graphs above pH 7.0, i t was found that although a great proport ion of the 
/ 
drugs were in non ionized form, not al l of them were absorbed. This might be 
J 
due to the part i t ion characteristics of the drug between the l ip id and aqueous 
phase, hence the buccal absorption was l imi ted by l ipophil ic character of the 
compound. 
The results of part i t ion coefficients study showed that among t h e four 
organic solvents, n-hexane and S^rensen buffer was the best system to 
i l lustrate the complicated structure of biological membrane. A relat ively good 
correlation (r=0.991) was observed (Fig 11) between the percentage of buccal 
absorption at pH 7.4 and the logari thms of K i n n-hexane-buffer system. 
Hence this system could be used as an in vitro indicator for the abi l i ty of the 
six local anaesthetics to penetrate the in vivo biological barriers. 
From the present results and in fo rmat ion obtained f rom the 
l i terature (54,74) (Table 6)，inter-relationship could be found between the onset 
of action and the pKa values. Agents w i th lower pKa values such as Et, L i , Me 
and Pr tend to possess a more rapid onset of action than agents such as A m 
and Bu. The reason was that the ionization of lower pKa compounds was 
greater than that of higher pKa compounds at physiological pH. For instance, 
8 3 
Fig 11. A plot of the mean percentage buccal absorption of the six local 
anaesthetics at pH 7.4 against their log K values in (•) ether, (•) n-
hexane and (•) octanol-S(t)reiisen buffer systems. 
？ 
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at a pH of 7.4, approximately 76% of prilocaine exists i n the cationic form 
•h-
whereas over 90% of amethocaine is present i n the cationic form. The 
durat ion of pharmacological effect was shown广dependent on the par t i t i on 
coefficient of the drug molecule; the higher the K values, the longer the 
I 
, du ra t ion of action. But i t was believed that drug w i th relatively h igh K value 
I 
1 would penetrate i n and out of the membrane readi ly which, resul ted i n a 
1 I ‘ 
拿 shorter durat ion and therefore the resul t obtained was contrary to the 
I 
i expected one. This could be explained by the fact tha t the dura t ion of 
anaesthetic activi ty was relied on the degree of binding to the membrane and 
plasma proteins. Add i t ion of larger a lky l ^ubst i tuents to the amine or 
aromatic end of a compound w i l l normal ly increase the p ro te in -b ind ing 
abi l i ty. For example, the prote in b ind ing of bupivacaine and etidocaine 
-J 
exceeds 90%, whereas their homologues, i.e. mepivacaine and lignocaine are 
only 65 and 75% protein bound respectively. I n terms of anaesthetic duration, 
Bu and Et are 2 to 3 times longer acting than Me and Li . More correctly, i t 
could be said that the durat ion of the local anaesthetics was not corresponding 
to its K value but to i ts protein binding aff ini ty. The result also showed that 
changes i n the l ip id solubil i ty of a local anaesthetic would alter i ts in t r ins ic 
anaesthetic potency. As seen i n the amide series, the addit ion of a buty l group 
to the amine end of Me lead to the formation of Bu, which is much more l ip id 
soluble and potent than Me. I t was generally accepted that the excretion of a 
var iety of basic drugs was dependent on the p H of the ur ine and the i r 
physicochemical propert ies (75). This could be explained i n terms of 
increasing reabsorption of the unionized l ip id soluble form of the drug as the 
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pH of the urine becomes more alkaline (76-77). The normal pH of urine was 
around 6.5 and therefore a considerable amount of the local anaesthetics 
would be reabsorbed f rom the glomerular f i l t ra te according to the data 
obtained from the B.A.T. I f the urine was made acidic, the percentages of the 
six local anaesthetics el iminated unchanged would increase since less of the 
nonionized f ract ion would be available for reabsorption. Conversely, at 
i 
alkaline ur inary pH, reabsorption via the renal tubules would increase and 
less drug would be eliminated unchanged in the urine. Therefore adjustment 
of ur inary pH to acidic conditions may be used as a method of removing local 
anaesthetics from the body i n cases of acute poisoning. 
I t can be concluded that the physicochemical properties of local 
anaesthetics play a very important part i n determing their absorption and 
el imination i n the body. I t is therefore necessary to consider these factors 
when one considers the clinical pharmacokinetics of local anaesthetics. 
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3.5. CONCLUSION 
A gas-l iquid chromatographic method was developed for the 
simultaneous assay of six local anaesthetics, inc lud ing amethocaine, 
bupivacaine, etidocaine, lignocaine, mepivacaine and prilocaine i n biological 
samples. These drugs and in terna l standard (clomipramine) i n basif ied 
samples were extracted into 5 ml n-hexane and the extract was analysed by a 
i 
temperature programming method (the column temperature was kept at 
210°C for 5 min, then raised to 280。C at the rate of 10。C/min) using a 3% WAV 
SP2250 glass column (2m x 2mm i.d.) connected to a ni trogen sensitive 
detector. The injector and detector temperature were maintained at 300°C. 
The pKa values, part i t ion coefficients (K) and the buccal absorptions of the six 
compounds were also determined i n the study. The results showed that the 
onset of action and the duration could be shown dependent on the pKa values 
and part i t ion coefficients respectively. A relatively good correlation (r=0.991) 
was observed between the percentage of buccal absorption at pH 7,4 and the 
logarithms of K in n-hexane-S(^rensen buffer system and hence the more l ip id 
soluble the local anaesthetic, the greater the buccal absorption. The buccal 
absorption test supplemented by the n-hexane-buffer part i t ion coefficient could 
be used as indicator for the abi l i ty of the anaesthetic molecule to penetrate 
biological barr iers. The l i p id penetrat ion of the drugs and thus the i r 
pharmacological action is also influenced by the pKa values of the compound. 
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CHAPTER 4 
IMPROVED GAS-LIQUID CHROMATOGRAPHIC METHOD FOR THE 
I i O 
QUANTIjtATION OF PLASMA PETHJDJNE AND NORPETHIDINE 
4.1. INTRODUCTION 
Pethidine ,(PTH or meperidine), was f i rst introduced as a potent 
analgesic in 1939 by Eisleb and Schaumann (78). I t achieves wide therapeutic 
use in hospital practice (78-79) part icular ly i n the control of post-operative 
pain and in the relief of many types of moderate to severe pains. Today, over 
fifty years after its introduction, pethidine is st i l l one of the most commonly 
used narcotic anagelsic drugs. When pethidine is administered into the body, 
it is extensively metabolized in the liver, primarily by N-demethylation and ， ， 
hydrolysis. The dnig and its metabolites are largely excreted in the urine. The 
amount of the dose excreted unchanged varies w i th urine pH, from 0.6 to 27% 
and the recovery of metabolites is also influenced by the ur inary p H (80). 
Major metabolites include norpethidine (NPTH), pethidinic acid and i ts 
conjugate (glucouronide)，norpethidinic acid and its conjugate. Other minor 
他 l ^h as pethidine ‘ N ‘ d e (81) and N-hydroxynorpetMdine (82) 
w e ^ l s o身o l a t e d (Fig 12). Although most of the metabolites are considered to 
be inactive, ^peth id ine， the only metabolite that can be found in the plasma 
is estimated to possess hal f the analgesic potency of pethidine and is tw.ce as 
potent as a convulsive compared to the parent drug. Hence, measurement of 
the drug and its N-demethylated metabolite，膽pethidine in the plasma of 
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Fig 12. Biotransformation of pethidine. 
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pat ients is of importance i n unders tanding the disposi t ion of the 
drug/metabolite i n the body, and this would allow the development of 
strategies for avoiding the adverse effects associated w i th the clinical use of 
pethidine. 
Different types of analytical methods have been reported to determine 
pethidine in biof luids. Classical spectrophotometic methods such as 
t 
colorimetry (83-85) and flourometry (86) were considered to be insensitive and 
non-selective. Carbon-14 radiolabelling technique which was expensive, was 
claimed to have l imited use i n man (87). Ion-selective electrodes (88) was 
reported in pharmaceutical preparations but was not applicable in biological 
samples. Recently, chromatographic methods have been applied successfully 
in the determination of nanogram amounts of PTH and NPTH i n plasma. 
These methods involve high performance l iqu id chromatography w i t h UV 
detection (89-90), and GC coupled w i t h mass spectrometer (91-95), flame 
ionization detector (FID) (96-99), electron capture detector (ECD) (100-101) and 
nitrogen-phosphorus detector (NDP) (102). The polarity of NPTH is relatively 
high and therefore the chromatographic property of this compound is poor. I n 
the GC methods described above heptafluorobutyric anhydride (98,102)， 
trifluoroacetic anhydride (99), and trichloroethyl chloroformate (100-101) have 
been employed as the der ivat izat ion agents i n order to enhance the 
detectability of NPTH. These procedures were time-consuming and not easy to 
perform. The other GC method described by Chan et al (103)，which did not 
include a derivatization step, was simple and satisfactory, but i t required 
large sample size (5 ml) and four etheral extraction steps for complete 
9 0 
drug/metabolite recovery. We described here a simple, sensitive and accurate 
GC method for the measurement of plasma concentrations of PTH and NPTH 
• . 
simultaneously i n surgical pat ients who have been given a single 





4.2,1 Materials and apparutus 
Pethidine hydrochloride was obtained f rom May & Baker L td . 
(Dagenham, U .K . )，norpe th id ine hydrochloride f rom Ster l ing Win th rop 
Research Inst i tu te (New York, USA) and chlorpheniramine hydrochloride 
f rom Astra Pharmaceutical Production AB (Sweden). Glass-dist i l led AR 
I 
grade n-hexane and methanol were purchased f rom Merck (Darmstadt, 
FRG). The fol lowing glassware was used: 15-ml capacity centrifuge tubes 
w i th well fitted screw caps containing PTEE linings, 15-ml capacity Quick-fi t 
glass tubes w i t h tapered base of 50 |j.l. A l l glassware was cleaned and 
silanized w i th 3% HMDS i n chloroform before use. The gas chromatograph 
was a Var ian Model 6000 equipped w i t h a nitrogen-phosphoros detector. A ‘ 
coiled glass column (2m x 2mm i.d., 6mm o.d.) was packed w i t h 3% WAV 
SP2250 on Chromosorb W, 80-100 mesh. The column was silanized w i t h 2 x 5 0 
III 3% HMDS and conditioned at 300。C overnight before use. The column 
temperature was maintained at 230。C and that of the. detector and injector 
. 、 » 
was at 260。C. The signal w^s recorded' and displayed by a flat>bed recorder 
(Linseis, Model L6512) The gas flow rates were: nitrogen (carrier gas) at 30 
ml/min，air at 175 ml /min and hydrogen at 4.5 ml/min. 
4.2.2. General assay procedure 
Plasma samples (1 ml) ^ pipetted into a 15-ml centrifuge tubes 
w i t h screw cap. Six microl i tres of a methanolic solut ion of 0.025 mg/ml 
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chlorpheniramine hydrochloride were added as the in te rna l standard, 
followed by 50 of 2M sodium hydroxide solution. The alkal ine plasma 
samples were extracted wi th 5 ml n-hexane using a mechanical shaker for 15 
minutes. Af ter centrifugation, the organic layers were transferred into 
evaporation tubes and evaporated to dryness i n a water bath under a gentle 
stream of nitrogen at 45。C. The residues were redissolved i n 10 | i l of 
methanol, and 2 \il aliquots were injected into the gas chromatograph. The 
concentrations of PTH and NPTH were determined by using, respectively, 
drug/marker, or metabolite/marker ‘ peak height ratios . f rom cal ibrat ion 
graphs. , 
4.2.3. Pharmacokmetics of pethidine in patients 
I n this study, witj j i the approval of the local Research Ethical 
Committee, five Chinese patients ( sex, 4M/1F; age, 38.418.4 yrs; weight, 
59.9±11.3 kg) who underwent either hernia repair or excision exostosis, and 
subsequently received single dose of pethidine (1 mg/kg) intramuscularly. The 
patients were ini t ial ly anaesthetized by 200 mg of thiopentone and a mixture of 
dinitrogen oxide, oxygen and halothane. The blood samples (5ml) were taken 
at 0，0.25, 0.5，0.75，1，2，3，4, 6，8，12 and 24 hours after dose, and plasma was 
separated as soon as possible and stored in the freezer at -20。C before analysis. 
Pharmacok inet ic parameters were obta ined f r om p lasma 
concentration-time points according to standard formulae (10). The areas 
under plasma concentrations plotted against t ime (AUG) were calculated 
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using the trapezoidal rule. The plasma clearance (Clp) was determined 
according to Eq. 2 (Chapter 1)，where Dose was the in t ramuscu lar ly 
administered pethidine dose and AUC was the area under the plasma 
concentration-time curve from zero to infinit ive. 
Clp = Dose [2] 
‘ AUC 
The f irst order rate constants for the decline of plasma concentration 
after administrat ion were obtained by l inear least square regression on 
log(plasma concentration) against t ime. The steady state volume of 
distribution (Vss) was calculated according to Eq. 5 (Chapter 1). 
Vss = Clp X MRT . . . . . [5] ‘ 
Al l these data were computed using the programme PKCALC (45). 
4.2.4 Calibration, recovery and precision 
Pethidine and norpethidine were dissolved in methanol to make 0.1， 
0.01 and 0.001 mg/ml stock solutions. These.solutions were subsequently used 
to spike drug-free plasma in appropriate volumes to obtain six standards w i th 
the following concentrations of PTH and NPTH: 10，20，50，100，250 and 500 
ng/ml. A methanolic solution (6 ^il) of 0.025 mg/ml chlorpheniramine 
hydrochloride was added to each sample as internal standard, 
Recovery of PTH and NPTH from plasma using this procedure was 
estimated by comparing values obtained from spike plasma w i th standard 
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n-hexane solutions (100 percent). Precision was determined by spiking two 
replicate samples of PTH and NPTH in blank plasma at the concentration of 
100 ng/ml before and after the analysis of patients' samples everyday. The 
results obtained by the present assay were paral lel checked and compared 




4么1 Choice of extraction solvent 
Al though recoveries were sat isfactory (>75%) when us ing 
dichloromethane, diethylether and their 3:1 v/v mixture (Table 7)，it was found 
that peaks due to some extrajctable endogeneous plasma components appeared 
at about 3 and 15 minutes i n the chromatogram. A further puri f icat ion step 
< 
such as back extract ion was required i n order to obta in a bet ter 
chromatogram. Otherwise ttvfese interfering peaks could mask the analytical 
peak of NPTH as well as lengthen the running time of the whole procedure. 
We also observed that these solvents produced a strong solvent f ront signal, 
resu l t ing i n unsteady baseline which could affect the peak height 
measurements and reduce the accuracy of the results. Other common 
solvents such as cyclohexane, ethylacetate and n-heptane were suggested not 
^ to be good enough for extracting the drugs (104) i n plasma sample. Based on 
f f\ 
the sup^b performance of n-hexane in the bupivacaine study, i t was chosen 
as the extracting medium in this experiment even though the recovery of 
NPTH was slightly lower (NPTH=65%). Q avoided using chloroform because 
this solvent, would react w i t h NPTH chemically to form an extract ion 
artefact, norpethidine ethylcarbamate according to the study of Siek et a l (105). 
A greater than 90% conversion of NPTH to norpethidine ethylcarbamate was 
reported in his study. 
4.3^ Choice of GC system 




Comparison of recovery of various organic solvents on PTH and NPTHL 
^ Recovery (Mean 土 S.D.) n=5 
Solvent PTH NPTH Comments 
Dichloromethane 82.3±3.6 74.8士2.2 The ana ly t i ca l peaks were 
m a s k e d by e n d o g e n o u s 
, substances 
Diethyl ether 92.6±2.5 88.6土4.1 Same as above 
Diethylether/Dichlo- 78.6土1.9 80.4±3.3 Same as above 
romethane (v/v=3:l) 
n-Hexane 85.8土2.8 64.9±3.4 No i n t e r f e r i n g peak was 
detected 
therefore i t shows a very poor resolut ion i n most of the GC columns. As 
discussed before, almost a l l the GC determinat ions of N P T H requi red 
derivatization. The pr imary purpose of this sample treatment was to increase 
the sensi t iv i ty of the determinat ion and improve the peak shape i n the 
chromatogram by converting the polar amine group to less polar amide group 
or i ts halo-substituted derivatives. The choice of column was very impor tant 
because a suitable column not only reduces the peak ta i l ing effect of NPTH, 
but also eliminates the tiresome derivatization treatment. Based on the l ike 
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dissolves l ike principle，(We)expected that a less polar GC column might elute 
the NPTH peak well. In order to search for this type of column, we have tested 
a number of GC systems. As shown i n Table 8，the 2% WAV and 10% WAV 
Carbowax columns were not suitable for the analysis since NPTH appeared to 
be adhered to the column materials and was not detected. The 3% W/W OV 
101 and 3% W/W SE 30 columns gave both ta i l ing and broad PTH and N P T H 
i 
peaks whereas the 3% WAV OV 17 and 3% WAV OV 25 produced good and 
symmetrical PTH peak but poor N P T H peak. I t impl ied that these systems 
were also not adequate for good resolut ion w i thou t the der iva t iza t ion 
procedure. I t was found that both the 8% W/W Carbowax 20M+2%KOH and 
3% WAV SP2250 columns could give good and sharp peaks of PTH and NPTH. 
I n fact, the former has been described (103) to determine PTH, N P T H and 
pethidine-oxide i n biological f luids previously using benzphetamine as the 
internal standard. As the retention times for both PTH and N P T H are shorter 
using the 3% WAV SP 2250 column, i t was chosen for the present assay. We 
have also accessed the capabil i ty of the two suitable analyt ical columns and 
showed that there was one advantage of the SP 2250 over the Carbowax 20M 
column. The former was stable up to a max imum temperature of 350°C 
whereas the lat ter could only tolerate up to 230°C. The operating temperature 
of the reference method using Carbowax for analysis was around 200。C which 
rendered decomposition of the stat ionary phase as we observed tha t the 
Carbowax mater ia ls mus t be pa r t l y or who l ly replaced a f te r us ing 
continuously for about two weeks time. On the other hand, the performance of 
the SP 2250 column was st i l l perfectly applicable for several months, imply ing 
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Tables. 
Comparison of the performance of various types of GC systems for the 
determination of PTH and NPTBL 
i 
System Temp. Retention Time Comments on peak shape 
(°C) (min) 
< — — — « « _ _ _ _ _ ___ ___ 
PTH NPTH 
1. 2% Carbowax 200 4.4 … G o o d PTH, NPTH not resolved 
2. 10% Carbowax 200 11,0 - Same as above 
3. 3% 〇V 17 200 5.6 7.45 Good PTH, broad and ta i l ing NPTH 
4 .3%OV25 170 4.3 6.3 Same as above 
5. 3% OV 101 160 3.4 3.8 Tai l ing NPTH, poor resolution 
6. 3% SE 30 180 2.4 4.7 Both tai l ing and broad 
S S ^ a g • &8 7.0 Good PTH and NPTH 
8.3% SP2250 230 3.3 4.5 Same as above 
- - -No t detected 
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that the proposed GC system was more suitable for routine pharmacokinetic 
study of PTH and NPTH. The PTH and benzphetamine peaks were very close 
and could not be resolved by the SP 2250 column and chlorpheniramine 
hydrochloride was eventually selected as a suitable internal standard after a 
series of compounds were tried. 
Figure 13 showed the typical chromatograms of extracts from blank 
- t 
plasma and patient's plasma using the above GC system under the optimized 
conditions. The analytical peaks of PTH and NPTH were well resolved w i th 
retention time of 3.3 and 4.5 minutes, respectively. The performance of the GC 
system used was considered adequate for .the assay of PTH and NPTH (Table 
9). A plot of peak height ratio of PTH and NPTH to chlorpheniramine was 
linear over the range of concentration of 10 to 500 ng/ml wi th % C.V. less than 
6.5% in ten determinations. The correlation coefficients of the cal ibration 
curves of PTH and NPTH were 0.9992 and 0.9998 respectively. The lowest 
detection l imi t was appromixately 5 ng/ml for PTH and 10 ng/ml for NPTH. 
I The results obtained w i th the present method and the modified reference i； 
methodise 103) (Figures 14a and 14b) were i n close agreement (r > 0.99 for both 
drugs)，which indicated that our new GC method was reliable and accurate. 
，jp.l n [ r , 
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Fig. 13. Typical chromatogram of (1) pethidine, (2) norpethidine and (3) 
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Table 9. 
The calibration range and day-to-day variation (n=10) of the GC assay for 
plasma PTH and NPTH. 
( 
Cone, (ng/ml) Peak height ratio 土 S.D. (% C.V.) 
丨 PTH NPTH 
10 0.15410.010 (6.5) 0.053土0.003 (5.7) 
20 0.306±0.013 (4.2) 0.112±0.007 (6.3) 
50 0.647±0.031 (4.8) 0.213±0.008 (3.8) 
100 1.470±0.098 (6.7) 0.44at0.021 (4.7) 、 
250 3.551±0.172 (4.8) 1.126±0.073 (6.5) . 
500 6.602±0.126(1.9) 2.280±0.105 (4.6) 
Correlation Coef. 0.9992 0.9998 
Calibration graph y = 0.0132x+0.0682 y = 0.00454x+0,00148 
Batch standard at 1.451±0.081 (5.9) 0.454±0.032 (7.0) 
O.lfig/ml (n=30) 
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Fig. 14a. A comparison of the PTH results obtained by the described GC 
method (y-axis) and a reference GC method (x-axis). 
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Fig. 14b. A comparison of the NPTH results obtained by the described 
GC method (y-axis) and a reference GO method (x-axis). 
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4.3.3. Pharmacokinetics of PTH and NPTH in Chinese patients after 
intramuscular (i.in.) dosing 
Figure 15 i l lust rated the mean plasma concentration-time curves of 
P T H and N P T H of the f ive Chinese pat ients after receiving a single 
in t ramuscular dose of pethidine. The ind iv idua l plasma concentrations of 
PTH and NPTH were tabulated i n Table A9 and AlO (p. 192-193). The estimated 
{ 
min imum lethal dose of PTH is approximately Ig. Toxic effects (106) are 
I 
usual ly associated w i t h plasma concentrations of P T H and N P T H greater 
than 2000 and 700 ng/ml respectively. The maximum plasma concentrations 
among the five patients was found to be 326 ng/ml for PTH and 35.3 ng/ml for 
N P T H which 
were wel l below the toxic level. Non-compartmeii tal analysis 
showed tha t the mean peak plasma concentration, the mean t ime for 
max imum absorpt ion and the mean e l im ina t ion hal f - l i fe of P T H was 
246.4土65.9 ng/ml, 0.73±0.35 hr, and 7.88±2.01 hrs respectively. Whereas N P T H 
appeared i n the plasma f rom 0.5 to 1 hour and the mean peak plasma 
concentration was 28.8±4.38 ng/ml. The mean el iminat ion half- l i fe of N P T H 
(39.6土 19.3hrs) was signif icantly greater than PTH. Table 10 summarized the 
mean pharmacokinetic data of PTH and N P T H of the five Chinese patients, 
whereas the pharmacokinetic data of each patient was shown in^Table A l l 
and A12 (p. 194-195). 
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Fig. 15. Mean plasma levels of pethidine (•) and norpethidine (•) at various 
time interval after intramuscular administration of pethidine (1 
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Table 10. 
A summary of mean phamacokinetic data for PTH and NPTH after 
administrating 1 mg/kg PTH to five Chinese patients. 
- • fc. 
Phamacokinetic Pethidine (土S.D.) Norpethidine (士S.D.) 
parameters 、 
i 
A U C o - o o (nghr/ml) 1810±442.7 1731±856 
El iminat ion tl/2 (hr.) 7.88士2.01 39.6土 19.3 
Tmax (hr.) 0.73土0.35 6.00土 1.41 
Cmax (ng/ml) 246.4±65.9 28.814.38 
Clp (ml/kgmin) 9.69±2.52 — 
Vss (L/kg) 6.54±1.69 -
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4.4. DISCUSSION 
； 广 
The sensitivity- of the majority of the established method based on gas 
chromatography wi th FID without prior derivatization (21,96-97,103) was low 
and did not enable the determination of NPTH in t t e plasma. The reported GC-
MS assays were extremely sensitive ^ o w n to 0.5 ng/ml) and selective but these 
methods increased the cost of a routine analysis. As far as derivatization is 
concerned, PTH and NPTH often form the same derivative which must be 
separated by part i t ion chron^atography i n a simple column separation before 
derivatization. Thus the proposed method was relat ively simple and the 
> ^ s i s S t r v i t ^ and 10 ng/ml For PTH and respectively) was good enough 
沾 to measure the compounds of interest in the plasma samples. 
OV-17 was a classical GC column used i n the determination of these 
narcotic analgesic drugs in the plasma (21,91-92,96-101). As observed by other 
workers (102-103)，we found that the chromatographic performance of OV 17 
was good for PTH but fa i r ly poor for NPTH. The ta i l ing NPTH peak could 
reduce the sensitivity of the whole assay and that might part ly explain why 
most methods omitt ing the derivatization step were comparatively insensitive. 
Owing to the unsatisfactory detection l imi t of the countercheck method (103)， 
the experimental condition of that method was slightly modified i n such a way 
that analysis was carried out by using a NPD instead of a FID; the lowest 
detection l im i t was increased from 25 ng/ml using 5 ml sample to 10 ng/ml 
using a 1 ml sample. 
Studies in patients following abdominal surgery suggested that blood 
PTH concentrations of 500-700 ng/ml were required for analgesia (107-108). 
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The concentration-analgesic respond relationship for PTH was extremely 
steep and dosage regimens of PTH which produce variable or f luctuat ing 
blood concentrations can be expected to achieve inconsistent relief of pain. But 
this regimen failed to take into account the pain tolerance when a patient-
I 
controlled analgesic therapy model i n 20 patients, who received self-
administered small intraveneous small doses of PTH, was studied (109). The 
( 
maximum plasma concentrations ranged from 132 to 892 ng/ml and of the 20 
patients, 19 obtained subjectively satisfactory analgesia. I n our small group, 
the PTH concentrations were well below the recommended levels (107-108)，but 
none of the patients suffered inadequate analgesia. The mean el iminat ion 
half-life (tl/2) of PTH was 7.88±2.01 hrs which was about 2 times higher than 
the two previously reported values (110-111), but was i n agreement w i th the 
current f indings (90). Since i r regular i t ies i n plasma concentrat ion i n 
individual subject occurred (108,112), we expected a significant different t l /2 i n 
one patient wi th in the small group could result in a significant change i n the 
mean value. However the mean t l /2 of the five Chinese patients fell w i th in the 
normal expected range (3-8 hrs). 
% 
^ f 
PTH was readily absorbed after intramuscular administrat ion and 
peak plasma concentrations were observed between 1 to 2 hrs which were 
similar to the data obtained in oral route (112). The mean Vss of PTH was 
6.54±1.69 L/kg suggested that this drug is extensively distr ibuted into the 
tissues and this obtained Vss value was higher than the l i terature value (4.71 
L/kg) (110). Although the mean concentrations of PTH in the plasma were 
higher than that of NPTH, their AUG values were similar. This indicated that 
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NPTH was eliminated slowly i n the plasma as indicated by its long t l /2. From 
the studies of Stambaugh and Wainer (111), the elimination hal f l ife of NPTH 
was estimated from the rate of its excretion i n urine, was around 12 hours 
---"MT—’-
产 \ 
\ and was dependent on the urine pH. But |ve have a surprisingly long half-life 
among the patients. NPTH was detected i n the plasma from 0.25 to 0.75 hr 
[ J 一 ‘ 
after PTH was administered and i t reached its max imum concentration at 
/ 
about 6 hrs. The half-life of NPTH (39.6 hrs) was relatively longer than the 
usual sampling time of 24 hours. Although i t was not suitable to extrapolate 
the curve to calculate this t l /2 from the last three or four points i n the the 
elimination phase, i t was diff icult to collect blood samples at various intervals 
over 24 hours so that the values determined were an est imatio^^^^^^xpected 
that i f this metabolite was given to healthy volunteers, m e t o g h t determine ^ 
this pharmacokinetic data more precisely and the other parameters such as 
clearance and volume of distr ibut ion which we could not found i n our study, 
could be compared wi th its parent drug, PTH. 
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4.5, CONCLUSION 
A sensitive and accurate gas-l iquid chromatographic method was 
described to determine pethidine and norpethidine i n plasma of Chinese 
patients who received a single dose (1 mg/kg of total body weight) of pethidine 
in t ramuscular ly . The chromatograph consisted of a 3% WAV SP 2250 on 
Chromosorb W glass column l i nked to a n i t rogen detector. Sample 
preparation was simple, being based on a single extraction of basif ied plasma 
samples w i t h n-hexane. The operating t ime of the assay was short and was 
suitable for rout ine pharmacokinetic studies of both drugs. The method was 
sensitive J o w n to 5 and 10 ng/ml for pethidine and norpethidine respectively 
f rom 1 m l plasma sample. L inear i ty was observed i n the range of 10 to 500 
ng/ml I n a pre l iminary study on 5 Chinese patients who received pethidine 
t reatment , the mean土S.D. peak plasma concentration, t ime for max imum 
absorpt ion and e l iminat ion half- l i fe were 246±66ng/ml，0.73±0.35 h r and 
7.88±2,01hrs respectively. The metabolite appeared in the plasma f rom 0.5 to 1 
hour and the mean peak plasma concentration was 28.8±4.38 ng/ml and i ts 
e l iminat ion half- l i fe was signi f icant ly greater than the parent compound, 
pethidine. 
1 1 1 
CHAPTERS 
DETERMINATION OF PETHIDINE AND ITS MAJOR METABOLITES JN 
HUMAN URINE BY GAS-LIQUID CHROMATOGRAPHY 
• • 
5,1.1]\TRODUCTION 
As mentioned i n the previous Chapter, major metaboli tes of 
pethidine (PTH) such as norpethidine (NPTH), pethidinic and norpethidinic 
acids (PTA and NPTA) and conjugates of pethidinic and norpethidinic acids 
(PTC and NPTC) were biotransformed after PTH was metabolized i n the l iver 
by N-demethylat ion, hydrolysis and conjugation. Whi le ..there were 'we l l 
established methods for the analysis of PTH and NPTH such as spectroscopy 
(83-86)，ion-selective electrodes (88) and chromatography (89-102), the 
measurements of other metabolites were very l imi ted. The reasons were 
either due to greater dif f iculty i n extracting these compounds via organic 
solvents or their amounts in the biological samples were very low compared 
w i th PTH and NPTH. For instance, the solubilities of PTA and NPTA in 
aqueous medium were rather high and therefore these two compounds 
required to undergo esterification (113) or extractive alkylation (114) prior to 
chromatography. The measurements of minor metabolites l ike pethidine N_ 
oxide (115) and N-hydroxynorpethidine (82) were performed by complicated 
GC-MS selected ion monitoring. Tc^oul tecent knowledge^ we^are not aware of 
any information in the l i terature concerning the analysis of PTH together 
w i th all its major metabolites in biological materials. A successful method of 
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this type could help us to further understand the metabolic routes of PTH 
among individuals. To achieve this purpose, we in i t ia l ly attempted to follow 
the procedure of the simultaneous HPLC assay of p-aminobenzoic acid and its 
conjugates (116) i n urine sai^ples by direct injection after centrifugation. We 
found that this method was not satisfactory because using UV detection at low 
wavelength (around 205 nm) the analytical peaks of PTA, NPTA, PTC and 
NPTC were subject to the interferences f rom the u r i na ry endogenous 
substances, and they were not resolved from the enhanced interfer ing peaks 
even when ion-pair reagent (heptanesulphonic acid) was added. We； now 
report a rel iable GC method to determine PTH and the above major 
metabolites i n human urine of eight Chinese patients who were receiving a 
single in t ramuscular dose of pethidine for post-operative analgesia. The 
method was based on the modification ofl'ou^ recently developed GC assay for 
monitoring the plasma levels of PTH and NPTH (Chapter 4). 
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5.2. EXPERIMENTAL 
5.2.1. Materials and apparatus 
Pethidine hydrochloride was obtained f rom May and Baker Ltd. 
(Dagenham, England), norpethidine hydrochloride from Ster l ing Winthrop 
Research Inst i tu te (New York, USA), chlorpheniramine hydrochloride f rom 
the Ast ra Pharmaceutical Production AB (Sweden) and p-glucuronidase 
i 
(from Helix pomatia) f rom Sigma (St, Louis, MO, USA). Absolute ethanol, 
acetic acid, d iethyl ether, methanol and sodium acetate (all of analyt ical 
grade) were purchased f rom E. Merck (Darmstadt, FRG). The fo l lowing 
glassware was used: 15-ml capacity centrifuge tubes w i th wel l f i t ted screw 
caps containing PTEE linings, and 15-ml capacity Quick-fit glass tubes w i t h 
tapered base of 50 jiL A l l glassware was cleaned and silanized w i t h 3% HMDS 
in chloroform before use. Stock solutions containing 1 mg/ml PTH, NPTH, 
PTA and NPTA were prepared i n methanol and stored at -20°C before use. 
The freeze dr ier (Savant Instruments, New York) consisted of a speed 
vacuum concentrator (SYC-IOOH), a refrigerated condensation trap (RT-IOOA) 
and a rotary vacuum pump (VP 100). 
5.2.2. Gas chromatograph 
The gas chromatograph was a Var ian Model 6000 equipped w i t h a 
nitrogen-phosphorus detector. A coiled glass column (2.4m x 2mm i .d ” 6min 
o.d. Supelco, Inc., Bellefonte, U.S.A.) was packed w i th 3% WAV SP2250 on 
Chromosorb W, 80-100 mesh. The column was silanized w i t h 2 x 50 j i l 3% 
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HMDS and condit ioned at 300°C overnight before use. The co lumn 
temperature was maintained at 230。C and that of the detector and injector 
was at 260。。. The signal was recorded and displayed by a flat-bed recorder 
(Linseis, Model L6512). The gas flow rates were: nitrogen (carrier gas) at 30 
ml/min，air at 175 ml /min and hydrogen at 4.5 ml/min. 
5.2.3. Synthesis ofPTA and NPTA 
Pethidinic and norpethidinic acids were synthesized by alkal ine 
hydrolysis of their corresponding esters, (PTH and NPTH respectively). A O.lg 
quantities of PTH and NPTH were separately placed i n a 25 m l round bottom 
flask f i l led w i t h 0.2 m l of conc. NaOH (6M) and 4.8 m l of ethanol. The 
mixtures were refluxed for 2 hours. After cooling to room temperature, 1 m l 
of 6M HCl was added to convert the sodium salts to the corresponding acids 
and the precipitates (NaCl) were f i l tered off. The acids i n the ethanolic layer 
were isolated and pur i f ied by recrystal l izat ion i n absolute methanol. The 
percentage yield for PTA and NPTA were around 48 and 36% respectively. The 
purit ies of these two compounds were checked by th in layer chromatography 
(69) and the results were satisfactory. 
Analytical procedures for assaying PTH and NPTH (assay I) 
A flow diagram of the assay procedures is shown i n Fig. 16. To <,| 
0.25/inl urine samples, 0.75 m l of acetate buffer (pH 5.4) was added to 15-ml . 
centrifuge tubes. The tubes were incubated at 37。C in a water bath for 18 
hours and then 20 of 5M sodium hydroxide solution, 5 of the in ternal 
115 
standard, chlorpheniramine hydrochloride (0.4 mg/ml) and 5 m l of freshly 
distilled diethyl ether were added to the mixtures. The tubes were mixed for 5 
min using an automatic shaker and centrifuged to break up the emulsions. 
The aqueous layers were separated and reserved for assay 11. The ether layers 
were transferred to 15-ml evaporating tubes and were evaporated under a 
gentle stream of nitrogen at 45°C. The residues were redissolved i n 10 )il of 
methanol and 1-j i l aliquots were taken for analysis. 
I 
5.2.5. Analytical procedures for assaying PTA and NPTA (assay 11) 
The 
aqueous phases (O.Slml) of the f rom assay I above were 
evaporated separately to dryness by freeze drying using t M Savant freeze-
dryer. The residues were each dissolved i n 0.5-ml absolute ethanol and 
transferred to 15-ml centr i fuge^ tubes containing 100 jj.1 of concentrated 
sulphuric acid. The tubes were then t ight ly capped and heated at 100。C in an 
oil bath for 1 hour. After the acid catalyzed hydrolysis, the tubes were cooled to 
room temperature and 0.5 m l of 2M NaOH was added to neutralize the acid i n 
the mix ture, fol lowed by the addi t ion of 5 \ i l of ch lo rphen i ramine 
hydrochloride (0.4 mg/ml) and 5-ml diethyl ether. The rest of the procedures 
were identical to that of assay L 
5.2.6. Analytical procedures for assaying total PTA and NPTA (assay HI) 
The procedure was the same as assay 11，except for an addit ional 
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Fig. 16. A flow diagram to show the analytical procedures of assaying PTH 
and its m^'or metabolites in mine samples, 
I . 
To 0.25 ml urine, add 0.75 ml of acetate To 0.25 ml urine, add 0.75 ml of acetate 
buffer (pH 5.4) buffer and 500 units of p-glucuronidase 
I 
Incubate at 37°C for 18 h Incubate at 37。C for 18 h 
r 
Cool to room temperature, add 20 ^il 5M Add 20 5M NaOH and 5 ml of diet] 
NaOH and 5 ml of diethyl ether, mix, ether, mix, centrifuge and discard 
centrifuge and chlorpheniramine (marker). organic layer. 
Organic l a y e r \ Aqueous layer (0.8 ml) Aqueous layer (0.8 ml) 
\ 丨 
Evaporate to freeze-dried. Follow the procedures of Assay I I 
dryness at 45。C. 
Y Assay III 
Redissolve in 0.5 ml of 
，f absolute ethanol and 100 
Redissolve residue in ^ 二 s u l p h u r i c acid, 
10 ^il methanol and inject 曲 t l y capped. 
1 Ml aliquot for PTH and Heat for I h i n a 100。C 
NPTH analysis. \ oil bath 
Assay I Add 0.5 ml of 2M. NaOH, 5.ml 
of diethyl ether and chlorpheniramine, 
mix centrifuge and save organic layer. 
T 
Evaporate to dryness at 45°C, redissolve 
residue in 10 jj.! methanol and 1 for PTA 




enzymic treatment before the acid hydrolysis. To 0,25-ml ur ine samples, 
0.75-ml acetate buffer solution (pH 5.4) and 500 units of (3-glucuronidase were 
added. The tubes were incubated at 37°C for 18 hours and the mixtures were 
mixed and centrifuged after adding 20 jjJ of 5 M sodium hydroxide solution 
and 5 m l of diethyl ether. The aqueous layers (0.8-ml) were saved and the rest 
of the procedures were identical to that of assay IL The amount of PTC and 
NPTC were deduced from the! differences between assays I I and I I I . 
5.2.7. Quan^ t^ t ion 
Calibration graphs were constructed by spiking PTH, NPTH, PTA 
and NPTA into drug-free urine samples. Di lu t ion of the stocks w i th methanol 
to prepare standards to cover the concentration range 0.4-6.4 j ig/ml for PTH 
and NPTH and 0.8-12.8 |ig/ml for PTA and NPTA. Between-day standards of 
concentration of 3.2 jag/ml were determined to obtain the between-batch 
variat ion of the assays. The calibration graph measurements were repeated 
six times during the course of study. The recoveries of PTH and N P T H after 
esterification of PTA and NPTA at 3.2 [xg/ml i n the urine samples were also 
determined. 
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5.3. RESULTS 
5.3.1. Choice of extracting solvent 
Dur ing the developing stages of the previous work (Section 4.3,1.， 
Chapter 4), various commonly used solvents were investigated for recovering 
PTH and NPTH in plasma samples. The percent recovery was determined for 
each drug by comparing the peak heights of extracted plasma w i th the peak 
heights of methanolic standards at 0.1 |ig/ml (external standard quantitation). 
I t was shown that diethyl ether gave higher recoveries (>90%) but tiirtier) a〜(v“ 
chromatograms (Table 7，Chapter 4). The in te r fe r ing peaks i n The 
chromatograms were due to the plasma .endogenous, materials and these 
substances were not found i n the extract of urine samples, and therefore 
diethyl ether was considered as the suitable extraction solvent in this assay. 
5.3么 Recovery of the esteiification ofPTA and NPTA 
The meanlS.D. conversion of PTA and NPTA to the corresponding 
ester at 3.2 jiig/ml were 65.4±3.7% and 63.7±2.6% respectively. The percentages 
of conversion of PTC and NPTC to PTA and NPTA respectively during the acid 
catalyzed hydrolysis were also ^eeessedr This was achieved by saving the 
aqueous layers (of those samples without treating p-glucuronidase after 
hydrolysis and extraction w i th ether, ie，assay I I ) and neutral ized w i th 
appropriate volumes of 5M sodium hydroxide. The aqueous mixtures were 
adjusted wi th buffer to pH 5.4，incubated and then followed the procedures of 
assay I I I . These results (amounts of PTC and NPTC) were compared wi th the 
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values obtained from the difference between assays I I and I I I . I t was found 
that a fraction of PTC and NPTC were hydrolyzed to their respective acids, but 
the quantit ies were usually not more than 7% (n=6). I n spite of this small 
percentage conversion, the present method st i l l provides a good estimation of 
these compounds i n patients' urine samples. 
5.3.3. Performance of the GC procedure 
The analytical peak亏 of PTH, NPTH and chlorpheniramine ( internal 
standard) were well resolved w i th good symmetry (Fig. 17) and the retention 
times were 3.3, 4.5 and 7.5 m in respectively. Af ter enzyme t reatment and 
esterification i n acidic medium, there was an increase i n the peak heights of 
PTH and NPTH (Fig. 18)，indicating that PTC and NPTC were converted to the 
corresponding acids accordingly. The performance of the .GC 'was^ 
summarized i n Tables 11 and 12. I t was found that the cal ibrat ion graphs 
were l inear over the range of 0,4-6.4 \ig/ml for PTH and NPTH (r=0.9998 and 
0.9994 respectively) and 0.8-12.8 ^ig/ml for PTA and NPTA (r=0.9994 and 0.9988 
respectively). The between-day coefficients of var ia t ion at 3.2 jLig/ml were 
4.02%，4.21%, 5.11% and 6.32% respectively. The corresponding 4owest 
detection l imi ts of PTH and NPTH were 0.01 [ig/ml and of PTA and NPTA 
were 0.02 )ig/ml. These values were s u f f i c i e n t l y � 脚 祐 t i y � i n the quant i tat ive 
determinat ion of the i r u r i na ry concentrat ions w i t h i n 24 hours af ter 
administration. 
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Fig. 17. Chromatograms showing (left) analytical peaks of PTH (1) at 0.71 
jig/ml，NPTH (2) at 2.8 [ig/ml in patient's urine sample spiked with 
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Fig. 18. Chromatograms showing (left) patient's urine sample after acid 
catalyzed esterification, (middle) patient's sample after both acid 
catalyzed and p-glu^uronidase hydrolysis. Note that the increase in 
height of peaks 1 and 2，and (right) blank urine. 
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Calibration and precision of PTH and NPTH assay (n=6). 
1 
Concentration Peak height ratio 土 S.D. (C.V.%) 
(| ig/ml) 
Pethidine Norpethidine 
0.4 0.165±0.00849 (5.15) 0.0673±0.00408 (6.06) 
0.8 0.347±0.0178 (5.13) 0.14210.00738 (5.20) 
1.6 0.624±0.0274 (4.39) 0.267±0.0112 (4.19) 
3.2 1.28±0.0448 (3.50) 0.541±0.0211 (3.90) 
4.8 1.96±0.0820 (4,18) 0.813±0.0273 (3.36) 
6.4 2.62±0.107 (4.08) 1.13±0.0295 (2.61) 
Batch standard 1.29±0.0519 丨(4.02) 0,537±0.0226 (4.21) 
at 3.2 j ig/ml 
(n=10) 
Cal ibrat ion y=0.409x-0.00513 y=0.175x-0.00786 
g raph (r=0.9998) (r=0.9994) 
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Table 12. 
Calibration and precision of PTA and NPTA assay (n=6). 
( 
Concentrat ion / Peak height ratio 土 S.D. (C.V.%) 
(|ig/ml) 
. I 
Pethidinic acid Norpethid in ic acid 
0.8 0,186±0.p0926 (4,98) 0.0795±0,00548 (6.89) 
1.6 0,317±0.0873 (2.78) 0.164±0.00100 (6.10) 
3.2 0.802±0,0413 (5.15) 0.339±0.0203 (5.99) 
4.8 1.25±0.0745 (5.96) 0.462±0.0196 (4.24) 
6.4 1.78±0.0667 (5.21) 0.627±0.0245 (3.91) 
12.8 3.5210.141 (4.01) 1.35±0.0326 (2.41) 
Batch standard 0.807±0.0412 (5.11) 0.327±0.0207 (6.32) 
at 3.2 | ig/ml 
(n=10) 
Cal ibrat ion y=0.283x-0.0860 y=0.105x-0.0151 
g raph (r=0.9994) (r=0.9988) 
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5.3.4. Application of the assay 
Eight Chinese pat ients who underwent ei ther hern ia repai r or 
excision exostosis were given a single dose (1 mg/kg of the total body weight) of 
pethidine int ramuscular ly , bu lked ur ine samples were collected i n plastic 
containers un t i l 24 hours after the intramuscular dose, the p H values were 
“々> ？ Ti x • 
；1,1 ^ 、 
measured and then广immediately stored i n a freezer at -20°C before analysis. 
Samples were assayed i n duplicate i n order to enhance the accuracy of the 
results. The amount of PTH and i ts metabolites were found to M . vary 
considerably among the eight subjects (Table 14). The excretion^of PTH, 
NPTH, PTA, NPTA, PTC and NPTA were between 0.97-15%, 2.0-6.0%, 
12,9-30.1%，4.18-17.2%，11.4-20.4% and 4.7-10.6% respectively over.24 hours 
af ter dosing. The percentage of unchanged drug and N-demethy la ted 
metabolite, NPTH excreted were smaller than the other metabolites. The dose 
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Table 13. 
Dose recovery of PTH and its metabolites over 24 hours in patients' mine. 
i 
Compound Recovery (%) 
• 
-
Patient pH PTH NPTH PTA NPTA PTC NPTC Total 
1 5.98 5.71 3.821 18.4 9.32 14.7 5.66 57.6 
2 5,15 15.0 4.46 13.6 8.02 17.1 7.65 65.8 
3 6.26 0.968 3.79 14.6 17.2 20.4 9.26 66.2 
4 5.39 13.3 2.04 12.9 8.09 11.4 10.6 58.3 
5 6.46 5.68 4.39 19.6 13.2 17.5 8.11 68.5 
6 5.77 3.72 5.37 26.4 4.18 12.8 4.65 57.1 
7 5.63 6.64 6.00 15.5 7.69 14.2 4.88 54.9 
8 6.07 1.94 4.77 30.1 5.06 12.6 9.72 64.2 
MEAN 6.62 4.33 18.9 9.10 15.1 7.57 61.6 
S.D. 5.05 1.19 6.29 4.26 3.02 2.28 5.14 
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5.4. DISCUSSION 
The chromatograms of the urine extracts were good in all cases. The 
analytical peaks suffered no interferences and baseline separation was 
obtained in the determination of PTH and NPTH. The signal to noise ratio of 
the solvent front i n the analyses of acids and conjugates were shown to be 
decreased (Fig 18)，but i t did not affect the measurements of the peak heights 
of drugs and marker peaks. Since the volumes of urine excreted by the 
patients during the 24 hours experimental period varied remarkably and a 
large difference i n the concentrations of the drug and metabolites could be 
expected. Therefore d i lu t ion of the .urine sample was required i f the 
concentrations of any drug were outside the calibration range. The addition of 
internal standard, chlorpheniramine, i n assay I I and I I I was crit ical. I t 
must be added after the neutralization of residue acid left after esterification, 
otherwise this internal standard would be destroyed by the acid. 
The above GC method involved very tedious analytical procedure. The 
loss of analytes and incomplete conversion dur ing the indirect sample 
treatments p ^ i b l y reduced the sensitivity of the assay and the lengthy steps 
further questioned its usefulness in routine analysis. Therefore ( ^ b e l i e v e a 
direct and simultaneous HPLC method to measure these compounds could 
compensate and improve those disadvantages. Before Q ) developed the 
described GC assay, jWe) were s t ruggl ing hard for a useful HPLC U t r 入 
I y f，\ 41 '.i 
determination b u t ^ ^ i d not succeed because of the physical properties of the 、 
analytes. Since PTH and NPTH are weak bases and PTA and NPTA are weak 
acids，it was diff icult to resolve these peaks simultaneously by compromising 
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the chromatographic parameters l ike pH of the mobile phase, flow rate and 
types of column. The step to achieve such type of HPLC measurement was st i l l 
dubious and without the presence of direct determination of the metabolites, 
j ^^descr ibed GC method was a good alternative i n providing a useful tool for 
measuring these compounds i n the pethidine disposition study. 
W i th the information obtained from the previous papers regarding 
the enzyme incubation period, ^ ^ | n o t i c e d that the reaction t ime for the 
enzymatic hydrolysis of conjugated metabolites at 37。C were usually long, for 
instances, 10 h for conjugated N-hydroxynorpethidine (82), 18 h for conjugated 
2-hydroxyimipramine (117). and 24 h for morphine-6-glucuronide ( 1 1 8 ) . 
Therefore(w^uggest |^ t® use^ a reasonably long incubation time (18 h) so as to 
attain a complete enzymatic process. 
The percentage yield i n the esterification of PTH and N P T H to PTA 
and NPTA 
were about 65%. These comparatively low recoveries were mainly 
due to incomplete react ion (equ i l i b r i um existed i n acid cata lyzed 
esterification), degradation or possible adhesion of the molecules onto the 
screw cap l inings dur ing the course of the reaction. Al though the recovery 
might be increased i f the reaction was performed under reflux condition, the 
major advantage of using screw-capped tubes was that, a large number of 
samples could be conveniently detejirfiSed at one time, which was definitely 
useful i n routine aii|aysis. The novelty of this analyt ical method was a 
negligible loss of PTC and NPTC after acid catalyzed esterification, which 
p rov ided : ' ^ an important key to estimate the amount of these compounds i n 
the urine samples. The regioselective reaction was l ikely because of the bulky 
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group effect of the glucuronyl w i th respect to the ethyl group. The nucleophilic 
(EtO-) attack on the carbonyl carbo堪 of PTA/NPTA was comparatively easier 
than/tfoat- of PTC/NPTC . Therefore whi le the acids were almost exclusively 
converted to esters, only less than 7% of the glucuronides were converted to 
the same products. 
The amounts of t l ie drugs found i n the u r ine va r ied among 
individuals (Table 13). The mean recoveries of PTH, NPTH, PTA, NPTA, PTC 
and NPTC were 6.62±5.05，4.33±1.19, 18.9土6.29，9.10±4.26，15.1 士3.02 and 
7.57士2.28% respectively. The excretions of PTA and PTC were higher than the 
other metabolites; conversely, a smal l amounts (around 5%) of unchanged 
PTH and the major metabolite, NPTH, were excreted i n the ur ine samples. 
Therefore i t seemed tha t hydrolysis and subsequent conjugation of the acid 
were the dominant routes of P T H metabolism i n the patients. The mean dose 
recovery (61.6±5.14%) was lower than 100% because the quant i t ies of these 
compounds excreted beyond 24 hours and quantit ies of other metabolites such 
as pethidine N-oxide, 4-hydroxypethidine and N-hydroxynorpeth id ine were 
not included i n th is study. None of the pat ients suffered f rom u r i n a r y 
acidosis. The p H values (5.15-6.46) of the ur ine samples were found to be 
w i th in the normal range. Since pethidine is a weakly basic drug (pKa=8.63), i t 
4 ， 
was l ike ly that 
pa t ien | with, lower ur ine p H excreted (Table 13) P T H more 
readily and these observations correlated well w i th the previous f indings (119). 
The speculat ion pf Or ien ta l subjects ^ w r e bet ter demethy la tors t h a n 
Caucasians subjects (120-121) could be fur ther ^ i f i e d i f more ur ine samples 
of different races using the described method. 
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5.5. CONCLUSION ^ ^ ^ 汰 、 ： � ” " ’ 
Procedures based on GC were established to determine pethidine and 
i ts major metabolites i n human urine. The chromatograph consisted of a 
glass column packed w i t h 3% w/w SP2250 on Chromosorb W，80-100 mesh, 
l inked to a ni trogen phosphorus detector. D ie thy l ether was used as the 
extraction solvent. Pethidini^ and norpethidinic acids, and their conjugated 
metabolites after P-glucuronidase treatment were converted to pethidine and 
norpethidine by acid catalyzed esterification. The retention times of pethidine, 
norpethidine and chlorpheniramine ( internal standard) were 3.3，4.5 and 7.5 
min, respectively. The calibration ranges of PTH/NPTH and PTA/NPTA were 
0.4-6.4 and 0.8-12.8 |Lig/ml respectively and w i th overall % C.V. of less than 
6.89% (n=8). The day-to-day variat ion at 3.2 |j.g/ml were between 4.02 to 6.32%. 
T h e i & ^ t detection l imits by using a 0.25 m l urine sample were 0.01 and 0.02 
j ig/ml for PTH/NPTH and PTA/NPTA respectively. The amount of unchanged 
drugs and metabolites excreted varied considerably among the subjects. The 
mean 24 hours ur inary recoveries i n eight patients of pethidine, norpethidine, 
pethid in ic acid, norpeth id in ic acid, and glucuronides of peth id in ic and 
norpethidinic acids were 6.62土5.05，4.33±1.19，18.9±6.29，9.10±4.26, 15.1 士3.02 
and 7.57±2.28% respectively, indicat ing that the major metabolic pathways of 
pethidine in the eight patients were hydrolysis followed by conjugation. Over 
60% of the dose was accounted for i n 24 hours af ter i n t ramuscu la r 
administrat ion of 1 mg/kg of pethidine. 
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CHAPTER 6 
PLASMA PROTEIN BINDING CHAEACTERISATION OF PETHIDINE 
AND NORPETHIDINE 
6.1. INTRDUCTION 
The fate of many drugs in the body is greatly influenced by their 
binding to plasma proteins (122-^123). Only the fraction of the drug i n the blood 
stream that does not bind to plasma proteins can leave the circulation, 
distr ibute throughout the body and reach the sites of action. Thus the 
nonprotein bound (free) drug is the best species correlated w i t h the 
pharmacologic properties and more closely related to the drug effect than the 
total (bound plus unbound) drug concentrations (124^125). However, almost all 
the pharmacokinetic studies and dosage adjustments in patients are based on 
the determination of total drug concentrations i n the plasma. This is because 
of the greater ease in measurement of total concentrations and the use of total 
drug seems to cause no problem as the relationship between free and total 
drug concentration is normal ly constant w i th in and between individuals 
(126). But i t wi l l not be the situation i f the binding changes significantly which 
can alter the relationship between these two drug concentrations and make 
the interpretation of total drug concentrations more difficult. Factors such as 
disease states (127) and concomitant drug therapy (128) can alter the extent of 
drug binding and ends up w i t h erroneous and misleading results. The 
binding of one drug (displaced agent) to plasma proteins can also be displaced 
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by another drug (displacing agent), and such type of drugs interaction has 
been demonstrated i n a number of clinically-used drugs, for examples, the 
displacement of warfarin by anti-inflammatory agents (129). The metabolite of 
trichloroacetic acid, chloral hydrate (130)，thiopental by halothane (131); and 
phenytoin (132) and diazapam (133) by enflurane. Although displacement of 
drug from its binding sites can only increase free drug concentration i n the 
plasma transiently and has no subsequent effect on the pharmacological 
activities, i t may give rise to changed pharmacokinetic characteristics such 
as a reduction i n metabolism (134) and elimination half-life (126). Therefore 
protein binding can be treated as an important pharmacokinetic parameter 
and these studies should be useful i n interpreting, pharmacokinetic data i n 
clinical practice. The purposes of our work are to determine the binding 
aff ini ty of pethidine (PTH) and its N-demethylated metabolite, norpethidine 
(NPTH), to plasma proteins and various plasma protein components, and to 
examine which is the major plasma component involved i n the prote in 
binding of these two drugs. 
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6,2, EXPERIMENTAL 
6.2.1. Chemicals and Materials 
Pethidine hydrochloride was obtained f rom May and Baker Ltd. 
(Dagenham, UK) and norpethidine hydrochloride from Winthrop Research 
Inst i tu te (New York, USA). Plasma proteins were purchased f rom Sigma 
Chemical Co. (St. Louis, MO, USA). Because the proteins f rom various 
animal species differ greatly i n their drug b inding properties f rom human 
and therefore al l the proteins were of human origin, they included albumin 
(USA) (Sigma A-8763), a i - ac i d glycoprotein (AAG) (Sigma G-9885), 
P-lipoproteins (Sigma L-2139) and y-globulin (Sigma HG-11). The dialysis 
buffer was S^rensen's phosphate buffer made by mix ing KH2PO4 (9.073 g/L) 
and Na2HP04.2H20 (11.87 g/L) and the p H was adjusted to 7.4 by using either 
one of the two solutions. Spectrapor dialysis membrane (molecular weight 
cutoff of 12,000-14,000) was obtained f rom Spectrum Medical Industries Inc. 
(Los Angeles, USA) and DIANORM® apparatus was purchased f rom 
Diachema AG (Zurich, Switzerland). 
6.2.2. Blood Sample Acquisition 
Fresh blood samples were obtained from two healthy, drug free and 
overnight-fasted male volunteers by antebrachial venipuncture. The samples 
obtained were immediately transferred into commercially available 10 m l 
plastic tubes containing ammonia heparin (Sarstedt, Numbrect, FRG) and 
centrifuged at lOOOg for 20 min to yield plasma which was stored at -20。C 
133 
before use. 
6.2.3. Equilibiimn Dialysis and Plasma Protein Binding Study 
Equ i l i b r ium dialysis was performed by means of a D IANORM® 
apparatus (Fig 19). Patients' plasma, drug-containing plasma or protein 
solutions (1 ml) were dialyzed against drug-free S^rensen's phosphate buffer 
(1 ml) i n two Teflon dialysis chambers of a dialysis cell, separated by a dialysis 
membrane. Incubation of the cells was carried out at 37。C for 4 hours w i th a 
rotat ion speed of 12 r.p.m. To determine the binding of PTH and N P T H to 
isolated human plasma protein components, 0.5 and 0.1 | ig/ml of PTH and 
NPTH were added to a range of protein concentrations, The concentration of 
various protein solutions were prepared to encompass the expected ranges i n 
human plasma (HSA=30-60 g/L; AAG=0.5-15 g/L; p-lipoproteins= 5g/L and 
Y-globulin=12 g/L). The effect of drug concentrations on protein b inding was 
determined w i th in the range of 0.05-2.0 jLig/ml for PTH and 0.025-1.0 \xg/ml for 
N P T H respectively. Plasma concentrations of PTH and N P T H i n the cell 
compartments were assayed after incubation by a recently established gas-
l iquid chromatographic method (Section 4.2.2” Chapter 4). Each experiment 
was repeated five times. 
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Fig. 19. A simplified diagram of a DIANORM apparatus containing five 
dialysing cells used for dialysis experiments. (1) Driving flange with 
guide rods, (2) Teflon cell base, (3) Teflon cell Kd, (4) spring loaded 
cell spacers and (5) bearing flange secured with 3 knurled nuts, 
I L U U J LJ J L U LLI i P 
f f I L 
A I A 
2 3 /i 
1 5 
N.B. A dialysing membrane is fixed in the position between (2) and (3). 
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6.2.4. Data Analysis and Interpretation 
Protein binding was calculated according to Eq. 17，where Cp and 
Cbu are the drug concentrations in plasma and buffer after dialysis: 
CD - Cbu X 100% [17] 
Cp 
Scatchard analysis (135) (Eq. 18) was plotted to calculate the 
association constants and total binding capacities of PTH and NPTH to HSA 
and AAG. 
B = -KB + nKPt [18] 
F 
where B and F are the bound and free molar concentrations of PTH or NPTH, 
K the association constant, n the binding capacity and Pt the protein 
concentration, 
I 
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6.3. RESULTS 
6.3.1. Protein binding at various concentrations of pethidine and norpethdine 
The (meanlS.D.) plasma protein binding at 0.05, 0.1，0.25, 0.5 and 1.0 
mg/ml of P T H concentration were 72.112.81, 54.4±2.99, 49.0±3.30，43.8土2.51 
and 43.3±2.68% respectively; and at 0.025，0.05，0.1，0.25 and 0.5 mg/ml of 
N P T H concentrations were 56.6±2,99，45.4±3.25，34.0士2.61，29.4±2.33 and 
26.7土3.88% respectively. A Scatchard plot was nonlinear for both P T H and 
NPTH (Fig 20 and 21)，indicating that more than one type of macromolecules 
or more than one class of b inding site on a single type of macromolecule may 
be involved i n the binding. The B/F ratios of P T H and N P T H .were almost 
l inear (nonsaturable binding) at bound concentrations above 0.22 and 0.15 
j imol/L respectively. The corresponding concentration b ind ing sites may be 
calculated f rom the above figures by u t i l i z ing the relat ion n K = (B/F)/Pt, as 
0.283 to 4.54 |LIM for P T H and 0.198 to 1.24 j i M for NPTH. Since B/F rat io is 
l inear ly related to protein concentration, the total b inding constants (nK) i n 
HSA (45 g/L) and AAG (1 g/L) would be 1.12 to 3.79x103 M - i and 30.5x103 to 
10.3x104 M - i respectively for PTH; and 14.6 to 52.4x103 M - i and 12.6 to 52.4x103 
M - i respectively for NPTH. 
6.3.2. Binding of pethidine and norpethidine with isolated plasma protein 
components at various concentrations 
Protein concentration-dependent bindings of PTH and N P T H to HSA 
and AAG were shown i n F ig 22 and 23 respectively. As the concentration of 
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I Fig. 20. Bound/unbound (B/F) concentration ratio of pethidine as a function of 
bound pethidine concentration (mmole/L) in plasma. 
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Fig. 21. Bound/unbound (B/F) concentration ratio of norpethidine as a 
I function of bound norpethidine concentration (mmole/L) in plasma, 
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Fig. 22. Percentage bound pethidine at 0.5 [ig/ml (•) and norpethidine at 0.1 
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Fig. 23. Percentage bound pethidine at 0.5 \ig/ml (•) and norpethidine at 0.1 
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HSA and AAG i n the buffer solution increased, the mean bound fract ion of 
PTH and NPTH increased unt i l a constant level was reached at 31% and 26% 
respectively. The degree of b inding was also governed by the total drug 
concentration in the plasma. Fig 24 and 25 i l lustrated the (mean±S.D.) bound 
fraction of PTH at HSA (45 g/L) and AAG (1 g/L) fell from 80土3.0 to 44±3.4% 
and 78±3.6 to 31±1.7% respectively w i th increasing PTH concentration and 
NPTH fell f rom 69±4.5 to 18±1.9% and 60±4.9 to 17±2.3% respectively w i t h 
increasing NPTH concentration. Data on the bindings of PTH and N P T H to 
plasma and physiological concentration of HSA, AAG, p-lipoproteins and 
y-globulin were presented i n Table 14. The bindings were determined w i th in 
the therapeutic plasma level of PTH (0.5 jig/ml) and normal plasma level of 
NPTH (0.1 jLig/ml) in vivo (106). The results represented the relative binding 
abi l i ty of PTH to plasma protein was i n the descending order of HSA, AAG, 
P-lipoproteins and y-globulin; and a similar trend was found i n N P T H except 
that the degree of binding to p-lipoproteins was sl ightly greater than AAG. 
•： The drugs bind to HSA is comparable to those determined in plasma, fur ther ,-、—-• • ."^…― • , 。 . , ， , , ” . . . « - « _ - > _ • . 、 . .、，>^... / ^ 
suggesting HSA is the major protein component involved i n these bindings. 
6.3.3. Displacement binding experiments 
The displacement experiments (Table 15) showed that P T H and 
NPTH have no subsequent effect on displacing the plasma site w i th respect to 
one another. The mean percentage bound of PTH and NPTH were around 41 
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Fig. 24. Percentage bound pethidine to albumin (HSA) at 45 g/L (•) and oci-
acid glycoprotein (AAG) at 1 g/L (•) as a function of pethidine 
concentration (|ig/inl). 
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Fig. 25. Percentage bound norpethidine to albumin (HSA) at 45 g/L » and oci-
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Table 14. 
Protein binding of pethidine and norpethidine to human plasma and protein 
fractions at physiological concentratiorL 
% binding (Mean±S.D.) 
Protein Protein conc. (g/L) PTH (0.5 [ig/ud) NPTH (0.1 |ig/ml) 
HSA 45 43.7±2.74 26.5士 2.37 
A A G 1 34.7±1.70 21.8土 1.70 
P-Iipoproteins 5 29.0±2.95 22.7±3.08 
Y-globulin 12 9.72±2.95 10.0±1.51 
Plasma* - 43.8±2.51 34.0±2.61 
* Obtained from the two male healthy volunteers. 
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Table 15. 
The displacement interactions on the plasma b inding of pethidine and 
norpethidine. 
NPTH conc. %PTH bound at 0.5^ig/ml PTH conc. %NPTH bound at 0.1|ig/ml 
(M-g/ml) (Mean±S.D.) (^ig/ml) (Mean±S.D.) 
0.01 41.47±2.66 0.05 34.35±2.50 
0.02 38.51±2.38 0.10 32.43±2.24 
0.05 41.61±2.97 0.20 31.44±2.61 
0.10 40.36±4.53 0.50 > 33.54±2.31 
0.20 43.08±4.59 1.0 33.08±2.88 
and 33% respectively even when the concentration of the corresponding 
displacing agent has increased twenty fo ld^ 
1 4 6 
6.4. DISCUSSION 
Simi lar to most of the pharmacokinetic studies, we used hepar in 
b:、、-� 、 � z . 
as the ant icoagulant i n blood collection. I t reported tha t a smal l 
amount of this agent i n the blood could activate l ipoprotein lipase and 
cause a decrease i n plasma triglycerides and an increase i n plasma fa t ty 
acids (136). Owing to the competition of these drugs and free fat ty acids for 
the b ind ing sites, these biochemical changes could reduce the b ind ing 
characteristics of drugs such as propanolol (137) and quin id ine (138). 
However � c K effect has not been shown i n alPl:he studies associated w i t h 
pethidine protein binding. 
The aspect of adequate methodology i n the study of drug-pfotein 
interact ion is usually the choice of assay procedure, device and materials. 
As mentioned i n Chapter 1，dialysis, u l t ra f i l t ra t ion , u l t racent r i fugat ion 
and gel f i l t ra t ion are the commonest employed methods but none of them 
has been considered sufficiently reliable and convenient to apply directly to 
the study (139) because of the diff icult ies i n knowing i f in vitro b ind ing 
results are va l id in vivo. Under most circumstances i t appeared tha t 
equi l ibr ium dialysis and u l t ra f i l t ra t ion were equivalent (140), but another 
study showed the value of free f rac t ion obtained was h igher t han 
u l t ra f i l t ra t ion (141). I n a recent study by Zhirkov et a l (142) the usefulness 
of u l t r a f i l t r a t i o n was dubious and quest ionable because of severe 
non-specific adsorption on the membranes and the authors concluded that 
th is method cannot subst i tute for the equ i l i b r ium dialysis i n b ind ing 
stud^; u l t racentr i fugat ion is very expensive and is not equipped i n every 
147 
laboratory; gel f i l t rat ion always requires large volume of protein solutions 
and i t is not suitable for drugs w i th relatively low protein af f in i ty too: 
Equ i l ib r ium dialysis has the disadvantages j l ike Donnan effect tsample 
V 久 - —, 、、 
dilutioi/), adsorption to the membrane materials and time consuming, but 
» 
th is technique is simple and can be easily performed at physiological 
temperature and is often regarded as the standard method i n our 
laboratory. 
Dur ing all stages of the experiments, the pH values and volume of 
plasma and buffer inside the cell compartments were not changed, and 
hence the suggested simultaneous correction for volume shift i n dialysis 
(143) was not accounted for i n the data analysis. The non-specific 
adsorpt ion to dialysis membranes were min imized by soaking the ‘ 
membranes w i th drug solutions before use and then rinsed w i th buffer 
solution and disti l led water. The dialysing t ime reported i n the previous 
work was 2 hours (119) for PTH and 3 hours (70) for i ts similar analogue, 
phenoperidine. I n our prel iminary study for the investigation of opt imum 
conditions, i t was found that NPTH (4 hours) has a longer equi l ibr ium 
t ime than PTH (3 hours) and a dialysing t ime of 4 hours was therefore 
chosen for all the experiments in this study. 
The plasma protein bindings of PTH and NPTH determined were 
43-72% and 27-57% over the drug concentration range tested. The mean 
(土S.D.) plasma PTH bound (54.4±2,99% at 100 ng/ml) agreed well w i th the 
reported mean value of 56.9% at 130 ngml (119). No information on the 
binding properties of NPTH was i n the l i terature so that no 
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compar ison w i t h the ob ta ined b i n d i n g d a t a can be made. 
Although the attract ion and specificity of or ientat ion of a drug 
molecule toward i ts b ind ing site on plasma prote ins may be an 
electrostatic one, th is in teract ion is reinforced by hydrogen bond, 
hydrophobic bond and dipole-induced dipole bonding. Many h igh l y 
albumin-bound drugs are poorly soluble i n water and for such drugs 
hydrophobic binding to hydrophobic sites on a lbumin is often impor tant 
(144). The part i t ion coefficients (69) between n-heptane and buffer (pH 7.4) 
of PTH and NPTH were 1.68 and 0.37 and proposed^ that the higher � 
bind ing a f f in i ty of the parent drug migh t be because of the greater 
hydrophobic property (in terms of K) associated w i t h i ts structure. Un l ike 
other drugs such as metoclopramide (145) and moric iz ine (146)，the 
binding of both PTH and NPTH to plasma, HSA and AAG at physiological 
concentrat ions of prote ins d isp layed obvious d rug concent ra t ion 
dependency, reflecting saturable binding. This k ind of dependency did not 
occur i n p-lipoproteins and y-globulin. Since the extent of drugs b ind ing 
correlated w i t h the amount of HSA and AAG available i n the plasma, a 
var ia t ion i n these proteins concentrations could reduce the consequent 
binding. This possibi l i ty was el iminated by the results of to ta l plasma 
proteins determinat ion (Table 18，Chapter 7) wh ich showed tha t the 
plasma proteins levels of a l l pat ients were wel l w i t h i n the norma l 
concentration range (60 - 80 g/L). 
^ ^ ^ s t u d y showed the major component involved i n the binding of 
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b o t h P T H a n d N P T H was m a i n l y H S A and A A G w h i l e p - l i pop ro te ins also 
contribute to these bindings but to a smaller extent compared w i th HSA. I t 
is recognized that most of the binding of acidic drugs can be accounted for 
the association w i th HSA. Basic drugs do bind to HSA but also associate 
w i th other plasma proteins, usually AAG. Therefore the binding results of 
PTH and NPTH displayed a typical binding characteristics of weakly basic 
drugs. ’ 
I r 、 足A'i(\Pj.�J 《 
I f a drug competitively displaces another drug, i t ix^gKi ha"^ a 
high af f in i ty (association constant) for the plasma protein relative to the 
displaced drug and/or must be in high enough free concentrations i n the 
plasma (147). PTH, having a greater association constant and higher 
plasma concentration, satisfies the cri teria and is expected to displace “ 
N P T H f rom the b inding sites easily. The obtained displacement data 
i l lustrated neither the lower association constant drug (NPTH) nor the 
higher association constant drug (PTH) at various concentrations could 
have direct displacement effect, — therefore speculated that their b inding 
• I 
sites on the plasma proteins might be different from one another or the j 
. , I 
binding of the two drugs involved was of non-competitive type. j 
f , . 他-
� 幻 . . . 
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6.5. CONCLUSION 
Drug binding to plasma proteins may have an effect on i ts 
d i s t r i b u t i o n , me tabo l i sm and e l im ina t i on , wh i ch leads to 
pharmacodynamic consequences and therefore studies on the 
characteristics of drug binding to plasma proteins should be useful i n 
interpreting pharmacokinetic data in clinical practice. 
Equi l ib r ium dialysis and incubation experiments were used to 
determine the binding of pethidine and its active metabolite, norpethidine, 
to isolated plasma proteins and human plasma. Drug-containing plasma 
samples or proteins solutions were dialysed against drug-free phosphate 
buffer (pH 7.4) i n Teflon cells (DIANORM®, Zurich, Switzer land) 
separated by a dialysis membrane. Prel iminary distr ibution tests showed 
that an equi l ibr ium was attained wi th in 4 hours at ST'^ C. The effects of 
drug concentration on protein binding was determined w i th in the usual 
therapeutic range of pethidine (0.05-2.0 [ig/ml) and norpethidine (0.025-1.0 
|ig/ml). The concentration of various protein solutions were prepared to 
encompass the expected ranges i n human plasma. Plasma concentrations 
of pethidine and norpethidine in samples were assayed by a GC method 
which has been developed recently (Section 4.2.2., Chapter 4). 
The results obtained showed that protein concentration-dependent 
binding exists i n albumin and ai-acid glycoprotein. The bound fraction of 
pethidine fell from 80 to 44% and from 77 to 31% wi th increasing pethidine 
concentration at 45 g/L albumin and 1.2 g/L a i -ac id g lycoprote in 
151 
respect ively. The bound f rac t i on of N P T H fe l l from 69 to 18% a n d f r o m 60 to 
17% w i t h i nc reas ing n o r p e t h i d i n e concent ra t ion a t 45 gfh a l b u m i n a n d 1.2 
g / L a 1-acid glycoprotein respectively. The results of displacement 
experiment indicated that the binding of pethidine to plasma proteins was 
not affected by the presence of norpethidine and vice-versa. Therefore i t 
could be concluded that there might have several non-competitive sites for 
pethidine and norpethidine or their binding sites might be different f rom 
one another. 
t ‘ 
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CHAPTER 7 
A COMPARATIVE STUDY OF PLASMA PETHIDINE A I ^ NORPETHIDINE 
CONCENTRATIONS EST CAUCASIAN, CHINESE AND NEPALESE PATIENTS 
AFTER INTRAMUSCULAR POST-OPERATIVE PETHIDINE 
7.1. INTRODUCTION 
I t is wel l recognized that the metabolism of some cl inical ly used 
drugs not only var ie / among individuals of the same ethnic patient group, but 
also var ie^among different ethnic patient groups. For instance, the difference 
in the debrisoquine oxidation (148-151) is .clearly evident i n some population 
groups such that Chinese and Japanese have about 1% slow metabolizers 
whereas European Caucasians have about 9% poor metabolizers. On the other 
hand, the aromatic hydroxylat ion of mephenytoin (151) for Chinese and 
Caucasian is s imi lar , but much higher among Japanese subjects. Other 
i m p o r t a n t classes w h i c h show i n t e r e t h n i c d i f fe rences i nc lude 
antihypertensive drugs, mydr iat ic drugs and ant imalar ia l drugs. Several 
explorative studies on the metabol ism of PTH under d i f ferent u r ina ry 
conditions (pH 2 to 4) among Caucasian, Chinese and Indian volunteers after 
a low dose of PTH have been reported (1205121,152.153). I n those studies, 
Caucasiany^appeared to hydrolyze and demethylate PTH more efficiently than 
Chinese subjects. Also, both Chinese and Ind ian subjects excreted 
significantly more NPTH in the urine while no difference was observed i n the 
ur inary recovery of unchanged PTH. I t was concluded that PTH was main ly 
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metabolized by demethylation i n the Oriental subjects, whereas Caucasian 
mainly el iminated the drug by hydrolysis under acidic ur inary pH. Ei ther 
routes of biotransformation are the major pathways of metabolism of PTH 
(Fig. 12, Chapter 4) and i t is important to note that demethylation, an oxidative 
pathway, is dependent on cytochrome P-450 activity while hydrolysis is not. I t 
is l ike ly that the existence of an interethnic difference i n the oxidative 
demethylation of PTH may be found in the PTH metabolism. These results 
p r o m p t e d ^ t o extend our study i n Chapter 4 to include the investigation of a 
number of different ethnic groups to detect i f there is an interethnic difference 
in PTH metabolism and disposition after a therapeutic dose. The difference i n 
the metabol ism of P T H was di f ferent between Or ienta l and Caucasian 
subjects (120-121) also provoked our interest i n investigating the existence of 
interethnic var iab i l i ty i n plasma binding of PTH and NPTH. Therefore, 
additionally, binding studies were carried out i n plasma of the three pat ient 
groups f rom different origins who received a single in t ramuscular dose of 
PTH for post-operative analgesia. 
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7.2, EXPERIMENTAL 
7.2.1. Chemicals and apparatus 
Fol in and Ciocalteu's phenol reagent was purchased f rom Sigma 
Chemical Co. (St. Louis, MO, USA). Lowry reagent was freshly prepared by 
mixing anhydrous NasCOg, 0.5M NaOH, 2% sodium amd potassium tartrates 
and 1% CUSO4. for the determination of total protein concentration. Other 
chemicals and apparatus used i n this experiment were the same as those 
listed i n Section 6.2.1. i n Chapter 6. 
7.2.2. Patients study 
After approval f rom the Research Ethics Committee of The Chinese 
University of Hong Kong, 30 patients who underwent various types of surgery 
(Table A23, p.205) were recruited from the Br i t i sh M i l i t a ry Hospital, Hong 
''产 ab � f 形 vw. 
Kong. Informed consent/and close medical supervision were given to a l l 
patients before and during course of the experiment. 
Caucasian (10 male; age, 25.6土4.4; weight, 74.1 土6.5 kg), Chinese (10 
male; age, 34.2士8.1; weight, 67.8±3.5 kg) and Nepalese (10 male; age, 26.3土1.9 
yrs; weight , 66.1士8.0 kg), were given post-operat ive 1 mg/kg P T H 
intramuscular ly (Table A23). Blood samples were obtained, v ia the ante-
cubital vein w i th the aid of an indwell ing 3-way stopper, at 0，0.25, 0.5，0.75, 1, 
2，3，4, 6, 8，12 and 24 hours after dose. A l l patients showed to have normal 
demographic data such as haemoglobin, plasma urea, creatinine, a lbumin 
and proteins. Plasma concentrations of PTH and NPTH were simultaneously 
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determined by a sensitive gas-liquid chromatographic technique as mentioned 
under Section 4.2.2., Chapter 4. A non-compartmenta l analysis, us ing 
statist ical moment theory (Eq. 2 and 5，Chapter to determined 
. . . t 
disposit ion parameters.(Signi f icance of differences of k inet ic parameters 
among the 3 ethnic groups was evaluated using fif^ Student's unpaired t test, 
w i t h p<0.05 considered to be the l im i t of significance. 
Plasma samples collected at various t ime intervals f rom each pat ient 
after the above pharmacokinetic studies were pooled together to give a bulked 
plasma samples. Since the bulked plasma samples f rom one Chinese and one 
Nepalese patients were not suff icient (less than 1 ml) for the b ind ing study, 
only 28 (10 Caucasian, 9 Chinese and 9 Nepalese patients) out of 30 patients 
involved i n the interethnic protein binding investigation. The patients' bulked 
plasma samples were stored at -20°C i n a freezer before study. 
7.2.3. Total Plasma Proteins Determination and Binding Study 
The to ta l plasma proteins i n patients' samples were determined 
克， 
according to Lowry's assay (154). One mi l lE i t re of 1:400 d i lu ted plasma 
samples (100 |li1 plasma i n 3.9 m l dist i l led water) were pipetted into test tubes 
(10 X 80 mm) fol lowed by the addi t ion of 1 m l of freshly prepared Lowry 
reagent. The solutions were wel l mixed and allowed to stand for 15 minutes. 
Then 3 m l of 1:10 d i lu ted Fol in and Ciocalteu's phenol reagent i n d ist i l led 
water was added and the tubes were placed i n a water bath set at 60。C for 15 
mini i tes. The 沙 w a s measured at 550 n m after the tubes 
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were cooled to room temperature. A reference blank and standards covered 
the calibration range of 10-100 g/L of total plasma proteins were prepared as 
above. Thej3dE). readings were converted to grams of proteins per l i t re by 
referr ing to the cal ibrat ion curve. The procedure of the prote in b ind ing 
experiment was followed under the Section 6.2.3. in Chapter 6. 
<j 
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7.3. RESULTS 
V.3.1. Plasma concentration-time profiles of pethidine 
The mean plasma concentration-time curves of PTH and N P T H after 
i.m. PTH dose (1 mg/kg) for the 3 ethnic groups^vstei^ shown i n Figures 26 and 
27. Ind iv idual concentration-t ime points for the 10 patients i n each of the 
groups were tabulated i n Tables A24 to A29 (p,206-211). I t appeared tha t the 
plasma concentrations of P T H and the t ime to reach i ts max imum plasma 
concentration dur ing the early par t of the experiment were almost the same 
among the 3 pat ient groups. However, Caucasians tend to el iminate P T H 
^ more rap id ly t han the other two groups. The N-demethy lated metabol i te 
appeared i n the plasma var ied f rom 0.25 to 1 h r after P T H administ rat ion. 
The mean t ime for reaching the max imum N P T H concentration was around 
？ 
6 hrs i n al l cases w i t h mean max imum plasma concentrations at 29.1，25.4 
and 26.1 ng/ml respectively for Caucasian, Chinese and Nepalese. 
'7.3.2. Comparison of pharmacokinetic parameters 
Table 16 summarized the kinet ic and disposition parameters of P T H 
and NPTH among the 3 ethnic groups. Whi le no significant difference (p>0.05) 
was observed i n the mean area under plasma concentrat ion-t ime curves, 
Tmax and Cmax of PTH, the mean e l iminat ion half- l i fe ( t l /2) of P T H and 
N P T H were higher i n the As ian groups than the European. The average 
plasma clearance (Clp) of P T H was smaller i n Chinese than Nepalese and 
Caucasian, a l though the difference between the two As ian groups was 
insignif icant. The Clp of P T H was also signi f icant ly greater i n Caucasian 
158 
(14.4±4.77 ml/minkg) than in the Chinese (9.96土2.93 ml/minkg) and Nepalese 
(12.6±2.91 ml/minkg) groups. 
Fig. 26. The mean plasma concentration of pethidine in Caucasian (•)， 
Chinese (A) and Nepalese (•) after receiving a single intramuscular 
dose (1 mg/kg of total body weight) of pethidine. 
Concentration (ng/ml) 
OOO p 
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Fig. 27. The mean plasma concentration of norpethidine in Caucasian (•), 
Chinese (A) and Nepalese (•) after receiving a single intramuscular 
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Table 16. 
The pharmacokinetic data (Mean±S.D.) of PTH and NPTH in the 3 ethnic 
groups. 
Patient AUCO-<- Vss Clp Tmax Cmax tl/2 
Group (nghr/ml) (L/kg) (ml/minkg) (hr) (ng/ml) (hr) 
Caucasian 
PTH 12871415 5.08±1.16 14.2 土4.77 0.86±0.13 228±66.2 4.53±1.32 
NPTH 1864±751 --： 5.50±1.72 31.014.85 39.1±15.3 
Chinese 
PTH 1779±417 5.97±1.72 9.96±2.93 1.08±0.69 227±53.3 8.07±3.11 , 
NPTH 2683±1880 — - - 5.70±1.64 26.0±5.53 71.0±50.2 
Nepalese. 
PTH 1399±364 6.04士 1.76 12.6±2.91 1.14±0.50 218±79.1 6.15 土 1.22 
NPTH 2676±1551 4.40土1.17 27.2±4.05 66.1±35.4 
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7.3.3. The interethnic binding study 
Table 17 r e p r e s e n t � the total protein concentration i n g/L and the 
• ‘ 
percentage bound of PTH among the three patients groups. The protein 
concentrations of all patients were wi th in the normal concentration rande (60-
80 g/L). The values of protein binding were varied considerably and that the 
variat ion was mainly due to the different PTH plasma levels (ranging from 
34.73 to 204.8 ng/ml) in the bulked samples. I t was probably that patients w i th 
a higher PTH plasma concentration would have a smaller bound fraction 
than those w i th a lower concentration. Accordingly, the (meantS.D.) % PTH 
bound at about 100 ng/ml for Caucasian, Chinese and Nepalese patients were 
61.0士 12.3%，55.5±10.2% and 58.0±11.7%. However, the plasma levels.of NPTH 
in all the bulked samples were low and beyond the detection l imi t of the assay 
(10 ng/ml), and therefore no information on this matter was obtained i n the 
study. 
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Table 17. 
Total plasma proteins and percentage of pethidine bound among the three ethnic 
groups. 
Patient Caucasian Chinese Nepalese 
%PTH bound protein %PTH bound protein %PTH bound protein 
conc (g/L) conc (g/L) conc (g/L) 
1 58.43(102.6) 64.8 58.62(118.0) 78.0 67.23(63.54) 70.8 
2 68.12(74.66) 70.0 66.72(58.89) 78.0 75.12(39.20) 70.0 
3 59.24(88.88) 67.5 55.14(125.3) 69.0 ‘ 61.52(87.33)- 77.2 
4 58.72(97.99) 71.7 39.23(188.7) 66.8 50.43(114.5) 73.8 
5 35.43(197.5) 69.6 45.25(135.0) 77.6 42.38(143.8) 66.9 
6 72.64(34.73) 71.6 70.12(55.52) 70.0 40.12(140.1) 79.0 
7 65.00(66.27) 65.5 47.24(169.7) 73.1 63.92(125.4) 70.4 
8 62.13(85.78) 74.7 54.24(76.12) 75.3 64.22(51.69) 73.9 
9 80.12(28.71) 68.5 62.45(87.33) 69.0 56.93(83.77) 67.5 
10 50.12(153.5) 70.0 —— …… …… 
Mean±S.D,60.99±12.28 55.45±10.23 57.99111.65 
(93.06±50.93) (112.7±47.24) (94.40±38.50) 
• � 
Figures inside the parenthes^ are the pethidine (ng/ml) plasma levels. 
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7.4. DISCUSSION 
Diseases such as c i r rhos is (155) a n d acute v i r a l h e p a t i t i s (156) appeared 
to produce substantially similar decreases in plasma clearance and increases i n , y 
f 
el imination half- l i fe of PTH. Patients involved i n this study were carefully 
examined to ensure that none of them has developed these types of symptoms “ ；c 乂 
during the experiment. I t was also reported that higher blood or plasma PTH 、 
concentrations in elderly patients (>70 yrs) compared w i th young volunteers (<30 
yrs) and speculated a decreased clearance in the elderly subjects was responsible 
. 1 
for those observations (157). I n order to minimize this complication, the average 
age of the patients i n the 3 groups were designed to be below 35 years old. 
The rate of absorption of PTH in all patients was rapid and the peak 
plasma concentration was reached around 1 hr after dosing. No signif icant 
difference was observed in the mean time to achieve maximal absorption (Tmax) 
among the patients between Asian groups, but Caucasian (0.86 h r ) 《 ' “ i n e ] t o 、 
absorb the drug faster than Chinese (1.08 hr) and Nepalese (1.13 hr). Simi lar 
results were reported (120-121) between Caucasian and Oriental groups (Chinese 
and Indian). The Vss obtained for Caucasian (5.08±1.16 L/kg) matched w i th the 
previous findings (110-111,155) but significantly lower than the other two groups, 
implying a greater distr ibution of PTH in the Asian groups. This can further be 
explained by the shorter t l /2 in Caucasian group. As the drug was relatively less 
distributed, i ts presence in the plasma can be el iminated more quickly and 
readily. Therefore the Clp of PTH in Caucasian was greater but the AUG (14.2 
ml/minkg; 1287 nghr/ml) was smaller than that of the Chinese (9.96 ml/minkg; 
1779 nghr/ml) and Nepalese (12.6 ml/minkg; 1399 nghr/ml) respectively. These 
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observations were contrary to ^ k ^ published results (120-121) which stated Chinese 
subjects have higher Clp value than Indian but lower than Caucasian. This was 
possibly due to the different study design. I n the previous reports (120-121), a 1/10 
therapeutic P T H dose was oral ly administered by volunteers whereas i n our 
study, a normal therapeutic i.m. dose (1 mg/kg) was given to patients. 
The disposition data of N P T H among the groups were more clearcut. 
The AUC of Chineese and Nepalese was signif icantly greater than Caucasian, 
( ^ c o c ^ q i V t r miHxr SLL 
veQ^etihi th is N-demethylated metabolite tend^to stay longer i n the plasma of 
Asian groups or these two groups tend to metabolize PTH more readily v ia the N-
demethylat ion route. These findings agreed w i t h J M ' hypothesis {recently | made^ 
(120). The d i f f e r e n c e s T m a x and广max among the 3 groups were insignif icant. 
The e l iminat ion t l /2 of N P T H var ied substant ia l ly among ind iv iduals . Two 
！' 
Chinese and Nepalese patients gave extraordinar i ly h igh value (>90 hrs) and 
resulted i n a mean t l /2 (71.0 and 66.1 hrs respectively) greater than ^ o b t a i n e d 
for a group of 5 Chinese patients i n the previous experiment (39.6 hrs, Chapter 4). 
Despite these exceptionally large tl/2, i n general, the mean el iminat ion half-l i fe of 
the Asian groups were greater than Caucasian patients, suggesting the la t ter 
group e l iminated N P T H more ef fect ive ly ' than the former groups. The other 
impor tant parameters such as Vss and Clp of N P T H could not be determined 
since this metabolite was generated via biotransformation after P T H dosing. The 
N P T H k inet ic parameters have not been properly documented as yet and 
therefore, as ment ioned earl ier, i t would be wor thwh i le to admin is te r an 
acceptable dose of N P T H to healthy volunteers so that a more useful and accurate 
set of data could be obtained. 
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From this preliminary study, it appeared that both Chinese and 
l~epalese patients did not eliminate PTH as effectively as the C~ucasian patients 
lfter a single i.m. dose and they produced more N-demethylated metabolite, 
NPTH, which stayed-longer in the plasma of the Asian groups. It is likely that the 
interethnic difference in the PTH metabolism exists, although it can not be 
:confirmed with certainty in this study. This statement can be further justified by 
;performing more studies by increasing the number of patients in each ethnic 
'lgrouP and recruiting patients from other races if possible. Since most of the major 
,' PTH metabolites are excreted in the urine, a study of their disposition by 
comparing the ratio of the unchanged drug to .metabolites:in ·the urine, could 
provide further information which may help to elucidate any difference in major 
metabolic route of pethidine among various ethnic groups. 
In the investigation of interethnic binding difference, it was found that 
the amount of PTH in the bulked plasma samples, hence the percentage bound 
PTH, varied greatly (from 30.1 to 80.1 %) among individuals within each ethnic 
group. Statistically, the mean % PTH bound among the three ethnic groups varied 
insignificantly (p«O.05) which gave approximately 57% bound at 100 ng/ml. 
Therefore the presence of interethnic variability of PTH protein binding W-aS-. 
cttL L\ 
possibly f ot ~ occur, but ~could not assume this type of phenomenon existing in 
other clinical drugs before any investigation is performed. 
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7.5. CONCLUSION 
A comparison of the pethidine pharmacokinetics among the 3 
different races (Caucasian, Chinese and Nepalese) showed tha t the t ime for 
maximum absorption, peak plasma concentration and el iminat ion half- l i fe of 
pethidine and norpethidine differed insignif icantly after int ramuscular dose of 
pethidine. However, the plasma pethid ine clearance of Caucasian (14,3 
ml /minkg) was greater than Chinese (9.96 ml /minkg) and Nepalese (12.6 
ml/minkg). The total NPTH appeared i n the plasma (AUCo -oo) of Asian groups 
was higher than that i n the Caucasian group. I t can be concluded tha t both 
Chinese and Nepalese patients did. not el iminate PTH as effectively as the 
Caucasian pat ients after a single i .m. dose and they produced more N -
demethylated metabolite, NPTH, which stayed longer i n the plasma of the Asian 
。� f�
groups. I t is l ikely that the interethnic difference between European and Asian i n 
the PTH metabolism is present and more work is required to potentiate and 
confirm the existence of the pethidine N-demethylation polymorphism. 
The mean plasma levels of pethidine and the mean percentage of 
drug bound for Caucasian (n=10) were 93.06±50.93 ng/ml and 59.09±14.55% 
respectively, Chinese (n=9) were 112.7±47.24 ng/ml and 55.45±10.23% respectively 
and Nepalese (n=9) were 94.40土38.50 ng/ml and 57.99土 11.65% respectively. This 
correlated well w i th the results from the experiment on the effect of pethidine on 
binding to plasma which gave 54.42±2.99% drug bound at a concentration of 100 
ng/ml. Unfortunately, the concentration^of norpethidine i n the 28 investigated 
subjects were so low that we could not measure the percentage of pethidine 
binding. 
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CHAPTERS 
FUTURE PROSPECTS OF THE WORK 
An analysis of the conclusions from the present invest igat ion 
revealed that some further studies on the physicochemical properties of local 
anaesthetics and the disposition of pethidine in man would enhance the 
knowledge of the clinical pharmacology of these pain relief drugs. 
F i rs t ly , i t would be of interest to invest igate the effect of 
vasoconstrictors on the plasma concentrations of local anaesthetics other than 
bupivacaine, which are commonly used in the interpleural administrat ion to 
produce post-operative analgesia. Since this type of drug monitor ing is st i l l 
l imited, the results so obtained could provide useful information i n handl ing 
these drugs more precisely and safely. As mentioned i n Chapter 1，the 
pharmacokinet ic parameters of a par t i cu la r d rug depend on i ts 
physicochemical properties. The work presented in Chapter 2 wi l l therefore be 
more valuable i f i t is extended to include other local anaesthetics. Ideally, the 
f 
number of drugs included in the investigation should be considerably large so 
that i t can reveal the a p ^ relationship of buccal absorption or l ipophil ici ty 
for both amide- and ester-type local anaesthetics w i th respect to thei r 
pharmacologic activities such as the onset of action, duration of action and 
their potency. Such a study would require the development of a versatile 
analytical procedure, based on GC technique, for the ident i f icat ion and 
determination of a family of local anaesthetics in biological fluids. 
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Secondly, the results i n the comparative study of plasma pethidine 
and norpethidine i n Caucasian, Chinese and Nepalese showed an interethnic 
difference i n the metabolism of pethidine after the patients receiving a single 
in t ramuscular dose of pethidine. I t would be useful to cont inue the 
investigation by increasing the number of patients i n each ethnic group and 
recrui t ing more patients f rom other races. This would fur ther jus t i f y and 
possibly confirm the observations current ly obtained. I t is also a good 
alternative to follow the comparative study by comparing the pharmacokinetic 
profi les of pethidine and norpeth id ine and examin ing whether such 
in tere thn ic difference i n peth id ine metabol ism exist i n in t ravenous 
* ‘ 
administrat ion or other administrat ion routes apart from the intrapiuscular 
route. 
Since most of the major pethidine metabolites are excreted i n the 
urine，a study of their disposition by comparing the ratio of the unchanged 
drug to metabolites i n the ur ine could provide useful in format ion i n the 
disposition fate of pethidine i n man, which may help elucidate more clearly 
the difference in major metabolic pathway of pethidine among various ethnic 
groups. The analytical method presented i n Chapter 5 w i l l be a helpful tool i n 
this type of research. But owing to i ts time-consuming sample treatment, an 
improved methodology may permit the determinat ion of a large number of 
urine samples. I t is practically useful to develop a direct HPLC method to 
measures these analytes i n ur ine. As ment ioned i n Chapter 5， the 
simultaneous determinat ion of a l l the major metabolites of pethidine is 
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h^^^tiev may be tackled i f the acidic and basic metabolites are determined 
separately. The basic parent drug and norpethidine can be conveniently 
measured by the GC method described in Chapter 5. The acidic metabolites 
(PTA and NPTA) and neutral metabolites (PTC and NPTC) can possibly be • 
determined by a normal phase HPLC, by injecting the ur ine sample directly 
into the system. 
Other analgesics such as fentanyl , morphine and thiopentone 
(Chapter 4) are usually administered prior to the post-operative analgesia 
produced by pethidine. Final ly, i t is necessary to examine i f these analgesic 
drugs have any displacement effect on the protein binding af pethidine and its 
metabolite, norpethidine, i n the plasma, which i n t u r n may change their 
pharmacokinetic properties accordingly. 
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APPENDIX: 
Table Al . 
葡 
Patients data (mean 土 S.D.). 
Pla in Adrenal ine 
Age (yr.) 49.0±14.8 46.3±11.2 
Weight (kg) 58.2±11.7 58.3±9.4 
Sex (M/F) 3/3 6/0 
Anaesthetic time 92.5±23.0 90.0±24.9 
(min) 
1 8 4 
Table A20. 
Plasma levels (ng/ml) of bupivacaine in plain group patients. 
r 
J I M E (minutes) 
Patient 0 5 10 15 2 0 3 0 4 5 6 0 120 240 360 480 
A 0 630 1200 1520 3040 2500 2220 1740 1140 770 610 
B 0 1810 1890 2050 2330 2540 2330 1710 980 600 480 420 
C 0 1000 1780 2000 2270 2050 1540 1260 1050 770 … ― 4 8 0 
D 0 540 880 980 1520 1440 880 820 600 340 - … - 2 5 0 
E 0 500 1150 2080 2460 3110 2620 1850 1440 930 … — 5 5 0 
F 0 1660 3060 2930 2720 2560 1920 1250 m 380 … - - 3 0 0 
m e a n 0 1023 1617 1873 2137 2457 1965 1518 1075 693 625 433 
S.D. 0 581 825 701 502 630 665 503 447 314 205 138 
S.E.M. 0 251 337 286 205 257 271 205 183 128 145 56.3 
no sample obtained 
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Table A3. 
Plasma levels (ng/ml) of bupivacaine i n adrena l ine group pat ients . 
JIME (minutes) 
Patient 0 5 10 15 20 30 45 60 120 240 360 480 
1 0 3220 2140 3460 3150 2460 1700 1660 1190 800 … - 5 8 0 
2 0 1540 2280 2980 3240 3080 2860 2140 1260 780 — - 630 
3 0 2660 2720 2840 2530 2410 … ― 1 3 0 0 960 520 390 …― 
4 0 1640 24^ 2960 2900 2750 2640 1890 910 500 • ― … 3 6 0 
5 0 3290 3530 3270 3480 2650 1980 1320 620 400 … - 3 5 0 
6 0 1820 3010 3320 3000 2840 2450 1960 1350 780 570 470 
M E A N 0 2326 2857 3138 3050 2698 2326 1712 1049 628 480 478 
S.D. 0 797 461 245 325 249 477 347 271 175 127 126 
S.E.M. 0 325 189 99.9 133 102 213 142 111 71.4 90.0 56.5 
no sample obtained 
1 8 6 
Table A4. 
P h a r m a c o k i n e t i c d a t a o f b u p i v a c a i n e i n p l a i n g r o u p p a t i e n t s . 
Pharmacokinetic Parameter 
.* ^  
AUCoo V d Clp T m a x Cmax t l /2 E l im ina t i on 
Constant 
(nghrml-l) (Ikg-l) (mlmin-lkg-l) (hr) (ngml-l) (hr) (hr-l) 
Patient 
A 13.6 0.995 183.7 30 3040 232 2.98x10-3 
B 9.80 2.14 255.0 30 2540 301 2.30x10-3 
C 10.6 1.80 236.2 20 • 2270 306 2.26x10-3 
D 5.17 2.70 791.8 20 1520 233 2.98x10-3 
E 12.2 1.22 204,7 30 3110 245 2.83x10-3 
F 7.90 3.47 316.5 15 2930 356 1.95x10-3 
MEAN 9.88 2.05 331.3 24.2 2570 279 2,55x10-3 
S.D. 3.03 0.928 230.2 6.65 606 50.4 4.37x10-4 
S.E.M. 1.24 0.379 93.98 2.71 247 20.6 1.78x10-4 
1 8 7 
Table A5. 
Pharmacokinetic data of bupivacaine i n adrenaline group patients. 
Phamacok ine t ic Parameter 
AUCU V d Clp Tmax Cmax t l /2 E l im ina t i on 
, 1 1 Constant 
(nghrml-i) (Ikg-l) (mlmin-lkg-l) (hr) (ngml-l) (hr) (hr-l) 
Patient 
1 12.1 1.42 207.4 15 3460 276.8 2.50x10-3 
2 12.6 1.30 198.3 20 3240 264.1 2.62x10-3 
3 7.12 1.59 351.0 15 2840 169.5 4.09x10-3 
4 8.38 1.51 298.5 15 2960 195.9 3.54x10-3 
5 7.81 2.35 320.2 10 3530 258.9 2.68x10-3 
6 11.6 1.33 216.2 15 3320 243.7 2.84x10-3 
m e a n 9.92 1.58 257.4 15 3230 234.8 3.05x10-3 
S.D. 2.41 0.393 65.90 3.16 274 42.61 6.31x10-4 
S.E.M. 0.986 0.160 26.90 1.29 112 17.46 2.28x10-4 
1 8 8 
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The pH and volume of the expelled solutions after buccal absorption test. 
p H of in i t ia l solution Expelled solution; recorded pH and volume(ml) 
(vol.=25 ml) 
Subject I Subject I I 
3.0 3.46,65 3.32,50 
4.0 4.26,60 4.37，55 
5.0 5.54,70 5.36,45 
6.0 6.20，50 6.07，40 
7.0 7.03，45 7.02，40 
7.4 7.41,45 7.39，40 
8.0 7.78，45 7.76，40 
9.0 8.84,50 8.42,40 
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Table A9. 
Plasma levels (ng/ml) of pethidine in 5 Chinese patients. 
T IME (hour) 
• -
I 
Patient 0 0.25 0.5 0.75 1 2 3 4 6 8 1 2 2 4 
KLK 0 154 169 176 185 158 147 123 96.4 76.3 72.8 15.6 
(0 149 173 190 181 156 145 125 100 78.4 70.3 16.2) 
M M K 0 97.9 142 165 184 173 144 123 89.5 80.7 - … 1 8 . 9 
(0 101 142 166 187 172 142 124 92.7 81.2 - - … 1 6 . 0 ) 
I 
KPW 0 95.9 273 303 249 128 70.2 64.5 55.3 57.2 25.8 17.7 , 
(0 97.6 280 304 246 128 72.6 62.5 56.7 56.8 26.1 15.1) 
M H L 0 158 251 326 193 153 144 120 65.2 64.3 46.1 30,7 
(0 166 236 320 184 151 152 121 60.3 70.3 47.4 32.7) 
CHL 0 234 202 212 148 136 97.6 81.7 80.0 57.2 33.1 —… 
(0 241 208 206 - 145 136 99.8 77.9 78.1 53.9 36.2 -----) 
__ ___ ... ； 
m e a n 0 148 207 236 192 150 121 102 77.3 67.1 44.5 20.7 
S.D. 0 56.5 54.7 73.8 36.4 17.9 34.9 27.5 17.0 10.9 20.7 6.79 
S.E.M.O 25.3 24.5 33.0 16.3 8.00 16.0 12.3 7.59 4.87 10.3 3.39 
The data i n parenthesis was determined by the reference method (103). 
1 9 2 
Table AIO. 





Patient 0 0.25 0.5 0.75 1 2 3 4 6 8 12 24 
-------------------------------------------------------
KLK 0 0 0 11.6 14.8 17.0 21.1 21.5 25.1 26.2 25.0 20.9 
(0 0 0 9.73 15.6 16.7 24.1 22.6 24.8 28.4 22.2 -21.8) 
MMK 0 0 0 17.0 21.4 23.8 22.8 23.8 21.4 19.1 ----- 12.7 
(0 0 0 14.7 23.7 - 23.1 25.1 24.2 21.7 19.8 ----- 11.7) 
KPW 0 0 10.6 14.3 13.3 18.5 25.0 32.2 ' 35.3 34.5 21.0 ·' 14.1 
(0 0 8.69 17.1 13.8 18.0 27.2 30.6 35.9 35.4 24.2 15.6) 
MHL 0 0 0 0 12.3 21.3 28.6 27.9 30.4 29.5 28.2 24.6 
(0 0 0 0 10.7 23.1 27.0 27.1 32.1 29.4 26.7 25.0) 
CHL 0 0 0 0 15.1 20.0 26.9 27.2 28.3 27.7 26.1 
(0 0 0 0 19.7 23.4 24.9 29.4 31.2 26.7 27.9 -----) 
-------------------------------------------------------
MEAN 0 0 2.12 8.58 15.4 20.1 24.9 26.5 28.1 27.4 25.1 18.1 
S.D. 0 0 4.74 8.06 3.55 2.61 3.02 4.10 5.30 5.60 3.02 5.56 
S.E.M. 0 0 2.12 3.61 1.59 1.17 1.35 1.83 2.36 2.50 1.51 2.78 
-------------------------------------------------------
The data in parenthesis was determined by the reference method (103) . 
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Table A34. 
P h a r m a c o k i n e t i c d a t a o f n o r p e t h i d i n e a m o n g 10 Ch inese p a t i e n t s . 
… Pharmacokinetic Parameter 
A U O Vss Clp Tmax Cmax tiy2 E l im ina t i on 
Constant 
(nghrml-l) (Ikg-l) (mlmin-lkg-l) (hr) (ng/ml) (hr) (hr-l) 
Patient 
K L K 1996 4.92 8.35 1.00 185 6.90 0.100 
M M K 1980 4.95 8.41 ‘ LOO 184 7.63 0.0908 
KPW 1459 8.37 11.4 0.75 303 10.5 0.0660 
M H L 2353 8.24 6.29 0.75 326 9.11 0.0761 
CHL 1260 6.23 13.2 0.15 234 5.28 0.131 
M E A N 1810 6.54 9.69 0.73 246 7.88 0.0928 
S.D. 442.7 1.69 2.52 0.35 65.9 2.01 0.00251 
S.E.M. 198.0 0.758 1.13 0.16 29.5 0.899 0.00112 
1 9 4 
Table A34. 
P h a r m a c o k i n e t i c d a t a o f n o r p e t h i d i n e a m o n g 10 Chinese pa t ien ts . 
Pharmacokinetic Parameter 
• -
A U O Tmax Cmax half-l i fe El imination 
Constant 
(nghrml-i) (hr) (ngml-i) (hr) (hr-i) 
Patient 
KLK 2021 8.00 26.2 49.0 0.0141 
M M K 854.5 4.00 23.8 24.0 0.0289 
KPW 823.5 6.00 35.3 14.5 0.0477 
M H L 2741 6.00 30.4 59.7 0.0116 
CHL 2216 6.00 28.3 50.9 0.0136 ‘ 
M E A N 1731 6.00 28.8 39.6 0.0232 
S.D. 856.0 1.41 4.38 19.3 0.0153 
S.E.M. 382.8 0.632 1.96 8.64 0.00686 
1 9 5 
Table A13. 
The effect of pethidine concentrations on the plasma protein binding. 
Percentage bound 
Cone. 1st 2nd 3rd 4th 5th Mean土S.D. 
(|ig/ml) 
0.05 72.65 69.43 75.21 74.24 68,97 72.10±2.81 
0.10 52.43 50.62 58.14 56.25 54.67 54.42±2.99 
0.25 49.42 46.73 53.66 50.21 45.13 49.03土 3.30 
0.50 42.77 46.24 39.86 44.72 45.18 43,75±2.51 




The effect of norpethidine concentrations on the plasma protein binding. 
Percentage bound 
“ - u 
Conc. 1st 2nd 3rd 4th 5th Mean±S.D. 
(lug/ml) 
0.025 54.63 59.72 54.84 60.07 53.93 56.6412.99 
0.05 47.12 45.45 43.72 41.08 44.63 45.40±3.25 
0.10 32.65 37.18 36,43 31.67 32.60 33.99±2.61 
0.25 29.34 30.64 25.32 31.11 30.24 29.35±2.33 
0.50 24.18 21.26 27.93 30.24 29.88 26.70±3.88 




The effect o f n o r p e t h i d i n e concent ra t ions on the p l a s m a p r o t e i n b i n d i n g of 
� p e t h i d i n e * . ‘ 
… Percentage bound 
Conc. 1st 2nd 1 3rd 4th 5th Mean 土 S.D. 
(|j,g/ml) 
0.01 45.07 39.73 38.25 42.87 41.44 41,47±2.66 
0.02 36.02 35.98 40.73 39.11 40.68 38.51±2.38 
0.05 44.89 43.90 42.00 37.76 39.52 41.61±2,97 
0.10 33.98 44.87 37.64 41.45 43.88 40.36 土4.53 
0.20 47.39 37.27 39.07 46.42 45.29 43.08土4.59 
* Pethidine concentration was kept at 0.50 jLig/ml. 
1 9 8 
Table A16. 
The effect of pethidine concentrations on the plasma pro te in b ind ing of 
norpethid ine*. . 
Percentage bound 
Conc. .1st 2nd 3rd 4th 5th Mean士S.D. 
(M-g/ml) 
0.05 37.09 31.25 � 33.67 33.01 36.72 34.35±2.50 
0.10 29.79 30.96 35.25 34.11 32.05 32,43±2.24 
0.20 27.68 34.23 30.55 31.19 33.57 31.44±2.61 
0.50 36.14 30.97 31.22 34.75 34.62 33.5412.31 
1.0 28.76 32.09 36.32 34.77 33.46 33.08±2.88 
— " —— — — —— —— — _ . . M — _ _ _ _ _ ____ ^ ^ _ _ _ _ _ _ _ ^ ^ |圓 _ f 
* Norpethidine concentration was kept at 0.10 jj.g/ml. 
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Table A19. 
Pecentage bound pe th id ine (0.5 | ig /ml) a n d norpe th id ine (0.1 j L i g /ml ) (enclosed 
by parenthesis) as a func t ion of H S A concentrat ion. 
Percentage bound 
Conc.(%) 1st 2nd 3rd 4th 5th Mean士S.D. 
3.0 27.84 32.03 29.74 35.65 31.14 31.28±2 91 
(12.62 10.43 9.84 15.44 12.96 12.26±2.23) 
4.0 42.93 37.64 45.66 35.73 40.24 40 44±3 98 
(20.44 18.13 22.66 17.43 21.11 19.95±2.16) 
4.5 47.21 45.37 50.11 51.22 44.26 47.63±2 99 
(29.14 28.62 32.44 27.93 25.13 28.65±2；62) 
5.0 48.67 53.42 51.13 52.65 47.98 50.77±2 39 
(36.11 28.64 32.13 26,17 30.94 30.80±3；74) 
6.0 58.14 63.72 62.63 65.11 56.72 61.26士3 64 
(33.43 37.62 30.66 31.24 37.94 34.18±3；45) 
2 0 2 
Table A20. 
Pecentage bound pethidine (0.5 \ig/ml) and norpethidine (0.1 ^g/ml) (enclosed 
by parenthesis) as a function of AAG concentration. 
• t.' 
Percentage bound 
Conc.(g/L) 1st 2nd 3rd 4th 5th Mean 士 S.D. 
0.5 19.26 23.11 14.85 17.93 19.84 19.01±3.03 
(10.92 12.63 14.85 .. 15.64 13.11 . 13.43土 1.87) 
0.8 28.34 31.13 22.89 25.76 27.53 27,13±3.06 
(17.43 22.66 20.24 21.98 21.40 20.74±2.05) 
1.0 35.13 32.64 37.13 33.66 34.98 34 71±170 
(25.48 28,66 27.49 30.48 28.77 28.18±1.85) 
1.2 40.13 36.43 42.48 39.68 38.73 39.49±2.20 
(28.64 35.13 33.24 36.14 30.23 32.68土 3.19) 
1.5 52.19 50.34 41.62 52.43 47.86 48 8914 46 
(40.72 42.63 36.82 44.71 39.24 40；82±3；04) 
2 0 3 
Table A21. 
Percentage bound pe th id ine to y -g lobu l in (12 g /L) a n d p-Jipoprotein^CS g/L) . 
、 Percentage bound 
Protein 1st 2nd 3rd 4th 5th MeanlS.D. 
Y-globulin 29.37 24.62 28.11 32.69 30.00 28.96±2.95 
(J-lipoprotein 29.73 27.67 22,43 23.15 20.67 22.73土3.08 
Table A22. 
Percentage bound norpethidine to y-globulin (12 g/L) and p-lipoproteins(5 g/L). 
Percentage bound 
Protein 1st 2nd 3rd 4th 5th Mean土S.D. 
y-globulin 20.64 21.73 16.97 19,23 21.76 20.07±2.02 
P-Iipoprotein 15.11 13.64 14.83 17.66 20.72 16.39±2.83 
2 0 4 
Table A23. 
C l i n i c a l records of the pa t ien ts i n p e t h i d i n e d ispos i t ion gtudy. 
Name 、 Age Race Weight (kg) Operation 
Koon Kowk Leung (KLK) 35 C 68 Inguinal Herniorhaphy 
Kwai Man Ming (MMK) 50 C 60.5 Inguinal Herniorhaphy 
Wong K im Ping (KPW) 36 C 68 Excision Exostosis 
Lai Man H in (MHL) 43 C 68 Excision Exostosis 
Lam K i Wing (KWL) 22 C 66 Urethrocystosis 
Lau Chi On (COL) 34 C 74 Nasopharyngeal Biopsy 
So Woon Hung (WHS) 30 C 69 Eua Sigmoidoscopy 
L iu Hoi Fat (HFL) 25 C 65 Inguinal Herniorhaphy 
Lau Kah Wah (KWLl ) 32 C 70 Circumcision 
Ip Kok Wing (KWI) 35 C 69 Excision Exostosis 
Danks James (JD) 24 E 77 Frenuloplasty 
Parks John (JP) 30 E 68 Vasectomy 
Tanner Br ian (BT) 21 E 80 Arthroscopy ‘ 
Talman David (DT) 19 E 78 Circumcision 
Davenport Anthony (DA) 28 E 77 Excision Exostosis 
Moffat Alexander (AM) 27 E 62 Inguinal Herniorhaphy 
Gable Stephen (SG) 23 E 79 Arthroscopy 
Wood Charles (CW) 27 E 69 Biopsy Tibia 
Gillett John (JG) 35 E 72 Cystoscopy 
Weaving Mark (MW) 25 E 69 Arthroscopy 
Gurung Kamalbdr (GK) 25 N 63 Lump Excision 
Thapa Nirmalkumar (TN) 25 N 65.5 Gynaecomastia 
L imbu Muniprasad (LM) 25 N 66 Dental Extraction 
Rai Jangaraj (RJ) 25 N 59 Inguinal Herniorhaphy 
Rai Gangaprasad (RG) 28 N 66 Arthroscopy 
Gurung Prasad 25 N 64 Arthroscopy 
Thapa Hareram (TH) 26 N 82 Arthroscopy 
Gurung Ghanash (GG) 26 N 72 Dental Extraction 
Magar Ranbahadur (MR) 31 N 52 Arthroscopy 
Pun Kaubahadur (PK) 27 N 71 Dental Extraction 
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Table A29. 
P l a s m a levels (ng/ml) o f norpe th id ine i n 10 Nepalese pa t ien ts . 
I 
、 TIME (hour) 
Patient 0 0.25 0.5 0.75 1 2 3 4 6 8 1 2 2 4 
JD 0 101 104 218 227 130 64.8 51.8 46.4 22.0 17.5 0.00 
JP 0 110 152 178 171 137 130 113 28.2 5.76 
BT 0 83.9 148 210 175 162 102 83.2 67.9 50.5 36.1 7.04 
DT 0 105 190 200 397 213 189 189 120 81.2 54.0 10.7 
AD 0 m 185 187 250 201 189 116 56.4 37.5 ― … … ― 
A M 0 14,4 127 200 166 82.7 72.6 70.0 60.8 58.9 - -…5 .37 
SG 0 40.0 71.1 87.6 180 177 162 115 92.7 85.4 … ― 9 . 2 2 
CW 0 78.2 98.4 162 137 134 94.2 60.4 46.1 30.9 3.83 —… 
JG 0 57.2 95.1 118 232 159 109 100 61.5 47.8 37.6 0 
M W 0 82.1 137 240 197 134 122 104 75.5 55.3 32.4 6.38 
M E A N 0 77.5 131 180 213 153 124 100 69.8 52.2 29.9 5.56 
S.D. 0 31.4 39.2 46.7 73.3 38.1 44.4 38.9 23.9 21.2 15.9 3.86 
S.E.M. 0 9.94 12.4 14.8 23.2 12.1 14.0 12.3 1.60 7.07 6.01 1.37 
2 0 6 
Table A29. 
P l a s m a levels (ng/ml ) of no rpe th id ine i n 10 Nepalese pa t ien ts . 
、 TIME (hour) 
Patient 0 0.25 0.5 0.75 1 2 3 4 6 8 12 24 
KLK 0 154 169 176 185 158 147 123 96.4 76.3 72.8 15.6 
M M K 0 97.9 142 165 184 173 144 123 89.5 80.7 - -…18 .9 
KPW 0 95.9 273 303 249 128 70.2 64.5 55.3 57.2 25.8 17.7 
M H L 0 158 251 326 193 153 144 120 65.2 64.3 46.1 30.7 
KWL 0 142 232 182 171 165 146 133 102 93.0 55.7 22.4 
COL 0 112 214 216 240 203 169 125 95.1 71.2 45.5 17.6 
WHS 0 119 208 237 199 142 110 97.3 77.0 64.4 31.7 10.5 
HFL 0 56.6 107 135 165 116 87.9 76,3 55.9 38.9 16.3 9.44 
K W L l 0 81.7 148 234 212 202 146 98.7 80.0 58.5 31.2 12.7 
W K I 0 131 151 177 193 1树 214 192 189 82.9 50.7 13.9 
M E A N 0 115 190 215 199 163 138 115 90.5 68.7 41.7 16.9 
S.D. 0 32.6 53.9 61.4 27.3 30.0 40.7 35.1 38.3 15.5 17.3 6.23 
S.E.M. 0 10.9 18.0 20.5 9.14 9.99 13.6 11.7 12.8 5.17 5.75 2,08 
2 0 7 
Table A29. 
P l a s m a levels (ng/ml) o f no rpe th id ine i n 10 Nepalese pa t ien ts . 
… TIME (hour) 
Patient 0 0.25 0.5 0.75 1 2 3 4 6 8 12 24 
GK 0 105 123 138 150 110 88.6 67.0 52.5 40.2 - 10.9 
T N 0 56.2 106 221 195 143 102 58.9 46.1 26.0 … - - 1 2 . 6 
L M 0 70.4 126 214 171 128 116 90.5 66.7 45.9 9.15 
i l J 0 103 133 145 149 160 137 113 64.0 16.6 … - - 5 . 8 9 
RG 0 66.5 81.7 110 152 146 131 91.5 79.7 62.6 7.46 
GP 0 74.1 97.3 128 152 116 90.3 83.6 62.8 44.6 23.8 6.50 
TH 0 248 307 368 336 197 168 129 108 81.4 41.7 10.5 
GG 0 42.6 98.6 104 139 207 188 137 115 91.2 59.2 20.5 
MR 0 148 161 172 348 175 138 110 69.2 50.7 39.1 6.42 
PK 0 61.0 125 163 211 175 132 103 71.9 59.6 44.9 12.5 
M E A N 0 98.0 136 176 200 156 129 98.4 73.7 51.9 41.7 10.2 
S.D. 0 60.6 64.0 78.1 78.0 33.0 32.2 25.2 22.3 22.9 12.7 4.37 
S.E.M. 0 19.2 20.3 24.7 24.7 10.4 10.2 7.96 7.04 7.25 5.67 1.38 
2 0 8 
Table A27. 
Plasma levels (ng/ml ) o f n o r p e t h i d i n e i n 10 Caucas ian pa t ien ts . 
TIME (hour) 
-V """"" •*— — — — — — — ^ ^ _ I ___ ___ _ I • 
Patient 0 0.25 0.5 0.75 1 2 3 4 6 8 1 2 2 4 
JD 0 0 10.5 17.3^ 19.3 22.6 24.7 28.1 27.2 26.4 23.9 16.0 
JP 0 0 0 0 18.1 23.6 25.7 30.2 28.0 21.2 
BT 0 0 0 14.2 19.2 22.6 25.3 28.7 32.0 30.5 27.0 20.9 
DT 0 0 0 14.2 18.6 23.8 28.4 32.6 37.3 35.5 32.2 27.7 
AD 0 0 0 11.9 16.5 19.3 23.1 28.5 
A M 0 0 0 14.9 18.3 25.6 28,1 26.3 24.1 22.7 … - - 1 7 . 7 
SG 0 0 0 21.7 24.8 29.7 33.1 38.6 41.3 39.1 …—28.0 
CW 0 0 0 0 16.1 18.2 22.8 26.1 25.4 23.9 20.7 --… 
JG 0 0 0 12.1 11.1 14.8 19.2 22.6 25.5 31.0 30.1 26.9 
M W 0 0 0 0 9.77 16.2 22.8 23.7 26.8 25.8 23.9 20.7 
M E A N 0 0 1.05 10.7 17.2 21.6 25.3 28.3 29.7 29.3 26.5 22.4 
0 0 3.31 7.87 4.27 4.53 3.86 4.69 5.97 5.40 3.98 4.62 
S.E.M. 0 0 1.05 2.49 1.35 1.43 122 1.48 1.99 1.80 1.50 1.63 
2 0 9 
I 
Table A28. 
Plasma levels (ng/ml ) of n o r p e t h i d i n e i n 10 Chinese pa t ien ts , 
… TIME (hour) 
Patient 0 0.25 0.5 0.75 1 2 3 4 6 8 1 2 2 4 
KLK 0 0 0 11.6 14.8 17.0 21.1 21.5 25.1 26.2 25.0 20.9 
M M K 0 0 0 17.0 21.4 23.8 22.8 23.8 21.4 19.1 ----- 12.7 
KPW 0 0 10.6 14.3 13.3 18.5 25.0 32.2 35.3 34.5 21.0 14.1 
M H L 0 0 0 0 12.3 21.3 28.6 27.9 30.4 29.5 28.2 24.6 
KWL 0 7.42 6.94 12.3 15.5 21.4 22.7 22.9 25.4 25.0 23.9 23.7 
COL 0 0 0 5.95 9.72 12.7 18.4 24.7 27.7 27.0 26,1 24.7 
WHS 0 0 0 0 10.9 13.5 14.3 14.0 13,1 12.7 12.7 10.9 
HFL 0 0 0 0 8.64 7.22 13.7 17.7 20.7 21.7 25.3 23.7 
K W L I 0 0 0 0 10.8 15.4 17.7 23.7 28.0 27.1 25.3 23.8 
W K I 0 0 0 、 0 16.2 20.4 26.9 27.4 26.9 26.7 25.1 23.8 
M E A N 0 0.742 1.75 6.12 13,4 17.1 21.1 23.6 25.4 24.9 23.1 19.8 
S.D. 0 2.35 3.79 7.00 3.77 5.02 5.07 5.16 6.02 5.97 4.56 5.37 
S.E.M. 0 0.742 1.20 2.22 1.19 1.59 1.60 1.63 1.91 1.89 1.52 1.70 
2 1 0 
Table A29. 
P l a s m a levels (ng/ml ) o f n o r p e t h i d i n e i n 10 Nepalese pa t ien ts . 
T I M E (hour) 
Patient 0 0.25 0.5 0.75 1 2 3 4 6 8 1 2 2 4 
GK 0 0 0 0 12.0 14.8 18.3 21.9 26.2 25.2 23.7 
T N 0 0 0 0 16.4 21.6 25.7 29.3 34.2 32.5 … - - 2 9 . 7 
L M 0 0 0 0 12.4 16.8 23.6 26.4 25.2 23.5 … - - 1 8 . 0 
RJ 0 0 0 10.4 16.2 18.3 21.7 25.4 24.5 23.1 … - - 2 0 . 9 
RG 0 0 0 0 14.7 16.8 19.3 20.8 19.6 18.8 … - - 1 5 . 1 
GP 0 0 0 16.4 19.2 23.1 27.2 19.7 28.6 26.8 25.7 24.0 
™ 0 0 10.3 18.0 23.5 26.7 28.4 30.1 32.4 31.6 29.4 27.0 
GG 0 0 0 0 13.6 19.2 23.5 25.9 23.9 22.4 21.0 19.9 
迎 0 0 0 13.5 16.3 25.2 27.9 26.3 25.2 23.6 20.8 17.3 
PK 0 0 0 0 14.8 19.3 23.1 22.8 20.6 17.8 16.0 14.1 
M E A N 0 0 1.03 5.83 15.9 20.2 23.9 25.9 26.1 24.5 22.6 21.0 
S.D. 0 0 3.26 7.78 3.40 3.89 3.50 3.25 4.63 4.79 5.12 5.09 
S.E.M. 0 0 1.03 2.46 1.07 1.23 1.11 1.03 1.46 1.51 2.30 1.61 
2 1 1 
Table A34. 
P h a r m a c o k i n e t i c d a t a o f n o r p e t h i d i n e a m o n g 10 C h i n e s e p a t i e n t s . 
Pharmacokinetic Parameter 
A U O Vss Clp Tmax Cmax t l /2 E l im ina t i on 
Constant 
(nghrml-l) (Ikg-l) (mlmin-lkg-l) (hr) (ngml-l) (hr) (hr-l) 
Patient 
JD 817.6 6.58 20.39 1.00 227 4.56 0.152 
JP 1346 4.53 12,38 0.75 178 4.67 0.148 
BT 1285 5.86 12.97 0.75 210 5.57 0:125 
DT 2119 3.37 7.87 1.00 3^7 5.27 0.132 
A D 1095 3.37 15.21 1.00 250 2.15 0.322 
A M 1186 5.89 14.05 0.75 200 5.18 0.134 
SG 1772 4.12 9.40 1.00 180 5.26 0.132 
CW 696.8 5.48 23.92 0.75 162 2.05 0.338 
J G 1244 6.25 13.40 1.00 232 5.60 0.124 
M W 1309 5.31 12.73 0.75 240 4.97 0.140 
M E A N 1287 5.08 14.23 0.86 228 4.53 0.175 
S.D. 414.9 1.16 4.77 0.13 66.2 1.32 0.825 
S.E.M. 131.2 0.368 1.51 0.042 20.9 0.418 0.261 
2 1 2 
Table A31. 
P h a r m a c o k i n e t i c d a t a o f p e t h i d i n e a m o n g 10 Ch inese p a t i e n t s . 
Pharmacokinetic Parameter 
‘ * t.' 
A U O V d Clp Tmax Cmax t l /2 E l im ina t ion 
, ^ Constant 
(nghrml-l) (lkg-1) (mlibin-lkg-l) (hr) (ngml-1) (hr) (hr-l) 
Patient 
K L K 1996 4.92 8,35 1.00 185 6.90 0.100 
M M K 1980 4.95 8.41 1.00 184 7.63 0.0908 
KPW 1459 8.37 11.42 0.75 303 10.5 0.0660 
M H L 2353 8.24 7.08 0.75 326 16.0 0.0433 
K W L 2052 5.21 8.12 0.75 182 7.63 0.0908 
COL 1890 4.92 8.82 1.00 240 7.24 0.0957 
WHS 1415 5.65 11.78 0.75 237 6.16 0.113 
H F L 986.7 8.39 16.89 1.00 165 6.72 0.103 
K W L l 1518 5.47 10.98 0.75 234 6.74 ‘ 0.103 
K W I 2141 3.59 7.79 3.00 214 5.18 0.134 
M E A N 1779 5.97 9.96 1.08 皿 8.07 0.0940 
S.D. 417.1 1.72 2.93 0.688 53.3 3.11 0.00248 
&E.M. 131.9 0.544 0.926 0.217 16.8 0.982 0.00783 
2 1 3 
i 
Table A34. 
P h a r m a c o k i n e t i c d a t a o f n o r p e t h i d i n e a m o n g 10 Chinese p a t i e n t s . 
Pharmacokinetic Parameter 
A U O Vss Clp Tmax Cmax t l /2 E l im ina t i on 
Constant 
(nghrml-l) (Ikg-l) (mjpiin-lkg-l) (hr) (ngml-l) (hr) (hr-l) 
Patient 
GK 1160 8.13 14.37 1.00 148 7.86 0.0882 
T N 1145 9.44 14.53 0.75 . 221 9.84 0.0704 
L M 1276 5.74 13.06 0.75 214 5.66 0:122 
R J 1013 5.54 16.45 2.00 160 4.90 0.141 
RG 1292 5.57 12.90 1.00 152 5.21 0.133 
GP 1038 7.15 16.05 LOO 152 5.46 0.127 
T H 1935 3.55 8.61 0.75 368 5.42 0.128 
GG 2059 5.04 8.09 2,00 207 7.27 0.0953 
M H 1501 4.33 11.11 1.00 348 4.81 0.144 
PK 1569 5.87 10.62 1.00 211 7.10 0.0976 
M E A N 1399 6.04 12.58 1.13 218 6.15 0.115 
S.D. 363.6 1.76 2.91 0.0475 79.1 1.22 0.0249 
S.E.M. 115.0 0.557 0.921 0.0150 25.0 0.386 0.00789 
2 1 4 
Table A33. 
P h a r m a c o k i n e t i c da ta o f n o r p e t h i d i n e a m o n g 10 Caucas ian pa t ien ts . 
Pharmacokinetic Parameter 
• - N.' 
A U O Tmax Cmax half-l ife El iminat ion 
Constant 
(nghrml-i) (hr) (ngml-i) (hr) (hr-i) 
Patient 
JD 1098 4.00 28.1 24.0 0.0289 
JP 1802 4.00 30.2 38.3 0.0181 
BT 1484 6.00 32.0 29.3 0.0237 
DT 2426 6.00 37.3 43.0 0.0161 
AD 1720 8.00 28.5 37.7 0.0184 
A M 1465 3.00 28.1 37.9 0.0183 
SG 2123 6.00 41.3 32.6 0.0213 
CW 954.5 4.00 26.1 23.0 0.0301 
JG 3578 8.00 31.0 76.1 0.00911 
M W 1991 6.00 26.8 49.2 , 0.00638 
— — — — — > _ — . ^ ^ _ _ ___ ^ ^ ___ ___ 
M E A N 1864 5.50 31.0 39.1 0.0190 
S.D. 751.2 1.72 4.85 15.3 0.00756 




P h a r m a c o k i n e t i c d a t a o f no rpe th id ine a m o n g 10 Chinese pa t ien ts . 
Pharmacokinetic Parameter 
A U O Tmax Cmax half-l i fe E l iminat ion 
Constant 
(nghrml-i) (hr) (ngml-i) (hr) (hr-i) 
Patient 
KLK 2021 8.00 26.2 49.0 0.0141 
M M K 854.5 4.00 23.8 24.0 0.0289 
KPW 823.5 6.00 35.3 14.5 0.0477 
M H L 2741 6.00 30.4 59.7 0.0116 
KWL 7202 6.00 25.4 196 0.0354 
COL 2506 6.00 27.7 60.2 0.0115 
WHS 1248 3.00 14.3 61.0 0.0114 
HFL 2256 8.00 21.7 68.8 0.0101 
K W L l 3238 6.00 28.0 79.0 0.00878 
W K I 3932 4.00 27.4 98.2 0.00706 
M E A N 2683 5.70 26.0 71.0 0.0187 
S.D. 1880 1.64 5.53 50.2 0.0138 
S.E.M. 594.4 0.517 1.75 15.9 0.00436 
2 1 6 
Table A35. 
Pharmacok ine t i c da ta of n o r p e t h i d i n e a m o n g 10 Nepalese pa t ien ts . 
Pharmacokinetic Parameter 
A U O Tmax Cmax half-l ife El iminat ion 
Constant 
(nghrml-l) (hr) (ngml-i) (hr) (hr-i) 
Patient 
GK 5489 6.00 26.2 145 0.00479 
T N 4883 6.00 34.2 97.8 0.00709 
L M 1464 4.00 26.4 37.3 0.0186 
RJ 2844 4.00 25.4 77.5 0.00894-
RG 1406 4.00 20.8 45.8 0.0151 
GP 2960 4.00 29.7 69.4 0,00999 
TH 3346 6.00 32.4 69.0 0.0100 
GG 2150 4.00 25.7 59.3 0.0117 
M H 1257 3.00 27.9 31.1 0.0223 
PK 958.3 3.00 23.1 29.1 0.0238 
1 . • 
M E A N 2676 4,40 27.2 66.1 0.0132 
S.D. 1551 1.17 4.05 35.4 0.00647 
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